Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific AASDH ACSF4, LYS2, NRPS998 ENSG00000157426 Aminoadipate-semialdehyde dehydrogenase 4 56338287-56387508 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036472, HPA036473 Approved Expressed in all Mixed parathyroid gland: 14.9 ABCA1 ABC1, HDLDT1, TGD ENSG00000165029 ATP-binding cassette, sub-family A (ABC1), member 1 9 104781002-104928237 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057283, CAB069889 Approved Approved Nucleoplasm
Vesicles Expressed in all Mixed adrenal gland: 38.1 ABCA9 EST640918 ENSG00000154258 ATP-binding cassette, sub-family A (ABC1), member 9 17 68974488-69061064 Predicted membrane proteins, Transporters Evidence at protein level HPA054823 Uncertain Mixed Mixed ovary: 33.3 ABCB7 ABC7, ASAT, Atm1p, EST140535 ENSG00000131269 ATP-binding cassette, sub-family B (MDR/TAP), member 7 X 75053172-75156732 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034982 Approved Supported Mitochondria Renal cancer:5.31e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 21.3 ABCB9 EST122234 ENSG00000150967 ATP-binding cassette, sub-family B (MDR/TAP), member 9 12 122920951-122981649 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB033052, HPA035113, HPA035114 Approved Supported Vesicles Glioma:4.62e-4 (unfavourable) Mixed Tissue enhanced testis: 23.9 cerebral cortex: 12.1 ABCC10 EST182763, MRP7, SIMRP7 ENSG00000124574 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 6 43427366-43450430 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041607, HPA045464 Approved Renal cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 12.4 ABCC3 cMOAT2, EST90757, MLP2, MOAT-D, MRP3 ENSG00000108846 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 17 50634777-50692252 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB037136, HPA048483 Approved Approved Plasma membrane Renal cancer:4.68e-6 (unfavourable), Pancreatic cancer:9.57e-4 (unfavourable) Mixed Mixed adrenal gland: 20.8 ABCC8 ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2 ENSG00000006071 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 11 17392885-17476845 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB011451, HPA042318 Approved Approved Nucleoli
Golgi apparatus
Cytosol Tissue enriched Tissue enhanced cerebral cortex: 11.7 adrenal gland: 7.6 ABCD1 adrenoleukodystrophy, ALD, ALDP, AMN ENSG00000101986 ATP-binding cassette, sub-family D (ALD), member 1 X 153724868-153744762 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:5.50e-4 (unfavourable) Expressed in all Expressed in all small intestine: 19.7 ABCD4 EST352188, P70R, PMP69, PXMP1L ENSG00000119688 ATP-binding cassette, sub-family D (ALD), member 4 14 74285423-74303056 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003396 Approved Expressed in all Expressed in all fallopian tube: 13.6 ABHD1 FLJ36128, LABH1 ENSG00000143994 Abhydrolase domain containing 1 2 27123789-27130812 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044390 Uncertain Mixed Tissue enriched 17 testis: 29.9 liver: 1.7 ABHD16A BAT5, D6S82E, NG26 ENSG00000204427 Abhydrolase domain containing 16A 6 31686949-31703444 Predicted membrane proteins Evidence at protein level HPA058606 Approved Endometrial cancer:2.63e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 1.7;testis: 1.3;thyroid gland: 1.3 esophagus: 0.9 ABHD3 LABH3 ENSG00000158201 Abhydrolase domain containing 3 18 21650897-21704805 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010729 Approved Approved Nucleus
Vesicles
Plasma membrane Melanoma:8.52e-4 (unfavourable) Expressed in all Expressed in all rectum: 72.4 AC007906.1 ENSG00000279018 16 53207941-53226385 Predicted membrane proteins Evidence at transcript level Not detected Mixed parathyroid gland: 2.1 AC016549.1 ENSG00000281325 5 14341288-14343089 Predicted membrane proteins No evidence Not detected Not detected all non-specific tissues: 0.0 AC024592.12 ENSG00000267740 19 5866171-5903787 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072209 Uncertain Mitochondria Not detected Mixed adrenal gland: 1.5 AC110615.1 ENSG00000279909 4 75949920-75957413 Predicted membrane proteins Evidence at transcript level Not detected Tissue enhanced epididymis: 14.6 skin: 7.3 ACKR2 CCBP2, CCR10, CCR9, CMKBR9, D6 ENSG00000144648 Atypical chemokine receptor 2 3 42804752-42887974 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013819, HPA073493 Supported Supported Nucleoplasm
Vesicles
Cytosol Mixed Tissue enhanced placenta: 22.8 adipose tissue: 5.2 ACSF2 ACSMW, FLJ20920 ENSG00000167107 Acyl-CoA synthetase family member 2 17 50426158-50474845 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA024693 Approved Approved Nucleoplasm
Microtubules
Cytosol Renal cancer:2.17e-4 (unfavourable), Urothelial cancer:2.41e-4 (favourable) Expressed in all Tissue enhanced kidney: 136.1 thyroid gland: 68.3 ACSL1 ACS1, FACL1, FACL2, LACS, LACS1, LACS2 ENSG00000151726 Acyl-CoA synthetase long-chain family member 1 4 184755595-184826818 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011316, HPA011964 Supported Supported Nucleus
Mitochondria Renal cancer:1.25e-5 (favourable) Expressed in all Expressed in all adipose tissue: 820.6 ACSL6 ACS2, FACL6, KIAA0837, LACS2, LACS5 ENSG00000164398 Acyl-CoA synthetase long-chain family member 6 5 131949973-132012243 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040470 Uncertain Group enriched Group enriched 6 bone marrow: 18.0;cerebral cortex: 62.1;parathyroid gland: 22.1;seminal vesicle: 28.7;testis: 51.2 adrenal gland: 6.5 ACSM1 BUCS1, MACS1 ENSG00000166743 Acyl-CoA synthetase medium-chain family member 1 16 20623237-20698890 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046291 Uncertain Group enriched Tissue enriched 55 breast: 293.3 prostate: 5.2 ACSM2A A-923A4.1, ACSM2, MGC150530 ENSG00000183747 Acyl-CoA synthetase medium-chain family member 2A 16 20451461-20487667 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057699 Supported Liver cancer:1.41e-5 (favourable) Group enriched Group enriched 578 kidney: 284.3;liver: 185.7 cerebral cortex: 0.4 ACSM2B ACSM2, HXMA, HYST1046 ENSG00000066813 Acyl-CoA synthetase medium-chain family member 2B 16 20536226-20576427 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057699 Supported Liver cancer:3.31e-4 (favourable) Group enriched Group enriched 85 kidney: 423.8;liver: 261.6 thyroid gland: 4.0 ACSM4 ENSG00000215009 Acyl-CoA synthetase medium-chain family member 4 12 7304284-7328724 Enzymes, Predicted membrane proteins Evidence at transcript level HPA049895 Uncertain Not detected Tissue enhanced ovary: 2.5;testis: 2.6 spleen: 1.2 ACSM6 bA310E22.3, C10orf129 ENSG00000173124 Acyl-CoA synthetase medium-chain family member 6 10 95194200-95228928 Enzymes, Predicted membrane proteins Evidence at protein level HPA044593 Uncertain Urothelial cancer:7.71e-4 (favourable) Tissue enriched Tissue enhanced stomach: 1.7 urinary bladder: 0.6 ACSS1 ACAS2L, AceCS2L, dJ568C11.3, MGC33843 ENSG00000154930 Acyl-CoA synthetase short-chain family member 1 20 25006230-25058980 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041014, HPA043228 Approved Lung cancer:8.33e-5 (favourable), Cervical cancer:9.37e-4 (favourable) Expressed in all Expressed in all placenta: 165.1 ADAM20 ENSG00000134007 ADAM metallopeptidase domain 20 14 70522358-70535015 Enzymes, Predicted membrane proteins Evidence at protein level HPA059377 Supported Not detected Tissue enriched 76 testis: 9.2 cerebral cortex,endometrium,skin: 0.1 ADAM28 ADAM23, eMDCII, MDC-Lm, MDC-Ls ENSG00000042980 ADAM metallopeptidase domain 28 8 24294040-24359018 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074034 Approved Plasma membrane
Mitochondria Endometrial cancer:3.17e-4 (favourable) Mixed Tissue enhanced epididymis: 428.3 stomach: 104.5 ADCY4 AC4 ENSG00000129467 Adenylate cyclase 4 14 24318349-24335093 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB005070, HPA048344 Approved Renal cancer:7.01e-4 (unfavourable), Endometrial cancer:8.20e-4 (favourable) Expressed in all Tissue enhanced placenta: 20.9 lung: 11.6 ADGRB3 BAI3, KIAA0550 ENSG00000135298 Adhesion G protein-coupled receptor B3 6 68635367-69389511 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 10 cerebral cortex: 53.2 adrenal gland: 5.2 ADGRL2 KIAA0786, LEC1, LPHH1, LPHN2 ENSG00000117114 Adhesion G protein-coupled receptor L2 1 81306160-81992436 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA043447 Approved Plasma membrane
Cell Junctions Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable) Expressed in all Mixed thyroid gland: 72.8 ADIPOR1 ACDCR1, PAQR1 ENSG00000159346 Adiponectin receptor 1 1 202940823-202958572 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Ovarian cancer:5.27e-4 (favourable), Pancreatic cancer:5.50e-4 (unfavourable) Expressed in all Expressed in all placenta: 135.5 ADORA2A ADORA2, RDC8 ENSG00000128271 Adenosine A2a receptor 22 24417879-24442360 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced bone marrow: 9.6 lymph node: 7.7 ADTRP AIG1L, C6orf105, dJ413H6.1 ENSG00000111863 Androgen-dependent TFPI-regulating protein 6 11712054-11807046 Predicted membrane proteins Evidence at transcript level HPA048113 Uncertain Uncertain Nucleoli Renal cancer:1.13e-5 (unfavourable) Mixed Tissue enhanced small intestine: 81.0 duodenum: 62.8 AFG3L2 SCA28, SPAX5 ENSG00000141385 AFG3-like AAA ATPase 2 18 12328944-12377314 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA004479, HPA004480 Supported Validated Mitochondria Renal cancer:6.05e-14 (favourable), Endometrial cancer:8.68e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 121.6 AGMO FLJ16237, TMEM195 ENSG00000187546 Alkylglycerol monooxygenase 7 15200318-15562015 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057900 Uncertain Vesicles Tissue enriched Tissue enhanced liver: 63.6 epididymis: 17.5 AGPAT1 LPAAT-alpha ENSG00000204310 1-acylglycerol-3-phosphate O-acyltransferase 1 6 32168212-32178096 Enzymes, Predicted membrane proteins Evidence at protein level HPA048478, HPA073355 Approved Supported Endoplasmic reticulum
Rods & Rings Breast cancer:1.93e-4 (unfavourable), Endometrial cancer:5.21e-4 (unfavourable) Expressed in all Mixed epididymis: 51.4 AGPAT2 BSCL, LPAAT-beta ENSG00000169692 1-acylglycerol-3-phosphate O-acyltransferase 2 9 136673143-136687423 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA019544 Uncertain Approved Centrosome Expressed in all Expressed in all adipose tissue: 299.8 AGPAT3 LPAAT-gamma ENSG00000160216 1-acylglycerol-3-phosphate O-acyltransferase 3 21 43865186-43986536 Enzymes, Predicted membrane proteins Evidence at protein level Renal cancer:2.29e-4 (favourable), Cervical cancer:8.31e-4 (unfavourable) Expressed in all Expressed in all small intestine: 58.7 AGPAT4 dJ473J16.2, LPAAT-delta ENSG00000026652 1-acylglycerol-3-phosphate O-acyltransferase 4 6 161129979-161274061 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053287, HPA060525 Approved Approved Nucleoli
Golgi apparatus
Vesicles Cervical cancer:1.45e-4 (unfavourable), Renal cancer:4.08e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 24.8 placenta: 12.2 AGPAT5 FLJ11210, LPAAT-e, LPAAT-epsilon ENSG00000155189 1-acylglycerol-3-phosphate O-acyltransferase 5 8 6708357-6759666 Enzymes, Predicted membrane proteins Evidence at protein level HPA010644, HPA010950 Approved Liver cancer:4.57e-4 (unfavourable), Colorectal cancer:8.82e-4 (favourable) Expressed in all Expressed in all testis: 46.7 AIG1 AIG-1, dJ95L4.1, FLJ10485 ENSG00000146416 Androgen-induced 1 6 143060496-143340304 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA060766 Approved Approved Golgi apparatus Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable) Expressed in all Expressed in all liver: 153.9 ALDH16A1 MGC10204 ENSG00000161618 Aldehyde dehydrogenase 16 family, member A1 19 49453169-49471048 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA059488 Approved Supported Mitochondria Expressed in all Expressed in all spleen: 17.9 ALDH3B2 ALDH8 ENSG00000132746 Aldehyde dehydrogenase 3 family, member B2 11 67662162-67681200 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045132 Approved Mixed Group enriched 5 breast: 88.2;esophagus: 103.8;skin: 122.4 tonsil: 19.7 ALG10 ALG10A, DIE2, FLJ14751 ENSG00000139133 ALG10, alpha-1,2-glucosyltransferase 12 34022281-34029694 Enzymes, Predicted membrane proteins Evidence at protein level HPA043329, HPA063387 Approved Approved Endoplasmic reticulum Mixed Mixed parathyroid gland: 4.6 ALG10B KCR1 ENSG00000175548 ALG10B, alpha-1,2-glucosyltransferase 12 38316578-38329728 Enzymes, Predicted membrane proteins Evidence at protein level HPA043329, HPA063387 Approved Approved Endoplasmic reticulum Mixed Mixed parathyroid gland: 7.6 ALG11 KIAA0266 ENSG00000253710 ALG11, alpha-1,2-mannosyltransferase 13 52012398-52029664 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047214 Approved Mixed Expressed in all thyroid gland: 23.4 ANO1 DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A ENSG00000131620 Anoctamin 1, calcium activated chloride channel 11 70078302-70189528 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032148 Supported Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 217.7;seminal vesicle: 295.7 skin: 116.0 ANO10 FLJ10375, MGC47890, SCAR10, TMEM16K ENSG00000160746 Anoctamin 10 3 43354859-43691594 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051569 Approved Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable) Expressed in all Expressed in all duodenum: 64.3 APOL1 APOL ENSG00000100342 Apolipoprotein L, 1 22 36253010-36267530 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018885, CAB056156 Supported Renal cancer:7.43e-6 (unfavourable), Urothelial cancer:2.01e-5 (favourable), Lung cancer:5.35e-4 (unfavourable) Expressed in all Expressed in all liver: 116.0 APOL2 APOL-II ENSG00000128335 Apolipoprotein L, 2 22 36226203-36239954 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001078 Uncertain Approved Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:5.06e-6 (favourable) Expressed in all Expressed in all gallbladder: 65.0 ARIH2OS C3orf71 ENSG00000221883 Ariadne homolog 2 opposite strand 3 48917788-48919385 Predicted membrane proteins Evidence at transcript level Mixed Mixed testis: 4.2 ARSE CDPX, CDPX1 ENSG00000157399 Arylsulfatase E (chondrodysplasia punctata 1) X 2934632-2968310 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA060518 Supported Golgi apparatus Colorectal cancer:8.95e-4 (favourable) Mixed Tissue enhanced kidney: 41.1;liver: 49.1 pancreas: 23.9 ARSF ENSG00000062096 Arylsulfatase F X 3041471-3112726 Predicted membrane proteins Evidence at protein level HPA000549 Uncertain Cytosol Tissue enhanced Group enriched 6 adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.1;esophagus: 2.3;kidney: 8.0;skin: 6.7 liver,urinary bladder: 0.6 ARSH ENSG00000205667 Arylsulfatase family, member H X 3006613-3033571 Predicted membrane proteins Evidence at transcript level Not detected Not detected epididymis: 0.9 ASIC1 ACCN2, BNaC2, hBNaC2 ENSG00000110881 Acid sensing (proton gated) ion channel 1 12 50057548-50083611 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA058870 Approved Golgi apparatus
Plasma membrane Tissue enhanced Tissue enriched 10 cerebral cortex: 57.0 parathyroid gland: 5.5 ASIC2 ACCN, ACCN1, ASIC2a, BNaC1, BNC1, hBNaC1, MDEG ENSG00000108684 Acid sensing (proton gated) ion channel 2 17 33013087-34174964 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA052112 Approved Tissue enhanced Group enriched 6 cerebral cortex: 8.7;cervix, uterine: 3.9;endometrium: 6.4;smooth muscle: 2.1 adrenal gland: 0.8 ASIC3 ACCN3, DRASIC, TNaC1 ENSG00000213199 Acid sensing (proton gated) ion channel 3 7 151048292-151052756 Predicted membrane proteins Evidence at protein level HPA049155 Approved Approved Nucleoplasm
Cytosol Tissue enhanced Tissue enhanced testis: 8.1 cerebral cortex: 5.8 ASIC4 ACCN4, BNAC4 ENSG00000072182 Acid sensing (proton gated) ion channel family member 4 2 219514170-219538772 Predicted membrane proteins Evidence at protein level HPA036042 Approved Golgi apparatus Tissue enriched Tissue enriched 8 cerebral cortex: 10.6 adrenal gland: 1.3 ASIC5 ACCN5, HINAC, INAC ENSG00000256394 Acid sensing (proton gated) ion channel family member 5 4 155829729-155866273 Predicted membrane proteins Evidence at protein level HPA014903, HPA029444 Approved Not detected Group enriched 19 duodenum: 2.4;small intestine: 1.3 all non-specific tissues: 0.0 ASTN1 ASTN ENSG00000152092 Astrotactin 1 1 176857302-177164973 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074112 Approved Golgi apparatus
Vesicles Tissue enriched Group enriched 6 adrenal gland: 19.7;cerebral cortex: 67.0 ovary: 7.4 ASTN2 KIAA0634 ENSG00000148219 Astrotactin 2 9 116425225-117415070 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027035 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:6.66e-16 (favourable) Expressed in all Expressed in all prostate: 42.3 ATG9A APG9L1, FLJ22169 ENSG00000198925 Autophagy related 9A 2 219209772-219229717 Predicted membrane proteins Evidence at protein level HPA059551 Uncertain Supported Vesicles Liver cancer:2.18e-5 (unfavourable) Expressed in all Expressed in all testis: 112.6 ATL1 AD-FSP, FSP1, SPG3, SPG3A ENSG00000198513 Atlastin GTPase 1 14 50532509-50633068 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027550 Approved Mixed Tissue enhanced cerebral cortex: 97.2 smooth muscle: 22.1 ATL2 ARL6IP2 ENSG00000119787 Atlastin GTPase 2 2 38294880-38377285 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029108 Approved Endometrial cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 100.9 ATL3 DKFZP564J0863 ENSG00000184743 Atlastin GTPase 3 11 63624087-63671921 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065702 Supported Endoplasmic reticulum Pancreatic cancer:1.04e-4 (unfavourable) Expressed in all Expressed in all testis: 66.0 ATP11A ATPIH, ATPIS, KIAA1021 ENSG00000068650 ATPase, class VI, type 11A 13 112690329-112887168 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035583, HPA035584 Approved Validated Vesicles Renal cancer:7.44e-4 (favourable) Expressed in all Expressed in all lung: 59.2 ATP11B ATPIF, ATPIR, KIAA0956 ENSG00000058063 ATPase, class VI, type 11B 3 182793500-182921635 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA036237, HPA036238 Uncertain Approved Microtubule organizing center
Cytosol Pancreatic cancer:1.09e-4 (unfavourable), Endometrial cancer:3.44e-4 (unfavourable) Expressed in all Expressed in all testis: 57.7 ATP13A2 CLN12, HSA9947, PARK9 ENSG00000159363 ATPase type 13A2 1 16985958-17011928 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB037038, CAB037111, HPA050910, HPA054717 Approved Liver cancer:3.33e-7 (unfavourable) Expressed in all Expressed in all cerebral cortex: 75.0 ATP13A3 AFURS1 ENSG00000133657 ATPase type 13A3 3 194402672-194498364 Predicted membrane proteins Evidence at protein level HPA029471 Approved Approved Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:1.60e-4 (unfavourable), Renal cancer:1.63e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 146.4 ATP1A1 ENSG00000163399 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1 116372668-116410261 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB018702, CAB069993 Supported Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 2441.5 ATP1A3 DYT12 ENSG00000105409 ATPase, Na+/K+ transporting, alpha 3 polypeptide 19 41966582-41997497 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB033630, HPA045367, HPA056446 Supported Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 376.4;heart muscle: 94.2 testis: 54.1 ATP2A1 ATP2A, SERCA1 ENSG00000196296 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 16 28878405-28904509 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002310, CAB032706 Supported Approved Endoplasmic reticulum Tissue enhanced Tissue enriched 95 skeletal muscle: 2782.7 esophagus: 29.2 ATP2A3 SERCA3 ENSG00000074370 ATPase, Ca++ transporting, ubiquitous 17 3923870-3964464 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA007180, CAB010882 Approved Cervical cancer:4.69e-5 (favourable), Head and neck cancer:2.51e-4 (favourable) Expressed in all Expressed in all lymph node: 119.9 ATP2B1 PMCA1 ENSG00000070961 ATPase, Ca++ transporting, plasma membrane 1 12 89588049-89709300 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB005605, HPA011166, HPA012945 Supported Supported Plasma membrane Liver cancer:7.74e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.0 ATP2C1 ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1 ENSG00000017260 ATPase, Ca++ transporting, type 2C, member 1 3 130850595-131016712 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB010207, HPA035116, HPA069684 Supported Validated Golgi apparatus Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable) Expressed in all Expressed in all prostate: 136.8 ATP5F1 ENSG00000116459 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1 1 111448864-111462773 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046067, HPA057347 Supported Supported Nucleoplasm
Mitochondria Renal cancer:3.26e-9 (favourable), Stomach cancer:8.07e-4 (favourable) Expressed in all Expressed in all heart muscle: 51.1 ATP5G1 ATP5G ENSG00000159199 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) 17 48892765-48895871 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:8.24e-6 (favourable), Cervical cancer:3.88e-4 (favourable) Expressed in all Expressed in all heart muscle: 406.5 ATP5G2 ENSG00000135390 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) 12 53632726-53677408 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051469 Approved Expressed in all Expressed in all fallopian tube: 769.8 ATP5G3 ENSG00000154518 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C3 (subunit 9) 2 175176258-175184607 Predicted membrane proteins Evidence at transcript level Renal cancer:2.31e-6 (favourable), Head and neck cancer:6.01e-4 (unfavourable), Colorectal cancer:9.90e-4 (favourable) Expressed in all Expressed in all heart muscle: 525.2 ATP6V0A1 a1, ATP6N1, ATP6N1A, Stv1, Vph1, VPP1 ENSG00000033627 ATPase, H+ transporting, lysosomal V0 subunit a1 17 42458844-42522611 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA022144 Supported Approved Nuclear speckles
Golgi apparatus
Vesicles
Cytosol Renal cancer:1.28e-4 (favourable), Pancreatic cancer:2.05e-4 (favourable), Urothelial cancer:6.90e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 201.5 ATP6V0B ATP6F, HATPL, VMA16 ENSG00000117410 ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 1 43974487-43978295 Predicted membrane proteins Evidence at transcript level HPA044281 Approved Cytosol Renal cancer:3.62e-6 (favourable), Pancreatic cancer:3.24e-4 (favourable), Liver cancer:4.79e-4 (unfavourable), Urothelial cancer:8.87e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 181.8 ATP6V0E1 ATP6H, ATP6V0E, M9.2 ENSG00000113732 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 5 172983757-173035445 Predicted membrane proteins Evidence at transcript level Expressed in all Expressed in all epididymis: 758.5 ATP6V0E2 ATP6V0E2L, C7orf32 ENSG00000171130 ATPase, H+ transporting V0 subunit e2 7 149872968-149880698 Predicted membrane proteins Evidence at transcript level Renal cancer:8.26e-7 (favourable), Pancreatic cancer:5.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 261.8 ATP8B3 ATPIK ENSG00000130270 ATPase, aminophospholipid transporter, class I, type 8B, member 3 19 1782075-1812276 Enzymes, Predicted membrane proteins Evidence at transcript level Renal cancer:4.80e-9 (unfavourable) Mixed Tissue enriched 7 testis: 28.7 bone marrow: 4.0 ATRAID APR3, C2orf28, HSPC013, p18 ENSG00000138085 All-trans retinoic acid-induced differentiation factor 2 27212027-27217178 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051353 Uncertain Expressed in all Expressed in all epididymis: 511.9 ATRN DPPT-L, MGCA ENSG00000088812 Attractin 20 3471040-3651122 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008853 Uncertain Approved Cytosol Renal cancer:2.19e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 83.4 ATRNL1 ALP, FLJ45344, KIAA0534 ENSG00000107518 Attractin-like 1 10 115093365-115948992 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038070 Uncertain Approved Nucleus
Mitochondria Mixed Tissue enhanced cerebral cortex: 34.0 testis: 22.6 AUP1 ENSG00000115307 Ancient ubiquitous protein 1 2 74526645-74529939 Predicted membrane proteins Evidence at protein level HPA007674 Approved Approved Nucleoplasm
Vesicles Renal cancer:2.97e-9 (unfavourable), Liver cancer:2.29e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 57.1 AWAT2 DGAT2L4, MFAT ENSG00000147160 Acyl-CoA wax alcohol acyltransferase 2 X 70040542-70049938 Enzymes, Predicted membrane proteins Evidence at protein level HPA062748 Approved Tissue enriched Tissue enhanced breast: 2.0;skin: 1.2 testis: 0.5 BAK1 BAK, BCL2L7, CDN1 ENSG00000030110 BCL2-antagonist/killer 1 6 33572547-33580293 Predicted membrane proteins, Transporters Evidence at protein level CAB005029 Supported Renal cancer:1.64e-5 (unfavourable), Endometrial cancer:1.71e-4 (unfavourable), Liver cancer:4.52e-4 (unfavourable), Lung cancer:5.64e-4 (unfavourable) Expressed in all Expressed in all duodenum: 49.2 BANP BEND1, DKFZp761H172, FLJ10177, FLJ20538, SMAR1, SMARBP1 ENSG00000172530 BTG3 associated nuclear protein 16 87949244-88118422 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047164 Approved Supported Nucleoplasm
Nuclear bodies Expressed in all Expressed in all testis: 14.1 BCAP29 BAP29, DKFZp686M2086 ENSG00000075790 B-cell receptor-associated protein 29 7 107579977-107629170 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029215, HPA049694 Supported Approved Cytosol Liver cancer:3.62e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 185.4 BCL2 Bcl-2, PPP1R50 ENSG00000171791 B-cell CLL/lymphoma 2 18 63123346-63320128 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000003, HPA055295 Supported Supported Nucleoplasm
Nuclear membrane Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 69.2 parathyroid gland: 34.6 BCL2L1 Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52 ENSG00000171552 BCL2-like 1 20 31664452-31723989 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level HPA035734, CAB072801 Approved Approved Mitochondria Renal cancer:8.89e-5 (favourable), Pancreatic cancer:5.87e-4 (unfavourable), Endometrial cancer:9.10e-4 (unfavourable), Melanoma:9.57e-4 (favourable) Expressed in all Expressed in all gallbladder: 100.9 BCL2L2 BCL-W, KIAA0271, PPP1R51 ENSG00000129473 BCL2-like 2 14 23298790-23311759 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB040539 Approved Renal cancer:1.99e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 89.1 BEST1 BEST, BMD, RP50, VMD2 ENSG00000167995 Bestrophin 1 11 61949821-61965515 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057464 Supported Group enriched Mixed cerebral cortex: 17.0 BEST3 MGC13168, MGC40411, VMD2L3 ENSG00000127325 Bestrophin 3 12 69643360-69699476 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA054582 Approved Tissue enriched Tissue enhanced cerebral cortex: 16.4;skeletal muscle: 12.2 testis: 5.9 BFAR BAR, RNF47 ENSG00000103429 Bifunctional apoptosis regulator 16 14632815-14669236 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Pancreatic cancer:4.74e-5 (unfavourable) Expressed in all Expressed in all placenta: 23.3 BMPR2 BMPR-II, BMPR3, BRK-3, PPH1, T-ALK ENSG00000204217 Bone morphogenetic protein receptor, type II (serine/threonine kinase) 2 202376936-202567751 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017385, HPA049014 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all cerebral cortex: 36.5 BRI3 ENSG00000164713 Brain protein I3 7 98252379-98310441 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042215 Uncertain Head and neck cancer:3.35e-4 (unfavourable) Expressed in all Expressed in all lung: 119.5 BSCL2 GNG3LG, SPG17 ENSG00000168000 Berardinelli-Seip congenital lipodystrophy 2 (seipin) 11 62690275-62709845 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042394 Approved Renal cancer:7.55e-5 (favourable) Expressed in all Expressed in all testis: 249.9 BTN2A2 BT2.2, BTF2, BTN2.2 ENSG00000124508 Butyrophilin, subfamily 2, member A2 6 26383096-26394874 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051504 Uncertain Supported Mitochondria Breast cancer:1.01e-4 (favourable) Expressed in all Mixed lymph node: 38.1 BVES HBVES, POP1, POPDC1 ENSG00000112276 Blood vessel epicardial substance 6 105096822-105137174 Predicted membrane proteins Evidence at protein level HPA014788, HPA018176 Supported Supported Cell Junctions Mixed Tissue enhanced smooth muscle: 24.7 testis: 20.7 C10orf128 Em:AC084727.5 ENSG00000204161 Chromosome 10 open reading frame 128 10 49154725-49188585 Predicted membrane proteins Evidence at transcript level HPA058166 Approved Renal cancer:2.86e-5 (unfavourable) Expressed in all Mixed lung: 40.5 C14orf180 C14orf77, NRAC ENSG00000184601 Chromosome 14 open reading frame 180 14 104579684-104590515 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Tissue enhanced Group enriched 19 adipose tissue: 34.6;heart muscle: 28.7 adrenal gland: 1.6 C16orf58 FLJ13868 ENSG00000140688 Chromosome 16 open reading frame 58 16 31489471-31509309 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024406 Uncertain Approved Nucleoplasm
Nucleoli
Golgi apparatus
Vesicles
Cytosol Expressed in all Expressed in all parathyroid gland: 81.3 C17orf62 FLJ90469, MGC4368 ENSG00000178927 Chromosome 17 open reading frame 62 17 82442589-82450829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045696 Uncertain Approved Plasma membrane
Cell Junctions Renal cancer:6.83e-11 (unfavourable) Expressed in all Expressed in all lymph node: 129.5 C1orf101 MGC33370 ENSG00000179397 Chromosome 1 open reading frame 101 1 244454377-244641177 Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 12 testis: 38.3 epididymis: 3.1 C1orf27 FLJ20505, odr-4, TTG1 ENSG00000157181 Chromosome 1 open reading frame 27 1 186375838-186421378 Predicted membrane proteins Evidence at protein level HPA015988, HPA031352 Uncertain Approved Nucleoplasm
Plasma membrane Ovarian cancer:9.92e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 75.0 C1orf95 DKFZp761P211 ENSG00000203685 Chromosome 1 open reading frame 95 1 226548800-226609214 Predicted membrane proteins Evidence at protein level Renal cancer:6.40e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 35.8 smooth muscle: 8.3 C20orf141 dJ860F19.4 ENSG00000258713 Chromosome 20 open reading frame 141 20 2814987-2815833 Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 106 testis: 96.9 placenta: 0.9 C3orf52 FLJ23186, TTMP ENSG00000114529 Chromosome 3 open reading frame 52 3 112086335-112131004 Predicted membrane proteins Evidence at protein level HPA008119, HPA011968 Uncertain Pancreatic cancer:3.85e-4 (unfavourable) Mixed Tissue enhanced skin: 23.2 stomach: 16.7 C5orf28 FLJ21657 ENSG00000151881 Chromosome 5 open reading frame 28 5 43444252-43483893 Predicted membrane proteins Evidence at protein level HPA059946 Approved Nucleoplasm Liver cancer:1.59e-4 (unfavourable), Renal cancer:2.85e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 64.8 C6orf136 Em:AB023049.8 ENSG00000204564 Chromosome 6 open reading frame 136 6 30647039-30653210 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046804 Uncertain Renal cancer:9.16e-8 (favourable), Urothelial cancer:7.51e-4 (favourable) Expressed in all Mixed parathyroid gland: 8.0 C9orf69 bA83N9.1 ENSG00000238227 Chromosome 9 open reading frame 69 9 136114581-136118863 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066070 Supported Supported Nucleoplasm Endometrial cancer:1.09e-4 (favourable) Expressed in all Expressed in all skin: 23.8 C9orf91 DKFZp547P234, FLJ38045 ENSG00000157693 Chromosome 9 open reading frame 91 9 114611206-114646422 Predicted membrane proteins Evidence at transcript level HPA017199 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 22.4 CACFD1 C9orf7, D9S2135, flower ENSG00000160325 Calcium channel flower domain containing 1 9 133459965-133470848 Predicted membrane proteins, Transporters Evidence at protein level HPA015280 Approved Nucleoplasm Renal cancer:2.83e-8 (favourable) Expressed in all Expressed in all thyroid gland: 16.6 CACNA1A APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6 ENSG00000141837 Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 19 13206442-13623990 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA064258 Supported Approved Nucleoplasm
Golgi apparatus
Vesicles Pancreatic cancer:4.32e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 18.1 stomach: 6.4 CACNA1C CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS ENSG00000151067 Calcium channel, voltage-dependent, L type, alpha 1C subunit 12 1970786-2697950 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039796 Supported Mixed Tissue enhanced smooth muscle: 30.9 endometrium: 26.2 CACNA2D3 HSA272268 ENSG00000157445 Calcium channel, voltage-dependent, alpha 2/delta subunit 3 3 54122547-55074557 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030849, HPA030850 Uncertain Nucleus
Cytosol Mixed Tissue enhanced cerebral cortex: 16.3 adrenal gland: 5.4 CACNG6 ENSG00000130433 Calcium channel, voltage-dependent, gamma subunit 6 19 53992288-54012669 Predicted membrane proteins, Transporters Evidence at transcript level HPA056615 Approved Nucleoli fibrillar center
Cytosol Mixed Group enriched 11 fallopian tube: 17.8;skeletal muscle: 33.9 lung: 2.3 CAMLG CAML, GET2 ENSG00000164615 Calcium modulating ligand 5 134738501-134752160 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA052636, HPA056472 Approved Approved Nucleus
Nucleoli
Vesicles Renal cancer:1.09e-5 (unfavourable) Expressed in all Expressed in all testis: 99.0 CATSPERD MGC39581, TMEM146 ENSG00000174898 Catsper channel auxiliary subunit delta 19 5720677-5778734 Predicted membrane proteins, Transporters Evidence at protein level HPA024056 Supported Tissue enhanced Tissue enriched 160 testis: 15.9 all non-specific tissues: 0.0 CCDC109B FLJ20647 ENSG00000005059 Coiled-coil domain containing 109B 4 109560205-109688726 Predicted membrane proteins, Transporters Evidence at protein level HPA048776 Approved Approved Nucleoplasm
Cytosol Renal cancer:7.35e-6 (unfavourable) Expressed in all Mixed lymph node: 36.7 CCDC51 FLJ12436 ENSG00000164051 Coiled-coil domain containing 51 3 48432164-48440456 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010980, HPA011408 Supported Supported Nucleoplasm
Centrosome
Mitochondria Expressed in all Mixed thyroid gland: 17.2 CCR10 GPR2 ENSG00000184451 Chemokine (C-C motif) receptor 10 17 42678889-42683917 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011684, HPA048007, HPA069188 Uncertain Supported Endoplasmic reticulum Mixed Mixed adipose tissue: 4.5 CCR2 CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R ENSG00000121807 Chemokine (C-C motif) receptor 2 3 46353734-46360928 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB003793 Approved Lung cancer:5.87e-4 (favourable) Mixed Tissue enhanced appendix: 53.0 spleen: 20.8 CD151 PETA-3, RAPH, SFA-1, TSPAN24 ENSG00000177697 CD151 molecule (Raph blood group) 11 832843-839831 Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002428, HPA011906 Supported Liver cancer:5.58e-4 (unfavourable), Thyroid cancer:6.92e-4 (favourable), Lung cancer:9.46e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 356.5 CD19 ENSG00000177455 CD19 molecule 16 28931939-28939346 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB016110 Supported Mixed Group enriched 11 appendix: 38.8;lymph node: 85.0;spleen: 48.2;tonsil: 70.8 urinary bladder: 5.7 CD200 MOX1, MOX2, MRC, OX-2 ENSG00000091972 CD200 molecule 3 112332347-112362812 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA031149 Approved Expressed in all Mixed cerebral cortex: 78.8 CD34 ENSG00000174059 CD34 molecule 1 207880972-207911402 CD markers, Predicted membrane proteins Evidence at protein level CAB000018, HPA036722, HPA036723 Supported Approved Nucleus
Plasma membrane
Cell Junctions Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable) Expressed in all Expressed in all placenta: 313.8 CD36 FAT, GP3B, GP4, GPIV, SCARB3 ENSG00000135218 CD36 molecule (thrombospondin receptor) 7 80369575-80679277 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA002018, CAB025866 Supported Stomach cancer:4.47e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 1614.0 CD37 TSPAN26 ENSG00000104894 CD37 molecule 19 49335171-49343335 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002492, HPA032120, HPA032121 Supported Endometrial cancer:4.51e-4 (favourable) Expressed in all Tissue enhanced lymph node: 244.2;spleen: 212.9 appendix: 133.5 CD81 TAPA-1, TAPA1, TSPAN28 ENSG00000110651 CD81 molecule 11 2376177-2397419 CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002507, HPA007234 Supported Supported Plasma membrane Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 2246.2 CD82 IA4, KAI1, R2, ST6, TSPAN27 ENSG00000085117 CD82 molecule 11 44564427-44620363 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002508, HPA028900, HPA061418 Supported Approved Vesicles Expressed in all Expressed in all esophagus: 132.1 CD9 BA2, MIC3, MRP-1, P24, TSPAN29 ENSG00000010278 CD9 molecule 12 6199715-6238271 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002490 Supported Supported Plasma membrane Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1009.8 CECR6 ENSG00000183307 Cat eye syndrome chromosome region, candidate 6 22 17116299-17121367 Predicted membrane proteins Evidence at protein level HPA068790 Approved Nucleoplasm
Vesicles
Plasma membrane Tissue enhanced Group enriched 7 cerebral cortex: 15.0;prostate: 10.9 testis: 1.9 CERS2 FLJ10243, LASS2, SP260 ENSG00000143418 Ceramide synthase 2 1 150960583-150975004 Predicted membrane proteins Evidence at protein level HPA027262 Approved Supported Nuclear membrane
Endoplasmic reticulum Expressed in all Expressed in all liver: 408.6 CERS3 LASS3, MGC27091 ENSG00000154227 Ceramide synthase 3 15 100400395-100544995 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006092, HPA024356 Uncertain Tissue enhanced Group enriched 9 esophagus: 48.3;skin: 60.7;testis: 32.1;tonsil: 14.9 breast: 4.2 CERS4 FLJ12089, LASS4, Trh1 ENSG00000090661 Ceramide synthase 4 19 8206736-8262421 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033734, HPA054729 Uncertain Approved Nucleus
Vesicles Lung cancer:3.45e-5 (favourable), Renal cancer:9.63e-5 (favourable), Cervical cancer:2.71e-4 (favourable), Head and neck cancer:7.83e-4 (favourable), Pancreatic cancer:8.05e-4 (favourable) Expressed in all Mixed thyroid gland: 80.7 CFAP54 C12orf55, C12orf63, FLJ31514, FLJ44112 ENSG00000188596 Cilia and flagella associated 54 12 96489571-96875555 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039897 Supported Approved Microtubules
Cytosol Not detected Mixed testis: 10.6 CFTR ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR ENSG00000001626 Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) 7 117465784-117715971 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001951, HPA021939 Supported Liver cancer:9.44e-4 (unfavourable) Tissue enhanced Tissue enhanced gallbladder: 89.6;rectum: 50.1 colon: 47.0 CHRNB1 CHRNB ENSG00000170175 Cholinergic receptor, nicotinic, beta 1 (muscle) 17 7445061-7457707 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005822, CAB011200 Approved Expressed in all Expressed in all skeletal muscle: 43.9 CKLF C32, CKLF1, CKLF3, CKLF4, HSPC224, UCK-1 ENSG00000217555 Chemokine-like factor 16 66552563-66566251 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA062779 Approved Vesicles Renal cancer:1.06e-9 (unfavourable), Liver cancer:5.67e-5 (unfavourable), Thyroid cancer:2.22e-4 (favourable) Expressed in all Expressed in all testis: 91.2 CKLF-CMTM1 ENSG00000254788 CKLF-CMTM1 readthrough 16 66552587-66579135 Predicted membrane proteins Evidence at transcript level HPA017136 Approved Mixed Mixed testis: 4.1 CLCC1 MCLC ENSG00000121940 Chloride channel CLIC-like 1 1 108929508-108963457 Predicted membrane proteins, Transporters Evidence at protein level HPA009087, HPA013210 Supported Validated Endoplasmic reticulum Colorectal cancer:1.33e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 38.0 CLDN12 ENSG00000157224 Claudin 12 7 90383721-90513402 Predicted membrane proteins Evidence at protein level HPA026945 Approved Cervical cancer:6.36e-4 (unfavourable) Expressed in all Expressed in all prostate: 40.8 CLDN7 CEPTRL2, CPETRL2, Hs.84359 ENSG00000181885 Claudin 7 17 7259903-7263983 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013063, HPA014703, HPA073662 Supported Approved Vesicles
Cell Junctions Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable) Expressed in all Mixed small intestine: 357.1 CLDND1 C3orf4 ENSG00000080822 Claudin domain containing 1 3 98497912-98523066 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029841 Approved Approved Nucleus
Nucleoli
Cytosol Renal cancer:5.84e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 400.9 CLEC7A CD369, CLECSF12, dectin-1, hDectin-1 ENSG00000172243 C-type lectin domain family 7, member A 12 10116777-10130258 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043244, HPA050229 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:1.31e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 67.3 bone marrow: 53.5 CLECL1 DCAL1 ENSG00000184293 C-type lectin-like 1 12 9715860-9733299 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced lymph node: 29.1;spleen: 23.2;tonsil: 29.6 appendix: 13.7 CLN3 BTS, JNCL ENSG00000188603 Ceroid-lipofuscinosis, neuronal 3 16 28477279-28495575 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063280 Uncertain Expressed in all Expressed in all placenta: 54.9 CLN6 FLJ20561, HsT18960, nclf ENSG00000128973 Ceroid-lipofuscinosis, neuronal 6, late infantile, variant 15 68206992-68257211 Disease related genes, Predicted membrane proteins Evidence at protein level HPA066046, HPA074162 Approved Approved Vesicles Renal cancer:4.87e-4 (favourable) Expressed in all Expressed in all appendix: 23.0 CLRN1 RP61, USH3, USH3A ENSG00000163646 Clarin 1 3 150926163-150972999 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054636 Uncertain Not detected Tissue enhanced adrenal gland: 6.8;duodenum: 1.6 testis: 0.8 CMTM1 CKLFH, CKLFH1a, CKLFSF1 ENSG00000089505 CKLF-like MARVEL transmembrane domain containing 1 16 66566393-66579137 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013801, HPA017136 Uncertain Approved Nucleoplasm Pancreatic cancer:5.68e-5 (unfavourable) Mixed Tissue enriched 6 testis: 28.8 spleen: 4.5 CMTM2 CKLFSF2, FLJ25732, MGC39436 ENSG00000140932 CKLF-like MARVEL transmembrane domain containing 2 16 66579448-66588275 Predicted membrane proteins Evidence at transcript level Mixed Tissue enriched 1014 testis: 711.4 bone marrow: 0.7 CMTM3 BNAS2, CKLFSF3, FLJ31762 ENSG00000140931 CKLF-like MARVEL transmembrane domain containing 3 16 66603874-66613892 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013870 Approved Nucleoplasm Renal cancer:4.42e-6 (unfavourable), Stomach cancer:1.85e-4 (unfavourable) Expressed in all Expressed in all testis: 69.3 CMTM4 CKLFSF4 ENSG00000183723 CKLF-like MARVEL transmembrane domain containing 4 16 66614750-66696707 Predicted membrane proteins Evidence at protein level HPA014704, HPA023890 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:4.72e-9 (favourable) Expressed in all Tissue enhanced thyroid gland: 63.9 parathyroid gland: 47.2 CMTM5 CKLFSF5, FLJ37521 ENSG00000166091 CKLF-like MARVEL transmembrane domain containing 5 14 23376808-23379772 Predicted membrane proteins Evidence at protein level HPA052338 Supported Group enriched Tissue enriched 20 cerebral cortex: 81.5 bone marrow,seminal vesicle: 4.0 CMTM8 CKLFSF8 ENSG00000170293 CKLF-like MARVEL transmembrane domain containing 8 3 32238679-32370325 Predicted membrane proteins Evidence at protein level HPA055077, HPA073258 Approved Approved Nucleoplasm Renal cancer:2.80e-4 (favourable) Expressed in all Mixed placenta: 24.7 CMTR2 AFT, FLJ11171, FTSJD1, MTr2 ENSG00000180917 Cap methyltransferase 2 16 71281389-71289715 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041700, HPA048265 Uncertain Approved Nuclear speckles
Cell Junctions Renal cancer:4.97e-5 (favourable) Expressed in all Mixed testis: 16.2 CNEP1R1 C16orf69, FLJ38101, NEP1-R1, TMEM188 ENSG00000205423 CTD nuclear envelope phosphatase 1 regulatory subunit 1 16 50024410-50037088 Predicted membrane proteins Evidence at protein level HPA042815, HPA077906 Uncertain Supported Cytosol Expressed in all Mixed testis: 32.7 CNIH1 CNIH, CNIL, TGAM77 ENSG00000100528 Cornichon family AMPA receptor auxiliary protein 1 14 54423560-54441431 Predicted membrane proteins, Transporters Evidence at protein level HPA002544 Approved Approved Vesicles Urothelial cancer:8.95e-4 (unfavourable) Expressed in all Expressed in all liver: 118.5 CNIH4 HSPC163 ENSG00000143771 Cornichon family AMPA receptor auxiliary protein 4 1 224356850-224379459 Predicted membrane proteins Evidence at protein level HPA044268 Approved Renal cancer:4.27e-6 (unfavourable), Head and neck cancer:1.72e-4 (unfavourable), Pancreatic cancer:4.61e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 27.1 COX20 FAM36A, FLJ43269 ENSG00000203667 COX20 cytochrome c oxidase assembly factor 1 244835322-244845057 Predicted membrane proteins Evidence at protein level HPA043617, HPA045490 Approved Validated Mitochondria Ovarian cancer:3.13e-4 (favourable) Expressed in all Expressed in all adrenal gland: 46.7 COX7A2 COX7AL, COXVIIa-L ENSG00000112695 Cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 6 75237675-75250323 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:3.43e-5 (favourable) Expressed in all Expressed in all testis: 635.8 CPT1A CPT1, CPT1-L, L-CPT1 ENSG00000110090 Carnitine palmitoyltransferase 1A (liver) 11 68754620-68844410 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008835 Supported Supported Mitochondria Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable) Expressed in all Expressed in all small intestine: 80.5 CPT1B CPT1-M, M-CPT1 ENSG00000205560 Carnitine palmitoyltransferase 1B (muscle) 22 50568861-50578465 Enzymes, Predicted membrane proteins Evidence at protein level HPA029583 Approved Mixed Expressed in all heart muscle: 110.6 CPT1C CPT1P, CPTIC, FLJ23809 ENSG00000169169 Carnitine palmitoyltransferase 1C 19 49690898-49713731 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014529 Supported Approved Centrosome Pancreatic cancer:1.84e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 34.3 adrenal gland: 7.0 CSNK1A1 CK1, CK1a, CK1alpha, CKIa, CKIalpha ENSG00000113712 Casein kinase 1, alpha 1 5 149492197-149551552 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016680, HPA051334 Uncertain Approved Cytosol Colorectal cancer:1.15e-4 (favourable), Pancreatic cancer:5.79e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 230.2 CTAGE1 CT21.1, CT21.2, CTAGE, cTAGE-1, cTAGE-2 ENSG00000212710 Cutaneous T-cell lymphoma-associated antigen 1 18 22413601-22417915 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922, CAB016204 Uncertain Not detected Tissue enriched 50 testis: 5.0 all non-specific tissues: 0.0 CTD-2521M24.10 ENSG00000269035 19 17436611-17460804 Predicted membrane proteins No evidence HPA041580, HPA042010 Uncertain Uncertain Nuclear membrane Not detected Not detected all non-specific tissues: 0.0 CX3CR1 CCRL1, CMKBRL1, CMKDR1, GPR13, V28 ENSG00000168329 Chemokine (C-X3-C motif) receptor 1 3 39263494-39281735 Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB032478, HPA046587 Approved Tissue enhanced Tissue enhanced cerebral cortex: 59.4 spleen: 16.8 CYB561A3 CYBASC3 ENSG00000162144 Cytochrome b561 family, member A3 11 61348745-61362299 Predicted membrane proteins Evidence at protein level HPA052548 Uncertain Expressed in all Expressed in all adrenal gland: 188.0 CYBRD1 CYB561A2, DCYTB, FLJ23462, FRRS3 ENSG00000071967 Cytochrome b reductase 1 2 171522247-171558133 Predicted membrane proteins Evidence at protein level HPA014757, HPA056736 Approved Approved Golgi apparatus
Cytosol Expressed in all Expressed in all thyroid gland: 379.4 CYC1 UQCR4 ENSG00000179091 Cytochrome c-1 8 144095027-144097525 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA001247 Supported Supported Mitochondria Renal cancer:5.89e-6 (favourable) Expressed in all Expressed in all skeletal muscle: 242.3 CYHR1 CHRP, KIAA0496, MGC13010 ENSG00000187954 Cysteine/histidine-rich 1 8 144449582-144465677 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA053653, HPA059543 Approved Validated Nucleoplasm Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable) Expressed in all Expressed in all testis: 51.5 CYP19A1 ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM ENSG00000137869 Cytochrome P450, family 19, subfamily A, polypeptide 1 15 51208057-51338610 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000355, HPA051194 Supported Approved Vesicles Mixed Tissue enriched 14 placenta: 173.9 testis: 12.4 CYP1A2 CP12, P3-450 ENSG00000140505 Cytochrome P450, family 1, subfamily A, polypeptide 2 15 74748844-74756202 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level CAB016531 Supported Group enriched Tissue enriched 168 liver: 268.7 thyroid gland: 1.5 CYP1B1 CP1B, GLC3A ENSG00000138061 Cytochrome P450, family 1, subfamily B, polypeptide 1 2 38066973-38109902 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011705, HPA026863 Approved Uncertain Mitochondria Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:2.76e-4 (unfavourable) Expressed in all Mixed fallopian tube: 75.4 CYP2D6 CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D ENSG00000100197 Cytochrome P450, family 2, subfamily D, polypeptide 6 22 42126499-42130906 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045223 Supported Uncertain Golgi apparatus Tissue enriched Tissue enhanced liver: 11.4;small intestine: 13.2 duodenum: 3.9 CYP39A1 ENSG00000146233 Cytochrome P450, family 39, subfamily A, polypeptide 1 6 46549580-46652830 Enzymes, Predicted membrane proteins Evidence at protein level Renal cancer:1.86e-4 (favourable) Tissue enhanced Tissue enhanced liver: 56.7 epididymis: 28.4 CYP3A43 ENSG00000021461 Cytochrome P450, family 3, subfamily A, polypeptide 43 7 99828013-99866102 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066463, HPA072245 Supported Uncertain Cytosol Liver cancer:3.41e-4 (favourable) Tissue enriched Tissue enriched 14 liver: 22.4 testis: 1.5 CYP3A5 CP35, P450PCN3, PCN3 ENSG00000106258 Cytochrome P450, family 3, subfamily A, polypeptide 5 7 99648194-99679998 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Liver cancer:3.72e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 117.9;liver: 93.1;small intestine: 191.3 stomach: 79.3 CYP4F22 FLJ39501 ENSG00000171954 Cytochrome P450, family 4, subfamily F, polypeptide 22 19 15508493-15552317 Disease related genes, Predicted membrane proteins Evidence at protein level HPA058960 Uncertain Group enriched Tissue enhanced esophagus: 14.1;skin: 34.3 seminal vesicle: 9.0 CYP7B1 SPG5A ENSG00000172817 Cytochrome P450, family 7, subfamily B, polypeptide 1 8 64587763-64798761 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017761 Uncertain Mixed Tissue enhanced parathyroid gland: 39.6 thyroid gland: 22.3 DAD1 OST2 ENSG00000129562 Defender against cell death 1 14 22564905-22589269 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA028882 Uncertain Approved Cytosol Liver cancer:7.73e-4 (unfavourable) Expressed in all Expressed in all epididymis: 507.2 DDR1 CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6 ENSG00000204580 Discoidin domain receptor tyrosine kinase 1 6 30876421-30900156 CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010162, CAB025656, HPA057194 Approved Approved Nucleoplasm
Cell Junctions Renal cancer:3.31e-10 (favourable) Expressed in all Mixed cerebral cortex: 51.7 DENND4B KIAA0476 ENSG00000198837 DENN/MADD domain containing 4B 1 153929501-153946696 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040188 Approved Nucleus
Golgi apparatus Renal cancer:9.27e-9 (unfavourable), Pancreatic cancer:3.18e-5 (favourable), Liver cancer:4.14e-4 (unfavourable) Expressed in all Expressed in all spleen: 40.9 DENND4C bA513M16.3, C9orf55, C9orf55B, FLJ20686 ENSG00000137145 DENN/MADD domain containing 4C 9 19230435-19373545 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014917, HPA015096 Approved Supported Golgi apparatus
Vesicles
Cytosol Renal cancer:3.51e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 47.3 DENND5A FLJ22354, FLJ33829, FLJ43455, KIAA1091, RAB6IP1 ENSG00000184014 DENN/MADD domain containing 5A 11 9138825-9265390 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052923, HPA055009 Uncertain Approved Golgi apparatus
Vesicles Renal cancer:1.14e-6 (unfavourable), Liver cancer:5.05e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 127.2 DENND5B MGC24039 ENSG00000170456 DENN/MADD domain containing 5B 12 31382223-31591097 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038865 Approved Approved Nucleoli
Microtubules Expressed in all Mixed testis: 29.1 DERL1 DER-1, DER1, derlin-1, FLJ13784, MGC3067, PRO2577 ENSG00000136986 Derlin 1 8 123013164-123042423 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA016562, CAB037269 Supported Validated Endoplasmic reticulum Endometrial cancer:5.66e-5 (unfavourable), Renal cancer:1.58e-4 (unfavourable), Breast cancer:2.43e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 76.6 DGAT2 ENSG00000062282 Diacylglycerol O-acyltransferase 2 11 75759512-75801535 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Endometrial cancer:2.84e-4 (unfavourable) Tissue enhanced Tissue enhanced adipose tissue: 492.5;liver: 170.3 skin: 116.3 DHCR24 DCE, KIAA0018, seladin-1 ENSG00000116133 24-dehydrocholesterol reductase 1 54849633-54887218 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037247, HPA063005 Approved Endometrial cancer:1.05e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 1100.8 DHCR7 SLOS ENSG00000172893 7-dehydrocholesterol reductase 11 71428193-71452868 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA044280 Approved Supported Endoplasmic reticulum
Cytosol Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 116.0 DHRS7B CGI-93, DKFZp566O084, MGC8916, SDR32C1 ENSG00000109016 Dehydrogenase/reductase (SDR family) member 7B 17 21123364-21193265 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012132, HPA016873 Uncertain Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.4 DIP2A C21orf106, Dip2, KIAA0184 ENSG00000160305 Disco-interacting protein 2 homolog A 21 46458899-46569852 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052516 Uncertain Approved Nucleus Head and neck cancer:9.35e-5 (favourable) Expressed in all Expressed in all testis: 13.9 DNAJC25 bA16L21.2.1 ENSG00000059769 DnaJ (Hsp40) homolog, subfamily C , member 25 9 111631352-111654351 Predicted membrane proteins Evidence at protein level HPA019122 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:3.73e-4 (favourable) Expressed in all Tissue enhanced liver: 16.7 parathyroid gland: 7.8 DPM2 MGC111193, MGC21559 ENSG00000136908 Dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory subunit 9 127935099-127938484 Disease related genes, Predicted membrane proteins Evidence at protein level HPA064623 Approved Endometrial cancer:2.20e-4 (favourable), Liver cancer:7.08e-4 (unfavourable) Expressed in all Mixed stomach: 25.0 DPP4 ADCP2, CD26, DPPIV ENSG00000197635 Dipeptidyl-peptidase 4 2 161992241-162074542 CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB045970 Supported Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 542.0 placenta: 167.8 DPY19L4 ENSG00000156162 Dpy-19-like 4 (C. elegans) 8 94719703-94793836 Predicted membrane proteins Evidence at protein level HPA024780 Approved Approved Vesicles Endometrial cancer:3.73e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 36.2 DSE DSEPI, SART2 ENSG00000111817 Dermatan sulfate epimerase 6 116254173-116444860 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014764, HPA052151 Uncertain Supported Nucleoplasm
Cytosol Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable) Mixed Mixed appendix: 37.1 DSEL C18orf4, FLJ11477, NCAG1 ENSG00000171451 Dermatan sulfate epimerase-like 18 67506582-67516980 Predicted membrane proteins Evidence at protein level HPA060942 Approved Nucleoplasm
Plasma membrane Tissue enhanced Mixed cerebral cortex: 5.3 DUOXA1 FLJ32334, mol, NIP, NUMBIP ENSG00000140254 Dual oxidase maturation factor 1 15 45117367-45129938 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041578 Approved Tissue enhanced Tissue enhanced esophagus: 122.6;skin: 107.8;thyroid gland: 111.5 epididymis: 59.7 EBPL EBRP ENSG00000123179 Emopamil binding protein-like 13 49660723-49691475 Predicted membrane proteins Evidence at protein level HPA049891 Approved Supported Endoplasmic reticulum Renal cancer:7.18e-8 (unfavourable), Ovarian cancer:1.38e-4 (unfavourable) Expressed in all Expressed in all liver: 61.3 EDRF1 C10orf137, DKFZp586F1019, FLJ21617 ENSG00000107938 Erythroid differentiation regulatory factor 1 10 125719515-125764143 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031820 Approved Nucleoplasm
Centrosome
Cytosol Renal cancer:3.16e-5 (unfavourable) Expressed in all Expressed in all testis: 27.5 EI24 EPG4, PIG8, TP53I8 ENSG00000149547 Etoposide induced 2.4 11 125569216-125584687 Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047165, HPA051029 Uncertain Supported Endoplasmic reticulum
Golgi apparatus
Cytosol Pancreatic cancer:9.28e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 1098.6 liver: 124.7 EIF2AK3 PEK, PERK ENSG00000172071 Eukaryotic translation initiation factor 2-alpha kinase 3 2 88556741-88627576 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB009204, HPA015737 Approved Expressed in all Mixed parathyroid gland: 36.7 ELOVL6 FLJ23378, LCE, MGC5487 ENSG00000170522 ELOVL fatty acid elongase 6 4 110045846-110199199 Enzymes, Predicted membrane proteins Evidence at protein level HPA042355 Uncertain Colorectal cancer:6.74e-4 (favourable) Expressed in all Mixed liver: 27.9 EMC3 TMEM111 ENSG00000125037 ER membrane protein complex subunit 3 3 9962537-10011116 Predicted membrane proteins Evidence at protein level HPA042372 Approved Approved Microtubules
Cytosol Renal cancer:2.81e-6 (favourable) Expressed in all Expressed in all testis: 90.7 EMC4 FLJ90746, MGC24415, PIG17, TMEM85 ENSG00000128463 ER membrane protein complex subunit 4 15 34224999-34230156 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026868, HPA053440 Approved Approved Cell Junctions
Focal adhesion sites Expressed in all Expressed in all epididymis: 120.7 EMC6 MGC2963, TMEM93 ENSG00000127774 ER membrane protein complex subunit 6 17 3668815-3669668 Predicted membrane proteins Evidence at protein level HPA062681 Uncertain Approved Nucleus
Centrosome Lung cancer:9.39e-5 (unfavourable), Cervical cancer:7.73e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 49.2 EMP1 CL-20, TMP ENSG00000134531 Epithelial membrane protein 1 12 13196716-13219939 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051931, HPA056250 Approved Nucleoplasm Ovarian cancer:2.26e-8 (unfavourable), Urothelial cancer:9.69e-8 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable) Expressed in all Expressed in all esophagus: 2208.3 EMP3 YMP ENSG00000142227 Epithelial membrane protein 3 19 48321509-48330553 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051163 Approved Nuclear bodies Renal cancer:2.31e-7 (unfavourable), Stomach cancer:3.13e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 199.1 ENTPD3 CD39L3, HB6, NTPDase-3 ENSG00000168032 Ectonucleoside triphosphate diphosphohydrolase 3 3 40387156-40428619 Enzymes, Predicted membrane proteins Evidence at protein level HPA071802 Approved Cytosol Mixed Tissue enhanced cervix, uterine: 33.4 urinary bladder: 15.2 ENTPD4 KIAA0392, LALP70, LAP70, LYSAL1, NTPDase-4, UDPase ENSG00000197217 Ectonucleoside triphosphate diphosphohydrolase 4 8 23385783-23457695 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017655 Supported Supported Vesicles Expressed in all Expressed in all parathyroid gland: 46.4 ENTPD7 FLJ30978, LALP1 ENSG00000198018 Ectonucleoside triphosphate diphosphohydrolase 7 10 99659506-99706240 Predicted membrane proteins Evidence at protein level HPA014351 Uncertain Approved Nucleoplasm Expressed in all Mixed small intestine: 24.2 EPHA1 EPH, EPHT, EPHT1 ENSG00000146904 EPH receptor A1 7 143390289-143408892 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB026144 Approved Renal cancer:1.14e-6 (favourable) Mixed Tissue enriched 24 parathyroid gland: 861.4 esophagus: 36.4 EPHA3 ETK, ETK1, HEK, HEK4, TYRO4 ENSG00000044524 EPH receptor A3 3 89107524-89482134 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010462 Approved Uncertain Nucleoplasm
Golgi apparatus
Cytosol Renal cancer:3.28e-7 (unfavourable) Mixed Tissue enhanced prostate: 49.0 gallbladder: 29.9 EPHA4 Hek8, TYRO1 ENSG00000116106 EPH receptor A4 2 221418027-221574202 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB028368 Supported Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 41.8 testis: 22.3 EPHA5 CEK7, EHK1, Hek7, TYRO4 ENSG00000145242 EPH receptor A5 4 65319563-65670495 Enzymes, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enriched 5 cerebral cortex: 18.0 cervix, uterine: 3.3 EPHA6 FLJ35246 ENSG00000080224 EPH receptor A6 3 96814581-97752460 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007397, HPA058047 Uncertain Validated Nucleoplasm Mixed Tissue enhanced ovary: 7.7;testis: 15.1 cerebral cortex: 3.6 EPHA8 EEK, Hek3 ENSG00000070886 EPH receptor A8 1 22563564-22603594 Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009660, HPA031433 Uncertain Mixed Tissue enhanced adrenal gland: 4.9;spleen: 2.7;testis: 1.9 cerebral cortex: 1.3 EPHB2 DRT, EPHT3, ERK, Hek5, Tyro5 ENSG00000133216 EPH receptor B2 1 22710839-22921500 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013647, HPA071200 Approved Supported Nucleus
Plasma membrane Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable) Tissue enhanced Mixed rectum: 27.8 EPHB6 HEP ENSG00000106123 EPH receptor B6 7 142855061-142871094 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035784 Approved Nuclear speckles Urothelial cancer:4.68e-5 (favourable), Cervical cancer:1.80e-4 (favourable), Glioma:6.96e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 22.6;skin: 25.0 cervix, uterine: 7.5 EPSTI1 BRESI1, MGC29634 ENSG00000133106 Epithelial stromal interaction 1 (breast) 13 42886388-42992271 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017362 Approved Approved Cytosol Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable) Expressed in all Mixed appendix: 44.1 ERGIC1 ERGIC-32, ERGIC32, KIAA1181, NET24 ENSG00000113719 Endoplasmic reticulum-golgi intermediate compartment 1 5 172834275-172952685 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018666, HPA018900 Supported Validated Nucleoplasm
Vesicles Expressed in all Expressed in all prostate: 238.4 ERGIC2 Erv41, PTX1 ENSG00000087502 ERGIC and golgi 2 12 29337352-29381189 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049695 Approved Supported Nucleoli
Vesicles Renal cancer:3.76e-6 (unfavourable), Pancreatic cancer:7.02e-6 (unfavourable), Liver cancer:8.06e-6 (unfavourable), Ovarian cancer:8.18e-4 (favourable) Expressed in all Expressed in all testis: 105.6 ERGIC3 C20orf47, CGI-54, Erv46, NY-BR-84, PRO0989, SDBCAG84 ENSG00000125991 ERGIC and golgi 3 20 35542021-35557634 Predicted membrane proteins Evidence at protein level HPA015242, HPA015968 Approved Supported Nucleoplasm Liver cancer:2.20e-7 (unfavourable), Renal cancer:9.81e-5 (unfavourable) Expressed in all Expressed in all epididymis: 520.8 ERMARD C6orf70, dJ266L20.3, FLJ11152 ENSG00000130023 ER membrane-associated RNA degradation 6 169751622-169781584 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041741 Approved Approved Cytosol Expressed in all Expressed in all testis: 33.0 ERN1 IRE1, IRE1P ENSG00000178607 Endoplasmic reticulum to nucleus signaling 1 17 64039142-64130819 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009495, HPA027730 Supported Renal cancer:1.68e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 53.7 ERN2 IRE1b ENSG00000134398 Endoplasmic reticulum to nucleus signaling 2 16 23690309-23713500 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016558 Uncertain Mixed Group enriched 6 cervix, uterine: 26.7;colon: 27.8;duodenum: 12.7;gallbladder: 25.2;rectum: 23.4;small intestine: 10.1;stomach: 49.9 appendix: 3.9 ERVFRD-1 envFRD, ERVFRDE1, HERV-FRD, HERV-W/FRD, syncytin-2 ENSG00000244476 Endogenous retrovirus group FRD, member 1 6 11102489-11111732 Predicted membrane proteins Evidence at protein level Not detected Group enriched 31 parathyroid gland: 29.8;placenta: 51.4 epididymis: 1.3 ERVV-2 ENSG00000268964 Endogenous retrovirus group V, member 2 19 53044738-53051076 Predicted membrane proteins Evidence at transcript level Mixed Tissue enriched 99 placenta: 13.5 kidney,testis,thyroid gland: 0.1 ERVW-1 ERVWE1, HERV-7q, HERV-W, HERV-W-ENV, HERVW ENSG00000242950 Endogenous retrovirus group W, member 1 7 92468380-92477986 Predicted membrane proteins, Transporters Evidence at protein level Tissue enriched Tissue enriched 11 placenta: 77.1 testis: 6.7 ESYT1 FAM62A, KIAA0747, MBC2 ENSG00000139641 Extended synaptotagmin-like protein 1 12 56118250-56144671 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016858, HPA076926 Approved Supported Endoplasmic reticulum
Vesicles Renal cancer:3.86e-4 (favourable) Expressed in all Expressed in all adipose tissue: 114.2 ETNK1 EKI, EKI1 ENSG00000139163 Ethanolamine kinase 1 12 22625075-22690665 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010712, HPA029407 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable) Expressed in all Expressed in all stomach: 45.8 EVI5 NB4S ENSG00000067208 Ecotropic viral integration site 5 1 92508696-92792404 Disease related genes, Predicted membrane proteins Evidence at protein level HPA027339, HPA053724 Approved Supported Golgi apparatus
Vesicles Expressed in all Mixed parathyroid gland: 15.2 EVI5L ENSG00000142459 Ecotropic viral integration site 5-like 19 7830233-7864976 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043099, HPA043563 Approved Approved Nuclear bodies Renal cancer:2.18e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 41.7 FA2H FAAH, FAXDC1, FLJ25287, SPG35 ENSG00000103089 Fatty acid 2-hydroxylase 16 74712955-74774831 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056614, HPA077840 Approved Approved Nuclear membrane Renal cancer:5.01e-6 (favourable), Pancreatic cancer:3.74e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 51.7;stomach: 57.9 gallbladder: 28.7 FADS1 D5D, FADS6, FADSD5, LLCDL1, TU12 ENSG00000149485 Fatty acid desaturase 1 11 61799625-61829318 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042705 Approved Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 89.6 FADS2 D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13 ENSG00000134824 Fatty acid desaturase 2 11 61792980-61867354 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006741 Approved Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 416.6 FADS3 CYB5RP, LLCDL3 ENSG00000221968 Fatty acid desaturase 3 11 61873519-61892051 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045224 Approved Renal cancer:1.50e-9 (unfavourable), Head and neck cancer:9.54e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 98.7 FADS6 ENSG00000172782 Fatty acid desaturase 6 17 74877299-74893781 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA016802 Uncertain Tissue enhanced Tissue enhanced epididymis: 22.6 small intestine: 10.3 FAIM2 KIAA0950, LFG, LFG2, LIFEGUARD, NMP35, TMBIM2 ENSG00000135472 Fas apoptotic inhibitory molecule 2 12 49866896-49904217 Predicted membrane proteins Evidence at protein level HPA018790, HPA048800 Supported Approved Intermediate filaments Tissue enriched Tissue enriched 7 cerebral cortex: 370.8 adrenal gland: 56.0 FAM134B FLJ20152, JK1 ENSG00000154153 Family with sequence similarity 134, member B 5 16473038-16617058 Disease related genes, Predicted membrane proteins Evidence at protein level HPA012077 Supported Nuclear bodies
Endoplasmic reticulum Renal cancer:5.25e-10 (favourable) Expressed in all Expressed in all heart muscle: 64.0 FAM134C DKFZp686B1036, FLJ33806 ENSG00000141699 Family with sequence similarity 134, member C 17 42579513-42610623 Predicted membrane proteins Evidence at protein level HPA016492 Uncertain Approved Nucleoplasm
Nuclear membrane
Cytosol Endometrial cancer:1.61e-4 (favourable), Renal cancer:6.82e-4 (unfavourable) Expressed in all Expressed in all testis: 48.6 FAM155A ENSG00000204442 Family with sequence similarity 155, member A 13 107163510-107866735 Predicted membrane proteins Evidence at protein level HPA039453, HPA058768 Supported Approved Nucleus
Vesicles
Centrosome Mixed Tissue enriched 6 cerebral cortex: 15.6 seminal vesicle: 2.4 FAM155B CXorf63, TED, TMEM28 ENSG00000130054 Family with sequence similarity 155, member B X 69505241-69532508 Predicted membrane proteins Evidence at transcript level HPA036093 Uncertain Breast cancer:4.61e-5 (unfavourable), Prostate cancer:1.83e-4 (unfavourable), Renal cancer:6.63e-4 (favourable) Mixed Tissue enhanced heart muscle: 12.9;seminal vesicle: 8.5;thyroid gland: 16.6 cerebral cortex: 2.5 FAM189B C1orf2, cote1 ENSG00000160767 Family with sequence similarity 189, member B 1 155247205-155255483 Predicted membrane proteins Evidence at protein level HPA006659, HPA050674 Uncertain Supported Nucleoplasm Renal cancer:3.43e-7 (unfavourable), Endometrial cancer:9.59e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Cervical cancer:4.98e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 6.7 FAM198B C4orf18, DKFZp434L142, FLJ38155 ENSG00000164125 Family with sequence similarity 198, member B 4 158124474-158173318 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007227 Uncertain Approved Nucleoplasm
Nucleoli fibrillar center
Golgi apparatus Expressed in all Expressed in all adrenal gland: 272.9 FAM210B C20orf108, dJ1167H4.1, DKFZP434A1114 ENSG00000124098 Family with sequence similarity 210, member B 20 56358915-56368663 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042652 Approved Approved Plasma membrane
Cytosol Renal cancer:1.44e-10 (favourable), Lung cancer:4.26e-4 (favourable), Cervical cancer:5.44e-4 (favourable) Expressed in all Expressed in all ovary: 131.1 FAM234B KIAA1467 ENSG00000084444 Family with sequence similarity 234, member B 12 13044284-13142521 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010803 Approved Endoplasmic reticulum Expressed in all Tissue enhanced cerebral cortex: 32.5 breast: 20.5 FAR1 FLJ22728, MLSTD2, SDR10E1 ENSG00000197601 Fatty acyl CoA reductase 1 11 13668670-13732346 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017322 Approved Validated Peroxisomes Colorectal cancer:2.27e-4 (favourable) Expressed in all Expressed in all stomach: 59.0 FAXDC2 C5orf4, FLJ13758 ENSG00000170271 Fatty acid hydroxylase domain containing 2 5 154818491-154859252 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Renal cancer:9.71e-10 (favourable), Liver cancer:3.87e-5 (favourable) Expressed in all Tissue enriched 6 parathyroid gland: 381.3 ovary: 66.6 FBXL17 DKFZP434C1715, Fbl17, Fbx13, FBXO13 ENSG00000145743 F-box and leucine-rich repeat protein 17 5 107859035-108382098 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036410, HPA036411 Uncertain Approved Nucleus Renal cancer:4.60e-8 (favourable), Thyroid cancer:3.27e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 43.5 FDFT1 ENSG00000079459 Farnesyl-diphosphate farnesyltransferase 1 8 11795573-11839309 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008874 Approved Supported Endoplasmic reticulum Renal cancer:6.59e-9 (favourable), Colorectal cancer:4.92e-5 (favourable) Expressed in all Expressed in all testis: 204.4 FITM1 FIT1 ENSG00000139914 Fat storage-inducing transmembrane protein 1 14 24131275-24132849 Predicted membrane proteins Evidence at protein level HPA019842 Uncertain Liver cancer:1.00e-3 (favourable) Mixed Group enriched 14 heart muscle: 45.3;skeletal muscle: 113.0 spleen: 5.5 FLVCR2 C14orf58, FLJ20371, MFSD7C ENSG00000119686 Feline leukemia virus subgroup C cellular receptor family, member 2 14 75578617-75663214 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA037984 Supported Renal cancer:2.53e-5 (favourable) Expressed in all Tissue enhanced testis: 38.5 small intestine: 27.4 FMR1NB CT37, FLJ25736, NY-SAR-35 ENSG00000176988 Fragile X mental retardation 1 neighbor X 147981329-148026667 Predicted membrane proteins Evidence at protein level HPA011284, CAB026403 Supported Tissue enhanced Tissue enriched 420 testis: 86.4 epididymis: 0.2 FPR2 ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH2, FPRL1, HM63, LXA4R ENSG00000171049 Formyl peptide receptor 2 19 51752026-51770526 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029154 Approved Mixed Tissue enhanced appendix: 71.3 spleen: 20.0 FUT2 SE, Se2, SEC2, sej ENSG00000176920 Fucosyltransferase 2 (secretor status included) 19 48695971-48705950 Blood group antigen proteins, Enzymes, Predicted membrane proteins Evidence at transcript level HPA014402 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:5.83e-4 (favourable) Mixed Tissue enhanced duodenum: 52.9 stomach: 32.5 FXYD3 MAT-8, PLML ENSG00000089356 FXYD domain containing ion transport regulator 3 19 35115879-35124324 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010856 Supported Supported Plasma membrane Renal cancer:1.15e-6 (unfavourable) Expressed in all Tissue enhanced colon: 1480.8;rectum: 1982.1 prostate: 686.5 FXYD6-FXYD2 ENSG00000255245 FXYD6-FXYD2 readthrough 11 117820163-117876667 Predicted membrane proteins Evidence at transcript level HPA068838 Approved Not detected Tissue enhanced kidney: 5.5 salivary gland: 2.2 G6PC2 IGRP ENSG00000152254 Glucose-6-phosphatase, catalytic, 2 2 168901240-168910000 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 13 pancreas: 2.9 testis: 0.2 GABRG3 ENSG00000182256 Gamma-aminobutyric acid (GABA) A receptor, gamma 3 15 26971282-27541991 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054010 Supported Tissue enhanced Tissue enhanced prostate: 10.6;testis: 16.4 cerebral cortex: 4.2 GAL3ST4 FLJ12116 ENSG00000197093 Galactose-3-O-sulfotransferase 4 7 100159244-100168750 Predicted membrane proteins Evidence at protein level HPA038137, HPA038138 Uncertain Approved Nucleoplasm
Cytosol Ovarian cancer:2.57e-4 (unfavourable), Renal cancer:4.14e-4 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable) Expressed in all Tissue enhanced skin: 32.6 smooth muscle: 14.6 GCLC GCS, GLCL, GLCLC ENSG00000001084 Glutamate-cysteine ligase, catalytic subunit 6 53497341-53616970 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009569, HPA036359, HPA036360 Approved Approved Nucleus
Nucleoli
Cytosol Renal cancer:3.83e-6 (favourable), Thyroid cancer:8.24e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 81.9 GDAP1 CMT2K, CMT4, CMT4A ENSG00000104381 Ganglioside induced differentiation associated protein 1 8 74321130-74488872 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014266, HPA024334 Supported Supported Mitochondria
Cytosol Endometrial cancer:1.82e-4 (unfavourable), Lung cancer:2.68e-4 (favourable), Thyroid cancer:4.54e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 77.0 parathyroid gland: 18.1 GDAP1L1 ENSG00000124194 Ganglioside induced differentiation associated protein 1-like 1 20 44247099-44280917 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054182, HPA063265 Approved Approved Endoplasmic reticulum Tissue enriched Tissue enriched 20 cerebral cortex: 55.7 adrenal gland: 2.8 GDPD1 FLJ37451, GDE4 ENSG00000153982 Glycerophosphodiester phosphodiesterase domain containing 1 17 59220467-59275967 Predicted membrane proteins Evidence at protein level Lung cancer:2.98e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 28.0 testis: 19.9 GDPD3 MGC4171 ENSG00000102886 Glycerophosphodiester phosphodiesterase domain containing 3 16 30104810-30113856 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041148, HPA041470 Uncertain Approved Nucleoplasm
Cytokinetic bridge
Cytosol Renal cancer:5.89e-9 (unfavourable) Expressed in all Mixed esophagus: 23.2 GDPD5 GDE2, PP1665 ENSG00000158555 Glycerophosphodiester phosphodiesterase domain containing 5 11 75434640-75525903 Predicted membrane proteins Evidence at protein level HPA065257, HPA066762, HPA069281 Uncertain Approved Golgi apparatus Renal cancer:6.59e-9 (unfavourable), Endometrial cancer:1.29e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 68.0 testis: 31.2 GFPT1 GFA, GFAT, GFAT1, GFPT ENSG00000198380 Glutamine--fructose-6-phosphate transaminase 1 2 69319769-69387254 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047240 Approved Nucleus
Nucleoli Colorectal cancer:7.13e-5 (favourable) Expressed in all Expressed in all thyroid gland: 81.6 GFPT2 GFAT2 ENSG00000131459 Glutamine-fructose-6-phosphate transaminase 2 5 180300690-180353387 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA056892, HPA059910 Uncertain Supported Vesicles Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 89.7 appendix: 26.2 GGT6 FLJ90165 ENSG00000167741 Gamma-glutamyltransferase 6 17 4556927-4560818 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023362, HPA027213 Approved Renal cancer:9.42e-7 (favourable), Lung cancer:4.35e-4 (favourable) Mixed Mixed colon: 55.8 GGT7 D20S101, dJ18C9.2, GGTL3, GGTL5 ENSG00000131067 Gamma-glutamyltransferase 7 20 34844720-34872860 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013204, HPA013339 Approved Approved Nucleus
Vesicles Endometrial cancer:1.26e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 50.1 GIMAP2 DKFZp586D0824, HIMAP2, IAN12, IMAP2 ENSG00000106560 GTPase, IMAP family member 2 7 150685697-150693641 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013589 Approved Renal cancer:1.29e-4 (unfavourable), Breast cancer:3.50e-4 (favourable) Expressed in all Mixed lymph node: 89.2 GJC1 CX45, GJA7 ENSG00000182963 Gap junction protein, gamma 1, 45kDa 17 44798448-44830816 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA071788 Uncertain Nucleoli
Cell Junctions
Cytosol Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 43.9;placenta: 50.9;smooth muscle: 48.2 seminal vesicle: 27.0 GK GK1, GKD ENSG00000198814 Glycerol kinase X 30653359-30731456 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060687 Approved Renal cancer:3.24e-9 (favourable) Expressed in all Tissue enhanced kidney: 110.2;small intestine: 100.8 duodenum: 89.7 GK2 GKP2, GKTA ENSG00000196475 Glycerol kinase 2 4 79406352-79408293 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA060687 Uncertain Not detected Tissue enriched 1517 testis: 151.7 all non-specific tissues: 0.0 GNPTAB GNPTA, KIAA1208, MGC4170 ENSG00000111670 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 12 101745497-101830938 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017754, HPA042343 Approved Approved Vesicles Endometrial cancer:8.48e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 64.0 GOLT1B CGI-141, GOT1, YMR292W ENSG00000111711 Golgi transport 1B 12 21501781-21518408 Predicted membrane proteins Evidence at protein level HPA055909, HPA066383 Approved Approved Vesicles Renal cancer:4.83e-10 (unfavourable), Liver cancer:1.99e-8 (unfavourable), Pancreatic cancer:2.32e-4 (unfavourable) Expressed in all Expressed in all placenta: 42.1 GOSR1 GOLIM2, GOS-28, GOS28, GS28, P28 ENSG00000108587 Golgi SNAP receptor complex member 1 17 30477362-30527592 Predicted membrane proteins Evidence at protein level HPA020590 Uncertain Renal cancer:2.26e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 54.8 GPAT3 AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324 ENSG00000138678 Glycerol-3-phosphate acyltransferase 3 4 83535914-83605875 Enzymes, Predicted membrane proteins Evidence at protein level HPA029414, CAB033749 Approved Uncertain Plasma membrane
Cytosol Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable) Mixed Tissue enhanced kidney: 89.3 duodenum: 41.9 GPAT4 AGPAT6, DKFZp586M1819, LPAAT-zeta, TSARG7 ENSG00000158669 Glycerol-3-phosphate acyltransferase 4 8 41577187-41625001 Enzymes, Predicted membrane proteins Evidence at protein level HPA016471 Approved Ovarian cancer:2.20e-4 (unfavourable), Prostate cancer:4.15e-4 (favourable), Urothelial cancer:5.65e-4 (favourable), Endometrial cancer:9.37e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 78.7 GPI AMF, NLK ENSG00000105220 Glucose-6-phosphate isomerase 19 34359480-34402156 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018655, HPA024305, CAB040563, HPA052171 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 308.2 GPM6A GPM6 ENSG00000150625 Glycoprotein M6A 4 175632934-176002664 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017338 Supported Tissue enriched Tissue enriched 36 cerebral cortex: 1107.6 lung: 30.7 GPM6B M6B, MGC17150, MGC54284 ENSG00000046653 Glycoprotein M6B X 13771031-13938638 Predicted membrane proteins Evidence at protein level HPA002913 Approved Ovarian cancer:2.67e-4 (favourable) Group enriched Tissue enriched 17 cerebral cortex: 838.3 seminal vesicle: 48.9 GPR108 LUSTR2 ENSG00000125734 G protein-coupled receptor 108 19 6729914-6737603 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041924, HPA041951, HPA063863 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 73.7 GPR137 C11orf4, GPR137A, TM7SF1L1 ENSG00000173264 G protein-coupled receptor 137 11 64270062-64289500 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA062871 Uncertain Approved Nucleus
Nucleoli
Actin filaments Liver cancer:5.34e-4 (unfavourable), Pancreatic cancer:6.18e-4 (favourable) Expressed in all Expressed in all testis: 147.8 GPR160 GPCR1, GPCR150 ENSG00000173890 G protein-coupled receptor 160 3 170037929-170085403 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006970 Approved Supported Plasma membrane Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 426.5 small intestine: 111.2 GPR17 ENSG00000144230 G protein-coupled receptor 17 2 127645864-127652639 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA029766 Approved Approved Vesicles Tissue enriched Mixed spleen: 12.3 GPR18 ENSG00000125245 G protein-coupled receptor 18 13 99254714-99261744 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013873 Supported Mixed Tissue enhanced lymph node: 52.2;testis: 25.1;tonsil: 32.9 appendix: 17.0 GPRC5C RAIG-3 ENSG00000170412 G protein-coupled receptor, class C, group 5, member C 17 74424851-74451653 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029776 Supported Uncertain Nucleus
Microtubule organizing center
Cytosol Renal cancer:1.58e-5 (favourable) Expressed in all Mixed thyroid gland: 103.7 GRAMD4 DIP, KIAA0767 ENSG00000075240 GRAM domain containing 4 22 46576012-46679790 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Head and neck cancer:3.04e-4 (favourable) Expressed in all Expressed in all skin: 53.3 GRIA3 GluA3, GLUR3, GLURC, MRX94 ENSG00000125675 Glutamate receptor, ionotropic, AMPA 3 X 123184153-123490915 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA058659 Uncertain Tissue enriched Tissue enhanced cerebral cortex: 56.8 adrenal gland: 11.4 GRM2 GPRC1B, mGlu2, MGLUR2 ENSG00000164082 Glutamate receptor, metabotropic 2 3 51707070-51718613 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065166 Approved Tissue enhanced Tissue enriched 10 cerebral cortex: 4.4 testis: 0.4 GSG1L KTSR5831, MGC18079, PRO19651 ENSG00000169181 GSG1-like 16 27787535-28063509 Predicted membrane proteins, Transporters Evidence at protein level HPA014479 Approved Tissue enriched Tissue enhanced cerebral cortex: 11.7;heart muscle: 8.8 fallopian tube: 2.7 GSTCD FLJ13273 ENSG00000138780 Glutathione S-transferase, C-terminal domain containing 4 105708778-105847728 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046160, HPA061782 Approved Supported Nucleus Expressed in all Mixed testis: 18.8 GUCY2C GUC2C, STAR ENSG00000070019 Guanylate cyclase 2C 12 14612632-14696585 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA037655, HPA073759 Uncertain Uncertain Vesicles Liver cancer:1.37e-5 (unfavourable) Group enriched Group enriched 13 colon: 38.4;duodenum: 70.6;rectum: 48.1;small intestine: 74.7 appendix: 4.5 HACD2 PTPLB ENSG00000206527 3-hydroxyacyl-CoA dehydratase 2 3 123490820-123585185 Enzymes, Predicted membrane proteins Evidence at protein level CAB019282 Approved Pancreatic cancer:9.59e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 68.9 HAS3 ENSG00000103044 Hyaluronan synthase 3 16 69105564-69118719 Enzymes, Predicted membrane proteins Evidence at protein level HPA031554, CAB033850 Supported Approved Microtubules Pancreatic cancer:5.36e-4 (unfavourable) Group enriched Tissue enhanced lung: 29.9;urinary bladder: 37.7 stomach: 12.1 HEATR5A C14orf125, DKFZP434I1735 ENSG00000129493 HEAT repeat containing 5A 14 31291791-31420582 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049539 Uncertain Renal cancer:1.11e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 17.9 HEPACAM2 FLJ38683 ENSG00000188175 HEPACAM family member 2 7 93188586-93226524 Predicted membrane proteins Evidence at protein level Colorectal cancer:9.73e-5 (favourable) Mixed Tissue enhanced colon: 65.6;rectum: 104.8;small intestine: 54.7 duodenum: 31.1 HEPH CPL, KIAA0698 ENSG00000089472 Hephaestin X 66162549-66268867 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005824 Approved Renal cancer:7.00e-6 (unfavourable), Glioma:6.23e-4 (unfavourable) Expressed in all Mixed smooth muscle: 117.4 HERPUD1 HERP, KIAA0025, Mif1, SUP ENSG00000051108 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 16 56932048-56944863 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037041, CAB037104, HPA040754, HPA041219 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.41e-9 (favourable) Expressed in all Expressed in all prostate: 379.0 HHATL C3orf3, GUP1, KIAA1173, MBOAT3, MSTP002, OACT3 ENSG00000010282 Hedgehog acyltransferase-like 3 42692663-42702827 Predicted membrane proteins Evidence at protein level HPA018174 Supported Tissue enhanced Tissue enhanced heart muscle: 333.2;skeletal muscle: 97.6 cerebral cortex: 53.4 HIATL1 FLJ14753 ENSG00000148110 Hippocampus abundant transcript-like 1 9 94374551-94461042 Predicted membrane proteins, Transporters Evidence at protein level HPA017978 Approved Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 251.1 HIATL2 MGC12945 ENSG00000196312 Hippocampus abundant transcript-like 2 9 96898066-97013580 Predicted membrane proteins Evidence at transcript level Expressed in all Mixed testis: 10.4 HIGD1A DKFZP564K247, HIG1 ENSG00000181061 HIG1 hypoxia inducible domain family, member 1A 3 42784298-42804531 Predicted membrane proteins Evidence at protein level HPA043336 Approved Supported Nucleoplasm
Mitochondria Renal cancer:3.99e-8 (favourable), Colorectal cancer:2.12e-4 (favourable) Expressed in all Expressed in all rectum: 333.6 HIGD1B CLST11240, CLST11240-15 ENSG00000131097 HIG1 hypoxia inducible domain family, member 1B 17 44846353-44850480 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Expressed in all Group enriched 6 lung: 55.6;placenta: 152.3 gallbladder: 18.2 HIGD1C Gm921 ENSG00000214511 HIG1 hypoxia inducible domain family, member 1C 12 50953922-50970506 Predicted membrane proteins Evidence at transcript level Not detected Tissue enhanced testis: 3.0 parathyroid gland: 2.5 HIGD2A MGC2198 ENSG00000146066 HIG1 hypoxia inducible domain family, member 2A 5 176388747-176389771 Predicted membrane proteins Evidence at protein level HPA042715 Uncertain Supported Mitochondria
Cytosol Liver cancer:9.47e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 168.2 HIGD2B HIGD2BP ENSG00000175202 HIG1 hypoxia inducible domain family, member 2B 15 72675783-72686149 Predicted membrane proteins Evidence at protein level HPA019016, HPA042715 Uncertain Not detected Tissue enriched 14 testis: 6.7 epididymis,thyroid gland: 0.4 HLA-F ENSG00000204642 Major histocompatibility complex, class I, F 6 29722775-29738528 Plasma proteins, Predicted membrane proteins Evidence at protein level Renal cancer:2.67e-4 (unfavourable) Expressed in all Tissue enhanced lymph node: 40.6 duodenum: 28.3 HSDL1 SDR12C3 ENSG00000103160 Hydroxysteroid dehydrogenase like 1 16 84122146-84145192 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045745 Supported Mitochondria Renal cancer:4.20e-7 (favourable), Liver cancer:3.50e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 45.6 HTR2A 5-HT2A, HTR2 ENSG00000102468 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 13 46831550-46897076 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014011 Supported Not detected Tissue enriched 8 cerebral cortex: 32.3 smooth muscle: 3.8 IFI27 FAM14D, ISG12, P27 ENSG00000165949 Interferon, alpha-inducible protein 27 14 94104836-94116698 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028875 Uncertain Ovarian cancer:8.80e-4 (favourable) Expressed in all Expressed in all spleen: 743.8 IFITM1 9-27, CD225, IFI17 ENSG00000185885 Interferon induced transmembrane protein 1 11 313506-315272 CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004810, CAB017615 Supported Supported Cytosol Renal cancer:5.77e-9 (unfavourable) Expressed in all Expressed in all epididymis: 904.7 IFITM10 ENSG00000244242 Interferon induced transmembrane protein 10 11 1732410-1750591 Predicted membrane proteins Evidence at transcript level Expressed in all Tissue enhanced adrenal gland: 12.7;cerebral cortex: 12.0 seminal vesicle: 4.0 IFITM2 1-8D ENSG00000185201 Interferon induced transmembrane protein 2 11 307631-315272 Predicted membrane proteins, Transporters Evidence at protein level HPA004337 Uncertain Renal cancer:2.37e-9 (unfavourable) Expressed in all Expressed in all appendix: 722.4 IFITM3 1-8U ENSG00000142089 Interferon induced transmembrane protein 3 11 319669-327537 Predicted membrane proteins, Transporters Evidence at protein level HPA004337 Uncertain Renal cancer:5.78e-7 (unfavourable) Expressed in all Expressed in all fallopian tube: 1027.4 IFITM5 BRIL, fragilis4, Hrmp1 ENSG00000206013 Interferon induced transmembrane protein 5 11 298200-299526 Disease related genes, Predicted membrane proteins Evidence at protein level HPA039258 Uncertain Mixed Tissue enhanced epididymis: 1.1 bone marrow: 0.5 IFNAR2 IFNABR ENSG00000159110 Interferon (alpha, beta and omega) receptor 2 21 33229901-33265675 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025889 Approved Renal cancer:7.54e-7 (unfavourable) Expressed in all Expressed in all spleen: 59.7 IKZF1 hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1 ENSG00000185811 IKAROS family zinc finger 1 (Ikaros) 7 50304124-50405101 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB009247, HPA035221, HPA035222 Supported Approved Nucleoplasm
Nucleoli
Vesicles Cervical cancer:2.02e-4 (favourable), Breast cancer:4.28e-4 (favourable), Head and neck cancer:8.63e-4 (favourable) Expressed in all Tissue enhanced lymph node: 84.0;tonsil: 58.0 appendix: 55.9 IL23R IL-23R ENSG00000162594 Interleukin 23 receptor 1 67166400-67259979 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056427 Uncertain Not detected Tissue enhanced adrenal gland: 2.1;testis: 2.2 rectum: 0.9 IL9R CD129 ENSG00000124334 Interleukin 9 receptor X 155997581-156010817 CD markers, Predicted membrane proteins Evidence at protein level CAB010497 Uncertain Urothelial cancer:1.90e-7 (favourable) Tissue enhanced Tissue enhanced urinary bladder: 8.8 lymph node: 2.9 INPP4A INPP4 ENSG00000040933 Inositol polyphosphate-4-phosphatase type I A 2 98444854-98594390 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001628 Approved Approved Nucleus
Nuclear membrane Endometrial cancer:3.70e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 38.8 INPP4B ENSG00000109452 Inositol polyphosphate-4-phosphatase type II B 4 142023160-142847432 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037681, HPA037682 Approved Approved Centrosome Pancreatic cancer:1.03e-4 (unfavourable) Mixed Mixed testis: 33.1 INTS1 DKFZp586J0619, INT1, KIAA1440, NET28 ENSG00000164880 Integrator complex subunit 1 7 1470277-1504367 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021658, HPA053009 Approved Approved Nucleoplasm Liver cancer:1.66e-4 (unfavourable), Pancreatic cancer:4.83e-4 (favourable) Expressed in all Expressed in all testis: 41.9 ITPRIPL1 KIAA1754L ENSG00000198885 Inositol 1,4,5-trisphosphate receptor interacting protein-like 1 2 96325331-96330517 Predicted membrane proteins Evidence at protein level HPA017985 Uncertain Mixed Tissue enriched 6 testis: 27.3 lymph node: 4.9 IYD C6orf71, DEHAL1, dJ422F24.1 ENSG00000009765 Iodotyrosine deiodinase 6 150368892-150405969 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA059627 Supported Supported Plasma membrane Liver cancer:6.22e-4 (favourable) Tissue enriched Tissue enriched 28 thyroid gland: 792.4 kidney: 27.9 JKAMP C14orf100, CDA06, HSPC213, HSPC327, JAMP ENSG00000050130 JNK1/MAPK8-associated membrane protein 14 59484443-59505410 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA031172, HPA071650 Supported Approved Nucleoplasm
Vesicles Liver cancer:3.09e-6 (unfavourable), Renal cancer:1.36e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 74.7 KCNJ1 Kir1.1, ROMK1 ENSG00000151704 Potassium channel, inwardly rectifying subfamily J, member 1 11 128836315-128867373 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA026962 Supported Tissue enriched Tissue enriched 118 kidney: 209.0 epididymis: 1.7 KCNJ10 Kir1.2, Kir4.1 ENSG00000177807 Potassium channel, inwardly rectifying subfamily J, member 10 1 160037467-160070248 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Tissue enriched Group enriched 6 cerebral cortex: 120.1;kidney: 27.8 spleen: 13.3 KCNJ11 BIR, Kir6.2 ENSG00000187486 Potassium channel, inwardly rectifying subfamily J, member 11 11 17385859-17389331 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA048891 Approved Renal cancer:1.56e-4 (favourable) Mixed Tissue enhanced skeletal muscle: 32.7 cerebral cortex: 10.2 KCNJ13 Kir1.4, Kir7.1, LCA16 ENSG00000115474 Potassium channel, inwardly rectifying subfamily J, member 13 2 232766464-232776568 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Tissue enriched Group enriched 6 parathyroid gland: 25.4;small intestine: 114.2 thyroid gland: 12.5 KCNJ15 IRKK, Kir1.3, Kir4.2 ENSG00000157551 Potassium channel, inwardly rectifying subfamily J, member 15 21 38157034-38307357 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA016702 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 259.2;thyroid gland: 215.5 lung: 63.5 KCNJ16 BIR9, Kir5.1 ENSG00000153822 Potassium channel, inwardly rectifying subfamily J, member 16 17 70053429-70135608 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at transcript level HPA059563 Approved Uncertain Vesicles Renal cancer:9.61e-7 (favourable), Thyroid cancer:6.58e-4 (favourable) Group enriched Group enriched 7 kidney: 207.9;parathyroid gland: 268.8;thyroid gland: 233.9 seminal vesicle: 31.9 KCNJ2 IRK1, Kir2.1, LQT7 ENSG00000123700 Potassium channel, inwardly rectifying subfamily J, member 2 17 70168673-70180048 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029109 Approved Mixed Tissue enhanced parathyroid gland: 46.5 fallopian tube: 11.6 KCNJ3 GIRK1, KGA, Kir3.1 ENSG00000162989 Potassium channel, inwardly rectifying subfamily J, member 3 2 154698299-154858352 Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA024231 Uncertain Group enriched Tissue enhanced cerebral cortex: 25.5;parathyroid gland: 39.5 seminal vesicle: 14.1 KCNJ4 HIR, hIRK2, HRK1, IRK3, Kir2.3 ENSG00000168135 Potassium channel, inwardly rectifying subfamily J, member 4 22 38426327-38455199 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Tissue enhanced Group enriched 25 cerebral cortex: 41.0;heart muscle: 11.7 gallbladder: 1.0 KCNJ5 CIR, GIRK4, KATP1, Kir3.4, LQT13 ENSG00000120457 Potassium channel, inwardly rectifying subfamily J, member 5 11 128891356-128921035 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA014722, HPA017353, CAB022569 Supported Mixed Tissue enhanced adrenal gland: 85.2 spleen: 19.1 KCNJ6 BIR1, GIRK2, hiGIRK2, KATP2, KCNJ7, Kir3.2 ENSG00000157542 Potassium channel, inwardly rectifying subfamily J, member 6 21 37607376-37916446 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Not detected Tissue enriched 7 cerebral cortex: 2.6 epididymis,stomach: 0.3 KCNJ8 Kir6.1 ENSG00000121361 Potassium channel, inwardly rectifying subfamily J, member 8 12 21764955-21775581 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031066 Uncertain Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 31.6 KCNJ9 GIRK3, Kir3.3 ENSG00000162728 Potassium channel, inwardly rectifying subfamily J, member 9 1 160081570-160090563 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA070478 Supported Tissue enriched Tissue enriched 112 cerebral cortex: 52.5 adrenal gland,testis: 0.4 KCNK2 K2p2.1, TREK-1 ENSG00000082482 Potassium channel, two pore domain subfamily K, member 2 1 215005775-215237093 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA056054 Uncertain Approved Mitochondria
Cytosol Mixed Tissue enhanced adrenal gland: 75.5 thyroid gland: 17.3 KCNMA1 KCa1.1, mSLO1, SLO ENSG00000156113 Potassium channel, calcium activated large conductance subfamily M alpha, member 1 10 76869601-77638595 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA054648 Approved Mixed Tissue enhanced smooth muscle: 147.6 endometrium: 122.5 KCNMB1 hslo-beta ENSG00000145936 Potassium channel subfamily M regulatory beta subunit 1 5 170374671-170389677 Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:4.13e-6 (unfavourable) Mixed Tissue enhanced seminal vesicle: 63.6;smooth muscle: 69.0 endometrium: 41.9 KCNMB2 ENSG00000197584 Potassium channel subfamily M regulatory beta subunit 2 3 178272932-178844429 Predicted membrane proteins, Transporters Evidence at protein level CAB022649 Uncertain Mixed Tissue enhanced epididymis: 41.5;fallopian tube: 22.1;ovary: 19.0 adrenal gland: 7.6 KCNMB3 KCNMB2, KCNMBL ENSG00000171121 Potassium channel subfamily M regulatory beta subunit 3 3 179236691-179267002 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015665, HPA019185 Approved Approved Nucleus
Mitochondria Not detected Mixed placenta: 5.9 KIAA1549 ENSG00000122778 KIAA1549 7 138831381-138981318 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level HPA019560 Approved Approved Nuclear membrane
Intermediate filaments Renal cancer:3.93e-7 (favourable) Mixed Mixed seminal vesicle: 10.4 KIAA1715 LNP, LNP1, Ul, ulnaless ENSG00000144320 KIAA1715 2 175923892-176002839 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014205 Approved Supported Nucleoplasm
Endoplasmic reticulum Expressed in all Expressed in all testis: 45.8 KIR2DL4 103AS, 15.212, CD158D ENSG00000189013 Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 19 54803535-54814517 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Mixed Not detected spleen: 0.3 KLB ENSG00000134962 Klotho beta 4 39406853-39451536 Predicted membrane proteins, Transporters Evidence at protein level HPA021136 Uncertain Tissue enriched Tissue enhanced adipose tissue: 20.6;liver: 9.1 testis: 5.1 KNCN FLJ32011, KINO, L5 ENSG00000162456 Kinocilin 1 46545644-46551527 Predicted membrane proteins Evidence at transcript level HPA046357 Uncertain Not detected Not detected testis: 0.7 KRTCAP2 KCP2 ENSG00000163463 Keratinocyte associated protein 2 1 155169408-155173475 Predicted membrane proteins Evidence at protein level Renal cancer:9.70e-11 (unfavourable) Expressed in all Expressed in all epididymis: 236.5 LCLAT1 AGPAT8, ALCAT1, FLJ37965, LYCAT ENSG00000172954 Lysocardiolipin acyltransferase 1 2 30447226-30644225 Enzymes, Predicted membrane proteins Evidence at protein level HPA031880, HPA049217 Uncertain Supported Endoplasmic reticulum
Cytosol Liver cancer:8.72e-4 (unfavourable), Head and neck cancer:9.67e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 19.2 LEMD2 dJ482C21.1, NET25 ENSG00000161904 LEM domain containing 2 6 33771202-33789136 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017340 Approved Validated Nuclear membrane Renal cancer:1.12e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 68.5 LEMD3 MAN1 ENSG00000174106 LEM domain containing 3 12 65169571-65248327 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA025078, HPA076986 Uncertain Supported Nuclear membrane Renal cancer:2.30e-4 (favourable) Expressed in all Expressed in all testis: 28.8 LEPR CD295, OBR ENSG00000116678 Leptin receptor 1 65420652-65641559 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030899 Approved Vesicles Tissue enriched Mixed liver: 69.9 LEPROTL1 my047, Vps55 ENSG00000104660 Leptin receptor overlapping transcript-like 1 8 30095398-30177208 Predicted membrane proteins Evidence at protein level HPA047911 Uncertain Renal cancer:1.94e-5 (unfavourable), Colorectal cancer:9.04e-4 (favourable) Expressed in all Expressed in all placenta: 119.4 LETMD1 HCCR1 ENSG00000050426 LETM1 domain containing 1 12 51047962-51060424 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA074361 Supported Nucleoplasm
Mitochondria Urothelial cancer:3.16e-4 (favourable), Renal cancer:3.26e-4 (favourable) Expressed in all Expressed in all thyroid gland: 61.5 LILRB1 CD85, CD85j, ILT2, LIR-1, LIR1, MIR-7 ENSG00000104972 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 19 54617158-54637528 Predicted membrane proteins Evidence at transcript level Renal cancer:3.08e-6 (unfavourable) Mixed Tissue enhanced appendix: 9.1;lymph node: 6.3;spleen: 10.1 smooth muscle: 3.7 LMBR1L FLJ10494, KIAA1174 ENSG00000139636 Limb development membrane protein 1-like 12 49096551-49110900 Predicted membrane proteins Evidence at protein level Renal cancer:4.45e-7 (unfavourable), Colorectal cancer:1.04e-4 (unfavourable), Pancreatic cancer:3.50e-4 (favourable) Expressed in all Tissue enhanced testis: 27.5 endometrium: 9.0 LPCAT2 AGPAT11, AYTL1, FLJ20481, LysoPAFAT ENSG00000087253 Lysophosphatidylcholine acyltransferase 2 16 55508998-55586670 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007891, HPA008433 Supported Supported Validated Endoplasmic reticulum
Lipid droplets Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 141.9 bone marrow: 56.6 LPCAT4 AGPAT7, AYTL3, FLJ10257, LPAAT-eta, LPEAT2 ENSG00000176454 Lysophosphatidylcholine acyltransferase 4 15 34358618-34367278 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030719 Uncertain Liver cancer:9.99e-4 (unfavourable) Expressed in all Mixed rectum: 39.2 LRRC37B ENSG00000185158 Leucine rich repeat containing 37B 17 32007872-32053504 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015134, HPA015135 Approved Approved Cytosol Mixed Tissue enhanced testis: 32.4 bone marrow: 16.5 LRRC55 FLJ45686 ENSG00000183908 Leucine rich repeat containing 55 11 57181747-57191717 Predicted membrane proteins, Transporters Evidence at protein level HPA014053 Uncertain Group enriched Tissue enhanced cerebral cortex: 6.6 lymph node: 2.4 LRRC8B KIAA0231, TA-LRRP ENSG00000197147 Leucine rich repeat containing 8 family, member B 1 89524836-89597864 Predicted membrane proteins, Transporters Evidence at protein level HPA017950 Uncertain Approved Nuclear speckles Colorectal cancer:7.15e-4 (favourable), Endometrial cancer:9.99e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 38.3 testis: 30.6 LRRC8D FLJ10470, LRRC5 ENSG00000171492 Leucine rich repeat containing 8 family, member D 1 89821014-89936611 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014745 Approved Nucleoplasm
Mitochondria Endometrial cancer:3.21e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 36.0 LRRC8E FLJ23420 ENSG00000171017 Leucine rich repeat containing 8 family, member E 19 7888505-7902021 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020466 Uncertain Mixed Mixed skin: 11.2 LSR ILDR3, LISCH7 ENSG00000105699 Lipolysis stimulated lipoprotein receptor 19 35248330-35267964 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007270 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.09e-4 (favourable) Expressed in all Expressed in all stomach: 131.1 LTB4R BLTR, CMKRL1, GPR16, LTB4R1, P2RY7, P2Y7 ENSG00000213903 Leukotriene B4 receptor 14 24311450-24318036 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003873 Approved Renal cancer:3.44e-15 (unfavourable), Pancreatic cancer:1.85e-4 (favourable) Expressed in all Tissue enhanced skin: 165.5 esophagus: 42.8 LTC4S MGC33147 ENSG00000213316 Leukotriene C4 synthase 5 179793980-179796647 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level Not detected Mixed fallopian tube: 7.4 MADD DENN, KIAA0358, RAB3GEP ENSG00000110514 MAP-kinase activating death domain 11 47269161-47330031 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038568 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 104.2 MAL ENSG00000172005 Mal, T-cell differentiation protein 2 95025677-95053996 Predicted membrane proteins Evidence at protein level HPA065691 Approved Centrosome Renal cancer:3.96e-9 (favourable), Endometrial cancer:5.18e-6 (unfavourable) Mixed Tissue enriched 7 esophagus: 2459.4 tonsil: 328.8 MAL2 ENSG00000147676 Mal, T-cell differentiation protein 2 (gene/pseudogene) 8 119165034-119245673 Predicted membrane proteins Evidence at protein level HPA043831 Uncertain Breast cancer:4.57e-6 (unfavourable), Renal cancer:2.39e-5 (favourable), Endometrial cancer:8.44e-5 (unfavourable), Pancreatic cancer:3.98e-4 (unfavourable) Expressed in all Mixed esophagus: 267.5 MARCH1 FLJ20668, MARCH-I, RNF171 ENSG00000145416 Membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase 4 163524298-164384050 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014600 Uncertain Supported Mitochondria Mixed Mixed lymph node: 36.5 MARCH11 MARCH-XI ENSG00000183654 Membrane-associated ring finger (C3HC4) 11 5 16067139-16180762 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA077262 Uncertain Vesicles Not detected Tissue enriched 20 testis: 89.9 cerebral cortex: 4.5 MARCH2 HSPC240, MARCH-II, RNF172 ENSG00000099785 Membrane-associated ring finger (C3HC4) 2, E3 ubiquitin protein ligase 19 8413270-8439017 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014063 Approved Uncertain Cytosol Endometrial cancer:1.05e-5 (favourable), Pancreatic cancer:6.21e-4 (favourable), Colorectal cancer:6.48e-4 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Expressed in all Expressed in all epididymis: 63.9 MARCH3 MARCH-III, MGC48332, RNF173 ENSG00000173926 Membrane-associated ring finger (C3HC4) 3, E3 ubiquitin protein ligase 5 126867714-127030808 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043406 Uncertain Mixed Mixed testis: 10.9 MARCH4 KIAA1399, MARCH-IV, RNF174 ENSG00000144583 Membrane-associated ring finger (C3HC4) 4, E3 ubiquitin protein ligase 2 216257865-216372027 Predicted membrane proteins Evidence at protein level HPA014348 Approved Mixed Tissue enriched 6 cerebral cortex: 9.1 stomach: 1.6 MARCH8 c-MIR, CMIR, MARCH-VIII, MIR, RNF178 ENSG00000165406 Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase 10 45454585-45594906 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014597 Approved Pancreatic cancer:2.71e-4 (favourable), Renal cancer:6.64e-4 (favourable) Expressed in all Expressed in all testis: 104.3 MARCH9 FLJ36578, RNF179 ENSG00000139266 Membrane-associated ring finger (C3HC4) 9 12 57755098-57760407 Predicted membrane proteins Evidence at protein level Lung cancer:1.54e-5 (favourable), Renal cancer:2.98e-5 (favourable), Ovarian cancer:1.59e-4 (favourable), Endometrial cancer:3.07e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 29.7 MARVELD2 DFNB49, FLJ30532, MRVLDC2, TRIC ENSG00000152939 MARVEL domain containing 2 5 69415112-69444330 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018119, HPA061726 Uncertain Supported Cell Junctions Renal cancer:2.84e-13 (favourable) Mixed Tissue enhanced thyroid gland: 19.7 small intestine: 8.9 MCOLN1 ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1 ENSG00000090674 Mucolipin 1 19 7522626-7534009 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031763, CAB032637 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable) Expressed in all Expressed in all spleen: 49.0 MCOLN3 FLJ11006, TRP-ML3, TRPML3 ENSG00000055732 Mucolipin 3 1 85018082-85048499 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA018106, HPA062137 Approved Approved Nucleoli
Cytosol Tissue enriched Tissue enhanced adrenal gland: 57.9;parathyroid gland: 42.1 epididymis: 17.3 MCTP1 FLJ22344 ENSG00000175471 Multiple C2 domains, transmembrane 1 5 94703741-95284575 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019018 Uncertain Approved Nucleoplasm
Cytosol Mixed Mixed bone marrow: 29.1 MCTP2 FLJ11175, FLJ33303 ENSG00000140563 Multiple C2 domains, transmembrane 2 15 94231538-94483952 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051176, HPA070541 Uncertain Validated Nucleoplasm
Cytosol Renal cancer:2.18e-5 (unfavourable) Mixed Mixed placenta: 28.3 MCU C10orf42, CCDC109A, FLJ46135 ENSG00000156026 Mitochondrial calcium uniporter 10 72692131-72887694 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016480 Approved Supported Mitochondria Liver cancer:6.06e-5 (unfavourable), Renal cancer:5.07e-4 (favourable) Expressed in all Expressed in all stomach: 41.1 MED24 CRSP100, CRSP4, DRIP100, KIAA0130, MED5, THRAP4, TRAP100 ENSG00000008838 Mediator complex subunit 24 17 40019097-40061215 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Expressed in all Expressed in all testis: 64.2 METTL21A FAM119A, HCA557b, HSPA-KMT, LOC151194 ENSG00000144401 Methyltransferase like 21A 2 207580631-207625928 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034712 Uncertain Approved Nucleus
Cytosol Liver cancer:1.87e-5 (unfavourable), Renal cancer:5.43e-4 (unfavourable) Expressed in all Expressed in all spleen: 22.4 MFSD1 FLJ14153, UG0581B09 ENSG00000118855 Major facilitator superfamily domain containing 1 3 158732198-158829719 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057924, HPA065858 Approved Approved Nucleus
Nucleoli Renal cancer:5.60e-5 (favourable) Expressed in all Expressed in all spleen: 35.8 MFSD11 FLJ20226, FLJ22196 ENSG00000092931 Major facilitator superfamily domain containing 11 17 76735865-76781449 Predicted membrane proteins Evidence at protein level HPA022001 Uncertain Approved Nuclear speckles Endometrial cancer:7.69e-4 (unfavourable), Urothelial cancer:7.90e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 33.9 MFSD12 C19orf28, MGC20700, PP3501 ENSG00000161091 Major facilitator superfamily domain containing 12 19 3538261-3574290 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042149, HPA043088 Uncertain Approved Nucleoplasm
Mitochondria Endometrial cancer:5.66e-6 (favourable), Lung cancer:2.34e-4 (unfavourable), Liver cancer:6.61e-4 (unfavourable), Stomach cancer:7.70e-4 (favourable) Tissue enriched Expressed in all skin: 64.2 MFSD6 FLJ20160 ENSG00000151690 Major facilitator superfamily domain containing 6 2 190408355-190509205 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022274 Approved Approved Nucleoplasm
Actin filaments
Cytosol Renal cancer:1.05e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 79.2 MGST2 MGST-II ENSG00000085871 Microsomal glutathione S-transferase 2 4 139665768-139740745 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010707 Approved Approved Nucleoplasm Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable) Expressed in all Expressed in all liver: 177.4 MIA3 FLJ39207, KIAA0268, TANGO, UNQ6077 ENSG00000154305 Melanoma inhibitory activity family, member 3 1 222618086-222668012 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055922, HPA056816 Supported Validated Vesicles Renal cancer:3.73e-4 (unfavourable) Expressed in all Expressed in all testis: 80.7 MICAL2 KIAA0750 ENSG00000133816 Microtubule associated monooxygenase, calponin and LIM domain containing 2 11 12094008-12263789 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030437 Approved Approved Golgi apparatus Renal cancer:3.63e-5 (unfavourable) Expressed in all Mixed testis: 80.0 MICAL3 KIAA0819 ENSG00000243156 Microtubule associated monooxygenase, calponin and LIM domain containing 3 22 17787649-18024559 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000639, HPA003421, HPA034882 Uncertain Validated Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 69.7 MOG BTN6, BTNL11 ENSG00000204655 Myelin oligodendrocyte glycoprotein 6 29656981-29672372 Disease related genes, Predicted membrane proteins Evidence at protein level HPA021873 Supported Tissue enriched Not detected cerebral cortex: 0.9 MOSPD1 dJ473B4 ENSG00000101928 Motile sperm domain containing 1 X 134887626-134915267 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031158 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all fallopian tube: 41.8 MOSPD3 CDS3, NET30 ENSG00000106330 Motile sperm domain containing 3 7 100612102-100615384 Predicted membrane proteins Evidence at protein level HPA041137, HPA048240 Uncertain Approved Nucleoplasm
Cytosol Expressed in all Expressed in all testis: 29.7 MPDU1 CDGIf, Lec35, PQLC5, SL15 ENSG00000129255 Mannose-P-dolichol utilization defect 1 17 7583529-7592789 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014845 Uncertain Supported Endoplasmic reticulum
Mitochondria Expressed in all Expressed in all rectum: 70.2 MPPE1 ENSG00000154889 Metallophosphoesterase 1 18 11882622-11909223 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012639 Uncertain Approved Nucleoplasm
Golgi apparatus Renal cancer:6.45e-7 (favourable), Melanoma:1.35e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 77.6 MPV17 SYM1 ENSG00000115204 MpV17 mitochondrial inner membrane protein 2 27309492-27325680 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Liver cancer:6.99e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 84.1 MPV17L2 FKSG24, MGC12972 ENSG00000254858 MPV17 mitochondrial membrane protein-like 2 19 18193182-18196948 Predicted membrane proteins Evidence at protein level HPA043111 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.30e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 16.2 MRS2 MRS2L ENSG00000124532 MRS2 magnesium transporter 6 24402908-24426194 Predicted membrane proteins Evidence at protein level HPA017642 Uncertain Ovarian cancer:5.14e-11 (favourable), Endometrial cancer:5.32e-4 (unfavourable), Thyroid cancer:8.03e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 29.8 MS4A1 B1, Bp35, CD20, MS4A2 ENSG00000156738 Membrane-spanning 4-domains, subfamily A, member 1 11 60455752-60470760 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000015, HPA014341, HPA014391 Supported Breast cancer:4.34e-5 (favourable) Mixed Group enriched 15 appendix: 249.3;lymph node: 780.6;spleen: 476.2;tonsil: 821.5 urinary bladder: 39.8 MS4A12 FLJ20217, Ms4a10 ENSG00000071203 Membrane-spanning 4-domains, subfamily A, member 12 11 60492778-60507430 Predicted membrane proteins Evidence at protein level HPA057657 Supported Tissue enriched Group enriched 19 colon: 239.6;rectum: 284.9 appendix: 14.0 MS4A13 ENSG00000204979 Membrane-spanning 4-domains, subfamily A, member 13 11 60515413-60542721 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA045017, HPA063626 Uncertain Not detected Tissue enriched 54 testis: 5.3 all non-specific tissues: 0.0 MS4A15 ENSG00000166961 Membrane-spanning 4-domains, subfamily A, member 15 11 60756953-60776732 Predicted membrane proteins Evidence at transcript level Tissue enhanced Tissue enriched 11 lung: 71.5 endometrium: 6.2 MS4A2 APY, FCER1B, IGER, MS4A1 ENSG00000149534 Membrane-spanning 4-domains, subfamily A, member 2 11 60088261-60098466 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059967 Supported Mixed Tissue enhanced lung: 24.8 gallbladder: 18.5 MS4A3 CD20L, HTM4 ENSG00000149516 Membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) 11 60056587-60071128 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019210 Supported Not detected Tissue enriched 254 bone marrow: 305.8 spleen: 1.2 MS4A4E ENSG00000214787 Membrane-spanning 4-domains, subfamily A, member 4E 11 60201253-60243088 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040075 Uncertain Mixed Mixed adipose tissue,gallbladder: 5.8 MS4A6E ENSG00000166926 Membrane-spanning 4-domains, subfamily A, member 6E 11 60334831-60396596 Predicted membrane proteins Evidence at transcript level HPA076623 Approved Vesicles Not detected Tissue enriched 36 testis: 61.4 appendix: 1.6 MS4A7 CD20L4, CFFM4, MS4A8 ENSG00000166927 Membrane-spanning 4-domains, subfamily A, member 7 11 60378482-60395951 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017418, CAB026387 Approved Expressed in all Tissue enhanced spleen: 321.1 lung: 125.3 MT-CO2 CO2, COX2, MTCO2 ENSG00000198712 Mitochondrially encoded cytochrome c oxidase II MT 7586-8269 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB016243, HPA051505, HPA054758 Supported Liver cancer:2.89e-4 (favourable), Pancreatic cancer:7.10e-4 (favourable) Expressed in all Expressed in all heart muscle: 42147.3 MTCH1 CGI-64, PSAP, SLC25A49 ENSG00000137409 Mitochondrial carrier 1 6 36968141-36986298 Predicted membrane proteins, Transporters Evidence at protein level HPA015971 Approved Renal cancer:1.16e-7 (favourable), Liver cancer:1.17e-4 (unfavourable), Endometrial cancer:2.06e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 568.7 MTFP1 HSPC242, MTP18 ENSG00000242114 Mitochondrial fission process 1 22 30425530-30429053 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA077396 Approved Mitochondria Expressed in all Expressed in all epididymis: 18.7 MTX1 MTX, MTXN ENSG00000173171 Metaxin 1 1 155208699-155213824 Predicted membrane proteins Evidence at protein level HPA011543 Uncertain Supported Mitochondria Renal cancer:3.39e-4 (unfavourable) Expressed in all Expressed in all testis: 71.3 NAA25 C12orf30, FLJ13089 ENSG00000111300 N(alpha)-acetyltransferase 25, NatB auxiliary subunit 12 112026689-112109022 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039322 Approved Supported Golgi apparatus
Cytosol Renal cancer:1.32e-8 (unfavourable), Liver cancer:5.53e-5 (unfavourable), Endometrial cancer:2.26e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 9.4 NAT14 KLP1 ENSG00000090971 N-acetyltransferase 14 (GCN5-related, putative) 19 55485004-55487568 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047187 Approved Mitochondria Renal cancer:3.61e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 26.8 NAT8 ATase2, GLA, Hcml1, TSC501 ENSG00000144035 N-acetyltransferase 8 (GCN5-related, putative) 2 73640832-73642393 Enzymes, Predicted membrane proteins Evidence at protein level CAB045990, HPA074519 Uncertain Approved Endoplasmic reticulum Tissue enriched Tissue enriched 18 kidney: 885.6 liver: 49.4 NCAM2 MGC51008, NCAM21 ENSG00000154654 Neural cell adhesion molecule 2 21 20998315-21543329 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA030900, HPA030901 Approved Supported Nuclear bodies
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 69.0 adrenal gland: 15.9 NCKAP1 HEM2, Nap1, NAP125 ENSG00000061676 NCK-associated protein 1 2 182909115-183038858 Predicted membrane proteins Evidence at protein level HPA020449 Approved Approved Cytosol Pancreatic cancer:3.81e-4 (unfavourable), Lung cancer:9.71e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 145.6 NCKAP1L HEM1 ENSG00000123338 NCK-associated protein 1-like 12 54497711-54548238 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA039490, HPA040772 Approved Uncertain Plasma membrane
Cytosol Expressed in all Mixed spleen: 55.8 NCKIPSD AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH ENSG00000213672 NCK interacting protein with SH3 domain 3 48673844-48686364 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB019267, HPA050005 Validated Plasma membrane
Cytosol Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 300.2 cerebral cortex: 35.1 NDFIP2 KIAA1165, N4wbp5a ENSG00000102471 Nedd4 family interacting protein 2 13 79481124-79556075 Predicted membrane proteins Evidence at protein level HPA009160 Uncertain Validated Vesicles Renal cancer:4.18e-5 (favourable), Head and neck cancer:5.99e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 96.3 NINJ1 NIN1 ENSG00000131669 Ninjurin 1 9 93121489-93134288 Predicted membrane proteins Evidence at protein level HPA045063 Uncertain Expressed in all Expressed in all bone marrow: 158.5 NINJ2 ENSG00000171840 Ninjurin 2 12 564296-663779 Predicted membrane proteins Evidence at protein level HPA058980 Approved Endoplasmic reticulum Head and neck cancer:5.31e-4 (favourable) Expressed in all Tissue enhanced lung: 55.8 bone marrow: 24.0 NKAIN1 FAM77C, FLJ12650 ENSG00000084628 Na+/K+ transporting ATPase interacting 1 1 31179745-31239554 Predicted membrane proteins Evidence at transcript level HPA006873 Uncertain Group enriched Tissue enhanced adrenal gland: 13.9;cerebral cortex: 13.1;skeletal muscle: 7.4 epididymis: 4.4 NKAIN4 bA261N11.2, C20orf58, FAM77A ENSG00000101198 Na+/K+ transporting ATPase interacting 4 20 63240784-63272694 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA029876 Approved Endometrial cancer:3.14e-4 (unfavourable) Tissue enriched Tissue enriched 13 cerebral cortex: 71.9 kidney: 5.5 NKG7 GIG1, GMP-17 ENSG00000105374 Natural killer cell granule protein 7 19 51371606-51372715 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071454 Approved Vesicles Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable) Expressed in all Tissue enhanced bone marrow: 352.2;spleen: 153.8 lymph node: 124.8 NKPD1 FLJ33600 ENSG00000179846 NTPase, KAP family P-loop domain containing 1 19 45149750-45160150 Predicted membrane proteins Evidence at protein level HPA043339 Uncertain Mixed Tissue enriched 18 skin: 13.9 breast,seminal vesicle: 0.7 NOX4 KOX, KOX-1 ENSG00000086991 NADPH oxidase 4 11 89324356-89498187 Predicted membrane proteins, Transporters Evidence at protein level HPA015475 Uncertain Approved Nucleus Renal cancer:6.14e-4 (favourable) Mixed Tissue enriched 12 kidney: 133.6 parathyroid gland: 10.7 NPC1 ENSG00000141458 Niemann-Pick disease, type C1 18 23506184-23586898 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA026618, CAB070132 Approved Liver cancer:2.26e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 110.9 NPIPB11 ENSG00000254206 Nuclear pore complex interacting protein family, member B11 16 29381354-29404029 Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Mixed parathyroid gland: 14.2 NPIPB3 KIAA0220, NPIPL3 ENSG00000169246 Nuclear pore complex interacting protein family, member B3 16 21402237-21448567 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Expressed in all skin: 229.8 NPIPB4 ENSG00000185864 Nuclear pore complex interacting protein family, member B4 16 21834569-21880827 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Expressed in all skin: 125.9 NPIPB5 ENSG00000243716 Nuclear pore complex interacting protein family, member B5 16 22479121-22536521 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Expressed in all skin: 271.1 NPIPB6 ENSG00000198156 Nuclear pore complex interacting protein family, member B6 16 28342555-28363508 Predicted membrane proteins Evidence at protein level HPA011188, HPA053611 Approved Approved Nucleoplasm Not detected Tissue enriched 23 testis: 54.7 skin: 2.3 NPSR1 GPR154, GPRA, PGR14 ENSG00000187258 Neuropeptide S receptor 1 7 34658239-34878332 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007489 Supported Tissue enhanced Not detected stomach: 0.5 NPY1R NPYR ENSG00000164128 Neuropeptide Y receptor Y1 4 163323961-163344832 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029903 Approved Nucleus
Mitochondria
Cytosol Breast cancer:7.68e-5 (favourable) Tissue enriched Tissue enhanced spleen: 153.9 breast: 39.0 NRG3 ENSG00000185737 Neuregulin 3 10 81875314-82987179 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level Group enriched Tissue enhanced cerebral cortex: 30.4 fallopian tube: 7.3 NRSN1 p24, VMP ENSG00000152954 Neurensin 1 6 24126122-24154900 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA061006 Approved Approved Nucleus
Vesicles Tissue enriched Tissue enriched 14 cerebral cortex: 96.7 adrenal gland: 6.7 NRSN2 C20orf98, dJ1103G7.6 ENSG00000125841 Neurensin 2 20 346782-359660 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015967 Approved Approved Nucleoplasm
Vesicles
Cytosol Pancreatic cancer:1.61e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 126.5 parathyroid gland: 68.4 NUP210L ENSG00000143552 Nucleoporin 210kDa-like 1 153992685-154155116 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA047195, HPA064245, HPA066707 Supported Approved Nuclear bodies Not detected Tissue enriched 93 testis: 47.5 seminal vesicle: 0.5 OCIAD1 Asrij, FLJ20455, OCIA, TPA018 ENSG00000109180 OCIA domain containing 1 4 48805212-48861817 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044803 Approved Approved Mitochondria Expressed in all Expressed in all cerebral cortex: 326.5 ODF4 CT136, OPPO1 ENSG00000184650 Outer dense fiber of sperm tails 4 17 8339864-8346046 Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 56 testis: 21.1 esophagus: 0.3 OMA1 FLJ33782, MPRP-1, YKR087C, ZMPOMA1 ENSG00000162600 OMA1 zinc metallopeptidase 1 58415384-58546802 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055120 Approved Approved Nucleoplasm
Mitochondria Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable) Expressed in all Expressed in all prostate: 32.2 OPA3 FLJ22187, MGA3 ENSG00000125741 Optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) 19 45527427-45602212 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044881 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:9.30e-12 (favourable), Liver cancer:5.60e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 18.0 OPN1LW CBBM, CBP, COD5, RCP ENSG00000102076 Opsin 1 (cone pigments), long-wave-sensitive X 154144224-154159032 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Not detected Not detected testis: 0.1 OPN1MW CBBM, CBD, COD5, GCP, OPN1MW1 ENSG00000268221 Opsin 1 (cone pigments), medium-wave-sensitive X 154182596-154196135 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level Not detected Not detected appendix: 0.2 OPN1MW2 ENSG00000166160 Opsin 1 (cone pigments), medium-wave-sensitive 2 X 154219756-154233286 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level Not detected Not detected all non-specific tissues: 0.0 OR51E2 PSGR ENSG00000167332 Olfactory receptor, family 51, subfamily E, member 2 11 4680171-4697854 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at transcript level Tissue enriched Tissue enriched 7 prostate: 38.9 placenta: 5.8 ORAI3 MGC13024, TMEM142C ENSG00000175938 ORAI calcium release-activated calcium modulator 3 16 30949066-30956461 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015022 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:3.87e-5 (unfavourable) Expressed in all Expressed in all prostate: 26.7 ORMDL1 ENSG00000128699 ORMDL sphingolipid biosynthesis regulator 1 2 189770323-189784371 Predicted membrane proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Renal cancer:5.84e-9 (unfavourable), Urothelial cancer:1.49e-5 (favourable), Ovarian cancer:3.04e-5 (favourable) Expressed in all Expressed in all epididymis: 153.1 ORMDL2 adoplin-2, HSPC160, MST095, MSTP095 ENSG00000123353 ORMDL sphingolipid biosynthesis regulator 2 12 55817919-55821879 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Endometrial cancer:3.30e-5 (favourable), Liver cancer:9.75e-4 (unfavourable) Expressed in all Expressed in all epididymis: 62.1 ORMDL3 ENSG00000172057 ORMDL sphingolipid biosynthesis regulator 3 17 39921041-39927601 Disease related genes, Predicted membrane proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Urothelial cancer:5.18e-4 (favourable), Lung cancer:9.29e-4 (favourable) Expressed in all Expressed in all adipose tissue: 165.1 OXA1L MGC133129, OXA1 ENSG00000155463 Oxidase (cytochrome c) assembly 1-like 14 22766522-22773041 Predicted membrane proteins, Transporters Evidence at protein level HPA003531 Approved Supported Mitochondria Renal cancer:4.82e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 139.8 P2RX1 P2X1 ENSG00000108405 Purinergic receptor P2X, ligand gated ion channel, 1 17 3896592-3916500 Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced seminal vesicle: 45.7;urinary bladder: 43.2 bone marrow: 26.3 P2RX2 DFNA41, P2X2 ENSG00000187848 Purinergic receptor P2X, ligand gated ion channel, 2 12 132618780-132622386 Disease related genes, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced epididymis: 26.2;seminal vesicle: 12.6 prostate: 9.0 P2RX3 P2X3 ENSG00000109991 Purinergic receptor P2X, ligand gated ion channel, 3 11 57338374-57370600 Predicted membrane proteins, Transporters Evidence at transcript level HPA057776 Uncertain Not detected Tissue enhanced heart muscle: 2.0;testis: 6.1 liver: 0.9 P2RX4 P2X4 ENSG00000135124 Purinergic receptor P2X, ligand gated ion channel, 4 12 121209857-121234106 Predicted membrane proteins, Transporters Evidence at protein level HPA039494 Approved Approved Actin filaments
Cytosol Endometrial cancer:6.30e-10 (favourable) Expressed in all Mixed placenta: 33.5 P2RX6 MGC129625, P2RXL1, P2X6, P2XM ENSG00000099957 Purinergic receptor P2X, ligand gated ion channel, 6 22 21009808-21028830 Predicted membrane proteins Evidence at protein level HPA028776, HPA028777 Approved Approved Nucleoli
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 3.4 skeletal muscle: 3.0 P2RX7 MGC20089, P2X7 ENSG00000089041 Purinergic receptor P2X, ligand gated ion channel, 7 12 121132819-121188032 Predicted membrane proteins, Transporters Evidence at protein level HPA034968, HPA042013, HPA044141 Approved Renal cancer:2.92e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.1 P2RY14 GPR105, KIAA0001 ENSG00000174944 Purinergic receptor P2Y, G-protein coupled, 14 3 151212117-151278467 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level CAB022646 Uncertain Renal cancer:1.72e-5 (unfavourable) Mixed Tissue enhanced placenta: 45.4 esophagus: 23.4 PARVB CGI-56 ENSG00000188677 Parvin, beta 22 43999211-44172949 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062601 Approved Cytosol Expressed in all Expressed in all skeletal muscle: 68.6 PCDH11Y PCDH22, PCDHY ENSG00000099715 Protocadherin 11 Y-linked Y 5000226-5742224 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000432 Uncertain Not detected Tissue enriched 6 cerebral cortex: 4.4 placenta,seminal vesicle: 0.7 PCDH20 FLJ22218, PCDH13 ENSG00000280165 Protocadherin 20 13 61409685-61415522 Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced cerebral cortex: 14.6;smooth muscle: 12.8 lung: 5.0 PCDHA10 CNR8, CNRN8, CNRS8, CRNR8, PCDH-ALPHA10 ENSG00000250120 Protocadherin alpha 10 5 140855883-141012344 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level Mixed Tissue enhanced cerebral cortex: 17.5 thyroid gland: 4.2 PCDHGA9 PCDH-GAMMA-A9 ENSG00000261934 Protocadherin gamma subfamily A, 9 5 141402932-141512979 Predicted membrane proteins Evidence at protein level HPA008755 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 9.6 endometrium: 4.1 PCDHGC3 PC-43, PC43, PCDH-GAMMA-C3, PCDH2 ENSG00000240184 Protocadherin gamma subfamily C, 3 5 141475947-141512979 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008755, HPA077289 Approved Approved Plasma membrane Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 377.1 cervix, uterine: 93.4 PCSK7 LPC, PC7, PC8, SPC7 ENSG00000160613 Proprotein convertase subtilisin/kexin type 7 11 117204337-117232525 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043181, HPA052957 Uncertain Nucleus
Nuclear membrane
Nucleoli Expressed in all Expressed in all smooth muscle: 305.0 PDPN aggrus, Gp38, GP40, PA2.26, T1A-2 ENSG00000162493 Podoplanin 1 13583465-13617957 Predicted membrane proteins Evidence at protein level HPA007534, CAB008376, HPA073453 Supported Approved Vesicles Tissue enhanced Tissue enhanced placenta: 192.4 appendix: 80.4 PEX10 RNF69 ENSG00000157911 Peroxisomal biogenesis factor 10 1 2403964-2413797 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA049458, HPA049755 Approved Approved Nucleoplasm Renal cancer:4.16e-6 (favourable), Breast cancer:4.50e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 19.3 PEX12 ENSG00000108733 Peroxisomal biogenesis factor 12 17 35574795-35578863 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA069386 Supported Renal cancer:3.58e-5 (favourable) Expressed in all Mixed parathyroid gland: 17.0 PEX13 ENSG00000162928 Peroxisomal biogenesis factor 13 2 61017225-61051990 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032141, HPA032142, CAB032689 Supported Supported Vesicles Pancreatic cancer:8.07e-5 (unfavourable) Expressed in all Expressed in all testis: 27.4 PEX16 ENSG00000121680 Peroxisomal biogenesis factor 16 11 45909669-45918812 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043286 Approved Urothelial cancer:9.06e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 27.5 PGAP2 CWH43-N, FRAG1, MRT21 ENSG00000148985 Post-GPI attachment to proteins 2 11 3797724-3826371 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA063099 Approved Approved Microtubules Liver cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all epididymis: 258.9 PHLDB2 FLJ21791, LL5b, LL5beta ENSG00000144824 Pleckstrin homology-like domain, family B, member 2 3 111732497-111976517 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035146, HPA035147 Approved Supported Plasma membrane
Cytosol Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable) Expressed in all Mixed placenta: 59.4 PHTF1 PHTF ENSG00000116793 Putative homeodomain transcription factor 1 1 113696831-113759489 Plasma proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA059486 Approved Nucleoli
Nuclear bodies Renal cancer:1.21e-6 (unfavourable) Expressed in all Tissue enhanced testis: 54.1 parathyroid gland: 18.8 PI4KA PI4K-ALPHA, pi4K230, PIK4CA ENSG00000241973 Phosphatidylinositol 4-kinase, catalytic, alpha 22 20707691-20859417 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009092, HPA075515 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 114.0 PIGA GPI3 ENSG00000165195 Phosphatidylinositol glycan anchor biosynthesis, class A X 15319451-15335580 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001174 Approved Pancreatic cancer:7.64e-4 (unfavourable) Expressed in all Mixed lung: 10.5 PIGH GPI-H ENSG00000100564 Phosphatidylinositol glycan anchor biosynthesis, class H 14 67581955-67600287 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031624 Approved Renal cancer:2.68e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 105.5 PIGN MDC4, PIG-N ENSG00000197563 Phosphatidylinositol glycan anchor biosynthesis, class N 18 62043567-62187118 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039922, HPA040374 Approved Supported Plasma membrane
Cytosol Colorectal cancer:6.51e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 31.3 PIGP DCRC, DSCR5, DSRC ENSG00000185808 Phosphatidylinositol glycan anchor biosynthesis, class P 21 37059170-37073170 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026921 Uncertain Approved Vesicles Expressed in all Expressed in all epididymis: 123.4 PIGQ GPI1, hGPI1 ENSG00000007541 Phosphatidylinositol glycan anchor biosynthesis, class Q 16 566995-584136 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039105, HPA039828, HPA061414 Approved Approved Nucleoplasm
Golgi apparatus
Vesicles Renal cancer:2.53e-6 (favourable) Expressed in all Expressed in all bone marrow: 24.2 PIGS ENSG00000087111 Phosphatidylinositol glycan anchor biosynthesis, class S 17 28553383-28571872 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA018149 Approved Liver cancer:1.86e-4 (unfavourable), Urothelial cancer:5.31e-4 (unfavourable) Expressed in all Mixed thyroid gland: 13.5 PIRT ENSG00000233670 Phosphoinositide-interacting regulator of transient receptor potential channels 17 10822475-10838445 Predicted membrane proteins, Transporters Evidence at transcript level HPA042337 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enhanced adrenal gland: 3.1;cerebral cortex: 2.7;rectum: 2.7 colon: 2.1 PKD2 Pc-2, PC2, PKD4, TRPP2 ENSG00000118762 Polycystic kidney disease 2 (autosomal dominant) 4 88007668-88077777 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB004544, HPA015794 Approved Validated Endoplasmic reticulum Expressed in all Expressed in all endometrium: 100.4 PLA2G15 GXVPLA2, LLPL, LYPLA3 ENSG00000103066 Phospholipase A2, group XV 16 68245304-68261062 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041702, HPA041727 Supported Approved Nucleoplasm
Vesicles Expressed in all Expressed in all placenta: 37.3 PLLP PMLP, TM4SF11 ENSG00000102934 Plasmolipin 16 57248547-57284687 Predicted membrane proteins Evidence at protein level HPA041862 Supported Renal cancer:6.21e-9 (favourable), Endometrial cancer:2.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.4 PLP1 GPM6C, PLP, SPG2 ENSG00000123560 Proteolipid protein 1 X 103773718-103792619 Cancer-related genes, Disease related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA004128 Supported Group enriched Tissue enriched 30 cerebral cortex: 3225.1 parathyroid gland: 106.1 PLPP2 LPP2, PAP-2c, PPAP2C ENSG00000141934 Phospholipid phosphatase 2 19 281040-291504 Enzymes, Predicted membrane proteins Evidence at protein level HPA055540 Uncertain Approved Mitochondria Endometrial cancer:3.21e-8 (favourable), Breast cancer:4.55e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 126.8 cervix, uterine: 91.2 PLPPR1 FLJ20300, LPPR1, MGC26189, PRG-3 ENSG00000148123 Phospholipid phosphatase related 1 9 101028709-101325135 Predicted membrane proteins Evidence at protein level HPA014760, HPA014968, HPA014979 Supported Approved Nucleoplasm Lung cancer:1.37e-4 (favourable) Group enriched Group enriched 6 cerebral cortex: 23.9;kidney: 15.7 epididymis: 3.2 PLPPR3 FLJ11535, LPPR3, PRG-2, PRG2 ENSG00000129951 Phospholipid phosphatase related 3 19 812488-821977 Enzymes, Predicted membrane proteins Evidence at protein level HPA052293, HPA057034 Uncertain Approved Nucleoplasm
Golgi apparatus
Cytosol Tissue enhanced Tissue enhanced bone marrow: 6.1;cerebral cortex: 9.6;fallopian tube: 8.8 testis: 2.1 PMP22 GAS3, HNPP, Sp110 ENSG00000109099 Peripheral myelin protein 22 17 15229777-15265326 Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all placenta,small intestine: 314.4 POLR1E FLJ13390, FLJ13970, PAF53, PRAF1 ENSG00000137054 Polymerase (RNA) I polypeptide E, 53kDa 9 37485935-37503697 Predicted intracellular proteins, Predicted membrane proteins, RNA polymerase related proteins Evidence at protein level HPA022527, HPA052400 Supported Supported Nucleus
Nucleoli fibrillar center Breast cancer:2.27e-4 (favourable) Expressed in all Expressed in all ovary: 51.4 POMT1 LGMD2K ENSG00000130714 Protein-O-mannosyltransferase 1 9 131502902-131523806 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA065252 Approved Golgi apparatus Pancreatic cancer:3.90e-5 (favourable), Renal cancer:4.68e-5 (favourable) Expressed in all Expressed in all testis: 62.7 POMT2 LGMD2N ENSG00000009830 Protein-O-mannosyltransferase 2 14 77274956-77320884 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003663 Uncertain Liver cancer:2.40e-4 (unfavourable) Expressed in all Expressed in all testis: 28.8 POPDC3 bA355M14.1, MGC22671, POP3 ENSG00000132429 Popeye domain containing 3 6 105158280-105179995 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012514 Uncertain Approved Nucleoli
Cytosol Head and neck cancer:4.43e-4 (unfavourable), Lung cancer:5.79e-4 (unfavourable) Mixed Group enriched 6 cerebral cortex: 8.8;heart muscle: 18.4;skeletal muscle: 41.8;testis: 9.7 epididymis: 3.4 PORCN DHOF, MG61, por, PORC, PPN ENSG00000102312 Porcupine homolog (Drosophila) X 48508962-48520814 Disease related genes, Predicted membrane proteins Evidence at protein level HPA049215, HPA058413 Approved Approved Vesicles Expressed in all Mixed adrenal gland: 34.6 PQLC1 FLJ22378 ENSG00000122490 PQ loop repeat containing 1 18 79902420-79951664 Predicted membrane proteins Evidence at protein level HPA051666 Uncertain Approved Nucleoplasm Expressed in all Expressed in all adipose tissue: 40.5 PQLC3 C2orf22, MGC33602 ENSG00000162976 PQ loop repeat containing 3 2 11155198-11178874 Predicted membrane proteins Evidence at protein level HPA061607 Approved Cytosol Expressed in all Expressed in all cervix, uterine: 54.2 PREB SEC12 ENSG00000138073 Prolactin regulatory element binding 2 27130756-27134675 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013582, HPA014133 Uncertain Approved Endoplasmic reticulum Expressed in all Expressed in all epididymis: 106.0 PRRT1 C6orf31, IFITMD7, NG5 ENSG00000204314 Proline-rich transmembrane protein 1 6 32148359-32154373 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055149 Approved Mixed Tissue enriched 8 cerebral cortex: 4.5 ovary: 0.6 PRRT2 DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC ENSG00000167371 Proline-rich transmembrane protein 2 16 29811382-29815892 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014447, HPA019203 Approved Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 92.9 ovary: 51.5 PSEN1 AD3, FAD, PS1, S182 ENSG00000080815 Presenilin 1 14 73136418-73223691 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB006844, HPA030760, HPA067496 Approved Approved Nucleus
Golgi apparatus
Cell Junctions Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 66.1 PSENEN PEN2 ENSG00000205155 Presenilin enhancer gamma secretase subunit 19 35745114-35747519 Disease related genes, Predicted membrane proteins Evidence at protein level HPA047435 Approved Renal cancer:8.70e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 369.9 PTCRA PT-ALPHA, PTA ENSG00000171611 Pre T-cell antigen receptor alpha 6 42915989-42925835 Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced lymph node: 3.2;spleen: 4.9 lung,tonsil: 2.1 PTGER2 EP2 ENSG00000125384 Prostaglandin E receptor 2 (subtype EP2), 53kDa 14 52314305-52328606 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Renal cancer:4.16e-4 (unfavourable) Mixed Mixed cervix, uterine: 27.3 PTGIR IP ENSG00000160013 Prostaglandin I2 (prostacyclin) receptor (IP) 19 46620468-46625118 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable) Mixed Tissue enhanced lung: 14.0 appendix: 8.4 PTPN5 PTPSTEP, STEP ENSG00000110786 Protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) 11 18727928-18792721 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031014, HPA072091 Supported Approved Endoplasmic reticulum Group enriched Tissue enriched 15 cerebral cortex: 58.9 testis: 3.8 PTPRO GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2 ENSG00000151490 Protein tyrosine phosphatase, receptor type, O 12 15322397-15597399 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA034525 Supported Tissue enhanced Tissue enhanced rectum: 33.5 cerebral cortex: 21.8 PXMP2 PMP22 ENSG00000176894 Peroxisomal membrane protein 2, 22kDa 12 132687606-132704991 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:2.75e-4 (favourable), Head and neck cancer:9.84e-4 (unfavourable) Expressed in all Expressed in all liver: 119.8 PXMP4 PMP24 ENSG00000101417 Peroxisomal membrane protein 4, 24kDa 20 33702754-33720319 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050077 Approved Approved Nucleoli fibrillar center
Peroxisomes Renal cancer:4.03e-10 (favourable), Lung cancer:3.88e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 29.8 RABAC1 PRA1, PRAF1, YIP3 ENSG00000105404 Rab acceptor 1 (prenylated) 19 41956681-41959390 Predicted membrane proteins Evidence at protein level CAB019320, HPA029171 Supported Approved Nuclear membrane
Nucleoli fibrillar center Expressed in all Expressed in all cerebral cortex: 107.6 RABGAP1 GAPCenA, TBC1D11 ENSG00000011454 RAB GTPase activating protein 1 9 122940833-123104866 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041651, HPA064860, HPA072273 Approved Validated Cytosol Renal cancer:6.06e-6 (favourable), Breast cancer:8.09e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 66.1 RALGAPA1 DKFZp667F074, GARNL1, GRIPE, KIAA0884, RalGAPalpha1, Tulip1 ENSG00000174373 Ral GTPase activating protein, alpha subunit 1 (catalytic) 14 35538352-35809304 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000851 Approved Approved Mitochondria
Cytosol Renal cancer:9.76e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 50.5 RALGAPA2 AS250, C20orf74, dJ1049G11.4, KIAA1272, RapGAPalpha2 ENSG00000188559 Ral GTPase activating protein, alpha subunit 2 (catalytic) 20 20389552-20712488 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042707, HPA043622 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.77e-5 (favourable) Expressed in all Expressed in all thyroid gland: 39.8 REEP1 C2orf23, FLJ13110, SPG31 ENSG00000068615 Receptor accessory protein 1 2 86213993-86338083 Disease related genes, Predicted membrane proteins Evidence at protein level HPA058061 Approved Mixed Tissue enhanced cerebral cortex: 54.2;testis: 90.8 smooth muscle: 34.1 REEP2 C5orf19, SGC32445, SPG72 ENSG00000132563 Receptor accessory protein 2 5 138439017-138446969 Disease related genes, Predicted membrane proteins Evidence at protein level HPA031813 Supported Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable) Tissue enriched Tissue enriched 5 cerebral cortex: 90.3 smooth muscle: 17.8 REEP4 C8orf20, FLJ22246, FLJ22277, PP432 ENSG00000168476 Receptor accessory protein 4 8 22138020-22141951 Predicted membrane proteins Evidence at protein level HPA042683 Approved Approved Cytosol Renal cancer:2.88e-5 (unfavourable), Liver cancer:4.14e-5 (unfavourable) Expressed in all Expressed in all skin: 66.5 REEP5 C5orf18, D5S346, DP1, TB2 ENSG00000129625 Receptor accessory protein 5 5 112876379-112922539 Predicted membrane proteins Evidence at protein level HPA003895, HPA069960 Approved Approved Endoplasmic reticulum Endometrial cancer:5.23e-6 (favourable), Renal cancer:2.05e-5 (favourable) Expressed in all Expressed in all thyroid gland: 341.6 RER1 ENSG00000157916 Retention in endoplasmic reticulum sorting receptor 1 1 2391775-2405444 Predicted membrane proteins, Transporters Evidence at protein level CAB037240, HPA051400 Supported Validated Golgi apparatus Renal cancer:8.23e-8 (unfavourable) Expressed in all Expressed in all testis: 183.8 RHBDD1 DKFZp547E052 ENSG00000144468 Rhomboid domain containing 1 2 226835581-226999215 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013972, HPA057125 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all testis: 32.2 RHBDD3 C22orf3, PTAG ENSG00000100263 Rhomboid domain containing 3 22 29259852-29268209 Predicted membrane proteins Evidence at protein level HPA043979 Approved Approved Microtubules Endometrial cancer:2.67e-6 (favourable), Renal cancer:2.24e-4 (unfavourable) Expressed in all Mixed testis: 10.5 RHBDF2 FLJ22341, iRhom2, RHBDL5, RHBDL6, TOC, TOCG ENSG00000129667 Rhomboid 5 homolog 2 (Drosophila) 17 76470891-76501790 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018080 Uncertain Renal cancer:3.96e-11 (unfavourable) Expressed in all Expressed in all appendix: 51.0 RNASEK MGC71993 ENSG00000219200 Ribonuclease, RNase K 17 7012417-7014532 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA044708 Uncertain Pancreatic cancer:1.92e-4 (favourable) Expressed in all Expressed in all adrenal gland: 470.3 RNF130 G1RZFP, GOLIATH, GP ENSG00000113269 Ring finger protein 130 5 179911651-180072118 Predicted membrane proteins Evidence at protein level HPA014499 Approved Cervical cancer:6.32e-4 (favourable) Expressed in all Expressed in all adipose tissue: 74.3 RNF139 HRCA1, RCA1, TRC8 ENSG00000170881 Ring finger protein 139 8 124474738-124487914 Disease related genes, Predicted membrane proteins Evidence at protein level HPA001202 Approved Pancreatic cancer:3.54e-4 (unfavourable) Expressed in all Expressed in all testis: 114.1 RNF170 ADSA, DKFZP564A022, SNAX1 ENSG00000120925 Ring finger protein 170 8 42849637-42897290 Disease related genes, Predicted membrane proteins Evidence at protein level HPA050931, HPA054621 Uncertain Expressed in all Expressed in all thyroid gland: 47.6 RNF182 MGC33993 ENSG00000180537 Ring finger protein 182 6 13924446-13980302 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012309 Approved Approved Nucleus
Golgi apparatus
Vesicles Endometrial cancer:4.66e-5 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.6 testis: 6.8 RNF185 FLJ38628 ENSG00000138942 Ring finger protein 185 22 31160183-31207019 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:4.82e-5 (favourable) Expressed in all Expressed in all thyroid gland: 86.4 RNF186 FLJ20225 ENSG00000178828 Ring finger protein 186 1 19814029-19815278 Predicted membrane proteins Evidence at protein level HPA034547, HPA035558 Supported Tissue enhanced Tissue enhanced duodenum: 136.0;epididymis: 82.8;small intestine: 47.7 kidney: 26.4 RNF19A DKFZp566B1346, dorfin, RNF19 ENSG00000034677 Ring finger protein 19A, RBR E3 ubiquitin protein ligase 8 100257059-100410015 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011455, HPA023652 Approved Urothelial cancer:3.28e-5 (favourable), Renal cancer:7.99e-5 (unfavourable) Expressed in all Expressed in all testis: 98.8 RNF19B FLJ90005, IBRDC3 ENSG00000116514 Ring finger protein 19B 1 32936445-32964685 Predicted membrane proteins Evidence at protein level HPA049587 Approved Approved Cytosol Liver cancer:5.41e-6 (unfavourable), Renal cancer:4.39e-5 (favourable), Head and neck cancer:3.39e-4 (favourable) Expressed in all Expressed in all testis: 154.8 RNF215 ENSG00000099999 Ring finger protein 215 22 30368811-30421771 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019262, HPA056498 Approved Approved Nucleoli
Microtubules Renal cancer:6.37e-10 (unfavourable) Expressed in all Expressed in all cerebral cortex: 19.3 RNF217 C6orf172, dJ84N20.1, IBRDC1, MGC26996 ENSG00000146373 Ring finger protein 217 6 124962545-125092633 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029598 Uncertain Renal cancer:4.60e-5 (unfavourable), Urothelial cancer:1.92e-4 (unfavourable) Expressed in all Tissue enriched 8 parathyroid gland: 94.6 testis: 12.4 RNF5 G16, NG2, RING5, RMA1 ENSG00000204308 Ring finger protein 5, E3 ubiquitin protein ligase 6 32178354-32180793 Predicted membrane proteins Evidence at protein level CAB034107, HPA065032 Uncertain Supported Endoplasmic reticulum Ovarian cancer:2.44e-4 (favourable) Expressed in all Mixed kidney: 18.5 RP11-231C14.4 ENSG00000169203 16 29483642-29505999 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Uncertain Nucleoplasm Not detected Expressed in all skin: 135.7 RP11-310K10.1 ENSG00000197991 Protocadherin-20 13 61409858-61427849 Predicted membrane proteins Evidence at transcript level Not detected Not detected testis: 0.5 RP11-330H6.5 ENSG00000173366 3 52221081-52231190 Predicted membrane proteins Evidence at transcript level Not detected Tissue enhanced lymph node: 3.8 tonsil: 2.2 RP11-347C12.1 ENSG00000198064 Putative NPIP-like protein LOC613037 16 30222937-30254510 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Not detected Mixed skin: 9.1 RP11-385J1.3 ENSG00000275163 3 178419123-178843300 Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 6 fallopian tube: 8.7 kidney: 1.5 RP11-468E2.6 ENSG00000259371 14 24120956-24131829 Predicted membrane proteins No evidence Not detected Not detected small intestine,testis: 0.5 RPN2 RIBIIR, RPN-II, RPNII, SWP1 ENSG00000118705 Ribophorin II 20 37178410-37241623 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008297, CAB019277, HPA025922 Supported Supported Endoplasmic reticulum Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable) Expressed in all Expressed in all epididymis: 358.1 RTN1 NSP ENSG00000139970 Reticulon 1 14 59595976-59870966 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002745, HPA040945, HPA044249 Supported Validated Endoplasmic reticulum Pancreatic cancer:3.69e-4 (favourable) Tissue enhanced Tissue enriched 8 cerebral cortex: 412.9 parathyroid gland: 48.8 RTN2 NSP2, NSPL1, SPG12 ENSG00000125744 Reticulon 2 19 45485289-45497061 Disease related genes, Predicted membrane proteins Evidence at protein level HPA034941, HPA034948 Approved Approved Nuclear speckles Renal cancer:5.58e-6 (unfavourable) Expressed in all Tissue enriched 6 skeletal muscle: 175.3 placenta: 27.3 RTN3 ASYIP, HAP, NSPL2, NSPLII, RTN3-A1 ENSG00000133318 Reticulon 3 11 63681446-63759891 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015649, HPA015650 Supported Supported Endoplasmic reticulum Liver cancer:1.30e-6 (unfavourable), Renal cancer:9.87e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1033.6 RTN4 ASY, KIAA0886, NOGO, NSP-CL ENSG00000115310 Reticulon 4 2 54972187-55112621 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB005388, HPA023977 Supported Validated Endoplasmic reticulum Head and neck cancer:1.00e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 638.6 SACM1L KIAA0851, SAC1 ENSG00000211456 SAC1 suppressor of actin mutations 1-like (yeast) 3 45689056-45745424 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039573, HPA069869 Approved Approved Nucleoplasm
Golgi apparatus Renal cancer:5.47e-7 (favourable) Expressed in all Expressed in all thyroid gland: 67.2 SCAMP2 ENSG00000140497 Secretory carrier membrane protein 2 15 74843730-74873365 Predicted membrane proteins Evidence at protein level HPA014699, HPA019194 Approved Supported Golgi apparatus
Vesicles Renal cancer:1.12e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 126.3 SCAMP5 MGC24969 ENSG00000198794 Secretory carrier membrane protein 5 15 74957219-75021496 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046645 Approved Renal cancer:1.34e-6 (favourable), Pancreatic cancer:5.67e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 276.3 parathyroid gland: 80.7 SCAP KIAA0199 ENSG00000114650 SREBF chaperone 3 47413694-47477126 Predicted membrane proteins Evidence at protein level HPA004713 Approved Renal cancer:4.33e-5 (favourable), Pancreatic cancer:7.14e-4 (favourable) Expressed in all Expressed in all adrenal gland: 67.3 SCD5 ACOD4, FADS4, FLJ21032, HSCD5, SCD4 ENSG00000145284 Stearoyl-CoA desaturase 5 4 82629539-82798857 Enzymes, Predicted membrane proteins Evidence at protein level HPA042380 Uncertain Renal cancer:2.32e-5 (favourable) Group enriched Tissue enhanced adrenal gland: 201.7;cerebral cortex: 502.5 epididymis: 117.9 SCNN1A ENaCalpha, SCNN1 ENSG00000111319 Sodium channel, non voltage gated 1 alpha subunit 12 6346843-6377730 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA012743 Supported Renal cancer:9.21e-8 (favourable), Pancreatic cancer:2.30e-4 (unfavourable), Ovarian cancer:8.86e-4 (unfavourable) Mixed Mixed cervix, uterine: 94.4 SCNN1B ENaCbeta ENSG00000168447 Sodium channel, non voltage gated 1 beta subunit 16 23278231-23381299 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015612 Uncertain Renal cancer:2.09e-6 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 71.5 esophagus: 45.0 SCNN1D dNaCh, ENaCdelta ENSG00000162572 Sodium channel, non voltage gated 1 delta subunit 1 1280436-1292029 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009540, HPA026884 Approved Supported Plasma membrane
Actin filaments Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable) Mixed Tissue enhanced testis: 13.8 cerebral cortex: 7.3 SCNN1G ENaCgamma, SCNEG ENSG00000166828 Sodium channel, non voltage gated 1 gamma subunit 16 23182715-23216883 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071194 Approved Nucleoplasm
Nucleoli
Plasma membrane Renal cancer:3.20e-7 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 24.5;kidney: 46.4 thyroid gland: 9.5 SCTR ENSG00000080293 Secretin receptor 2 119439843-119525301 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA007269 Uncertain Tissue enhanced Tissue enhanced duodenum: 27.4;lung: 13.0;pancreas: 14.3 stomach: 4.2 SDHD PGL, PGL1 ENSG00000204370 Succinate dehydrogenase complex, subunit D, integral membrane protein 11 112086773-112120013 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045727 Approved Renal cancer:1.99e-10 (favourable) Expressed in all Expressed in all kidney: 303.5 SDR16C5 RDH-E2, RDHE2 ENSG00000170786 Short chain dehydrogenase/reductase family 16C, member 5 8 56300010-56320776 Enzymes, Predicted membrane proteins Evidence at protein level HPA025224 Supported Head and neck cancer:7.88e-4 (favourable) Mixed Group enriched 6 breast: 14.9;esophagus: 36.4;lung: 40.3;skin: 73.0;small intestine: 22.1;stomach: 21.3;tonsil: 26.3 cervix, uterine: 5.6 SDR42E1 HSPC105 ENSG00000184860 Short chain dehydrogenase/reductase family 42E, member 1 16 81988855-82011488 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA014388 Uncertain Mixed Mixed skin: 10.7 SEC11A SEC11L1, sid2895, SPC18, SPCS4A ENSG00000140612 SEC11 homolog A, signal peptidase complex subunit 15 84669538-84716716 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047533 Approved Nuclear membrane
Golgi apparatus Endometrial cancer:1.94e-5 (favourable), Head and neck cancer:5.99e-5 (unfavourable), Thyroid cancer:2.95e-4 (favourable) Expressed in all Expressed in all thyroid gland: 211.4 SEC61A1 ENSG00000058262 Sec61 translocon alpha 1 subunit 3 128051641-128071683 Predicted membrane proteins, Transporters Evidence at protein level CAB022076 Supported Endoplasmic reticulum Renal cancer:6.84e-9 (unfavourable), Liver cancer:1.07e-6 (unfavourable), Endometrial cancer:7.82e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 217.0 SEC61A2 FLJ10578 ENSG00000065665 Sec61 translocon alpha 2 subunit 10 12129637-12169961 Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:1.08e-5 (favourable), Urothelial cancer:8.75e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 51.4 testis: 32.3 SEC62 Dtrp1, HTP1, TLOC1 ENSG00000008952 SEC62 homolog, preprotein translocation factor 3 169966635-169998373 Predicted membrane proteins Evidence at protein level HPA014059, HPA061450 Approved Approved Endoplasmic reticulum
Intermediate filaments Expressed in all Expressed in all thyroid gland: 202.4 SEC63 DNAJC23, ERdj2, PRO2507, SEC63L ENSG00000025796 SEC63 homolog, protein translocation regulator 6 107867756-107958189 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA053295, HPA060535 Supported Supported Endoplasmic reticulum Breast cancer:3.32e-4 (unfavourable), Cervical cancer:4.01e-4 (unfavourable), Renal cancer:6.16e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 87.1 SEL1L3 KIAA0746 ENSG00000091490 Sel-1 suppressor of lin-12-like 3 (C. elegans) 4 25747427-25863760 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040045, HPA058792 Approved Validated Nucleus Urothelial cancer:4.33e-4 (favourable) Expressed in all Expressed in all lymph node: 148.5 SEZ6 ENSG00000063015 Seizure related 6 homolog (mouse) 17 28954901-29006440 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011777 Supported Uncertain Intermediate filaments Tissue enriched Tissue enriched 51 cerebral cortex: 54.1 duodenum: 1.0 SF3B1 Hsh155, Prp10, PRPF10, SAP155, SF3b155 ENSG00000115524 Splicing factor 3b, subunit 1, 155kDa 2 197389784-197435091 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050275 Approved Validated Nuclear speckles Expressed in all Expressed in all endometrium: 345.5 SFT2D2 dJ747L4.C1.2, UNQ512 ENSG00000213064 SFT2 domain containing 2 1 168225938-168253025 Predicted membrane proteins Evidence at protein level HPA042207 Approved Liver cancer:4.86e-4 (unfavourable) Expressed in all Mixed bone marrow: 21.3 SFXN4 ENSG00000183605 Sideroflexin 4 10 119140767-119165667 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018028, HPA020872 Approved Supported Vesicles Expressed in all Expressed in all thyroid gland: 47.1 SFXN5 BBG-TCC ENSG00000144040 Sideroflexin 5 2 72942036-73075619 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015473, HPA056866 Approved Approved Nucleoplasm
Mitochondria Pancreatic cancer:2.26e-6 (favourable) Expressed in all Tissue enhanced cerebral cortex: 39.5 epididymis: 18.2 SGMS1 MGC17342, MOB, SMS1, TMEM23 ENSG00000198964 Sphingomyelin synthase 1 10 50305586-50625163 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045191 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.95e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 114.4 SGSM3 DJ1042K10.2, RabGAP-5, RABGAP5, RUSC3, RUTBC3 ENSG00000100359 Small G protein signaling modulator 3 22 40370591-40410289 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048980 Approved Supported Golgi apparatus Endometrial cancer:4.47e-5 (favourable) Expressed in all Expressed in all stomach: 76.7 SLC10A7 C4orf13, DKFZp313H0531, DKFZp566M114, DKFZp779O2438, MGC25043 ENSG00000120519 Solute carrier family 10, member 7 4 146253975-146521964 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039996, HPA057906 Uncertain Approved Nucleoli Expressed in all Mixed epididymis: 16.0 SLC11A2 DCT1, DMT1, NRAMP2 ENSG00000110911 Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 12 50979401-51028566 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032139, HPA032140 Uncertain Supported Mitochondria Lung cancer:3.07e-6 (favourable) Expressed in all Expressed in all thyroid gland: 74.8 SLC12A5 KCC2, KIAA1176 ENSG00000124140 Solute carrier family 12 (potassium/chloride transporter), member 5 20 46021690-46060152 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA072058 Supported Glioma:8.45e-4 (unfavourable) Mixed Tissue enriched 8 cerebral cortex: 94.5 adrenal gland: 12.0 SLC12A6 ACCPN, KCC3 ENSG00000140199 Solute carrier family 12 (potassium/chloride transporter), member 6 15 34229996-34338060 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034563 Uncertain Approved Vesicles
Cytosol Renal cancer:3.33e-6 (favourable) Expressed in all Mixed testis: 46.2 SLC12A7 DKFZP434F076, KCC4 ENSG00000113504 Solute carrier family 12 (potassium/chloride transporter), member 7 5 1050376-1112035 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041652 Approved Uncertain Cytosol Liver cancer:2.12e-6 (unfavourable), Urothelial cancer:3.16e-5 (favourable) Expressed in all Mixed duodenum: 25.0 SLC13A4 SUT-1, SUT1 ENSG00000164707 Solute carrier family 13 (sodium/sulfate symporter), member 4 7 135681237-135729258 Predicted membrane proteins, Transporters Evidence at transcript level HPA048582 Approved Mixed Tissue enriched 10 placenta: 76.2 testis: 7.3 SLC13A5 NACT ENSG00000141485 Solute carrier family 13 (sodium-dependent citrate transporter), member 5 17 6684713-6713567 Predicted membrane proteins, Transporters Evidence at protein level HPA044343, HPA057088 Approved Uncertain Nucleoplasm Tissue enriched Tissue enriched 9 liver: 118.1 salivary gland: 12.8 SLC14A1 HsT1341, JK, RACH1, RACH2 ENSG00000141469 Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 18 45724127-45752520 Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA058353, HPA059570 Supported Supported Vesicles Group enriched Group enriched 5 prostate: 132.1;urinary bladder: 51.9 cerebral cortex: 18.2 SLC16A6 MCT6, MCT7 ENSG00000108932 Solute carrier family 16, member 6 17 68267026-68291267 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054459, HPA066328 Uncertain Approved Vesicles Group enriched Tissue enhanced epididymis: 39.8 esophagus: 12.1 SLC16A7 MCT2 ENSG00000118596 Solute carrier family 16 (monocarboxylate transporter), member 7 12 59596067-59789855 Predicted membrane proteins, Transporters Evidence at protein level HPA005911 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.85e-5 (favourable) Mixed Mixed adipose tissue: 24.8 SLC16A8 MCT3, REMP ENSG00000100156 Solute carrier family 16 (monocarboxylate transporter), member 8 22 38078134-38084093 Plasma proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA075017 Approved Intermediate filaments
Focal adhesion sites Mixed Mixed prostate: 5.7 SLC17A3 NPT4 ENSG00000124564 Solute carrier family 17 (organic anion transporter), member 3 6 25833066-25882286 Predicted membrane proteins, Transporters Evidence at protein level HPA016569 Uncertain Tissue enriched Tissue enriched 9 kidney: 167.2 liver: 18.5 SLC19A3 THTR2 ENSG00000135917 Solute carrier family 19 (thiamine transporter), member 3 2 227685210-227718012 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038898 Approved Approved Nucleoplasm
Cytosol Mixed Tissue enhanced adipose tissue: 50.1;placenta: 34.5 duodenum: 12.7 SLC1A3 EA6, EAAT1, GLAST ENSG00000079215 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 5 36606355-36688334 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002573, HPA037467, HPA037468 Supported Approved Nucleoli
Mitochondria Tissue enriched Tissue enriched 16 cerebral cortex: 519.6 adipose tissue: 31.7 SLC20A1 Glvr-1, GLVR1, PiT-1 ENSG00000144136 Solute carrier family 20 (phosphate transporter), member 1 2 112645857-112663827 Predicted membrane proteins, Transporters Evidence at protein level CAB019279, HPA035834 Approved Approved Vesicles Renal cancer:3.44e-5 (unfavourable), Head and neck cancer:6.56e-5 (unfavourable) Expressed in all Expressed in all colon: 51.9 SLC20A2 Glvr-2, GLVR2, MLVAR, PiT-2 ENSG00000168575 Solute carrier family 20 (phosphate transporter), member 2 8 42416475-42541926 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA026540 Approved Renal cancer:1.01e-4 (favourable), Breast cancer:7.67e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 137.7 SLC22A14 OCTL2, ORCTL4 ENSG00000144671 Solute carrier family 22, member 14 3 38282294-38318575 Predicted membrane proteins, Transporters Evidence at transcript level Not detected Tissue enriched 20 testis: 13.4 kidney: 0.6 SLC22A16 CT2, FLIPT2, OAT6, OKB1 ENSG00000004809 Solute carrier family 22 (organic cation/carnitine transporter), member 16 6 110424687-110476641 Predicted membrane proteins Evidence at protein level HPA036902 Uncertain Tissue enriched Group enriched 8 bone marrow: 13.0;parathyroid gland: 16.1;testis: 38.4 smooth muscle: 2.7 SLC23A1 SLC23A2, SVCT1, YSPL3 ENSG00000170482 Solute carrier family 23 (ascorbic acid transporter), member 1 5 139367196-139384553 Predicted membrane proteins, Transporters Evidence at protein level HPA047612 Supported Group enriched Group enriched 5 duodenum: 27.5;fallopian tube: 85.7;kidney: 41.7;small intestine: 73.4 liver: 10.7 SLC25A15 D13S327, HHH, ORC1, ORNT1 ENSG00000102743 Solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 13 40789412-40810111 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA042146 Approved Renal cancer:1.74e-4 (favourable), Liver cancer:2.16e-4 (favourable), Urothelial cancer:5.46e-4 (unfavourable) Expressed in all Expressed in all liver: 49.6 SLC25A16 D10S105E, GDA, HGT.1, ML7 ENSG00000122912 Solute carrier family 25 (mitochondrial carrier), member 16 10 68477999-68527474 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036243, HPA044580 Uncertain Approved Mitochondria Expressed in all Mixed prostate: 13.7 SLC25A19 DNC, MCPHA, MUP1, TPC ENSG00000125454 Solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), member 19 17 75272981-75289510 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Liver cancer:1.21e-7 (unfavourable), Endometrial cancer:8.72e-5 (unfavourable) Expressed in all Expressed in all testis: 49.5 SLC25A23 APC2, FLJ30339, MGC2615 ENSG00000125648 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 19 6436079-6465203 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA009675, HPA050883 Approved Supported Mitochondria Renal cancer:1.10e-12 (favourable), Endometrial cancer:1.29e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 141.8 SLC25A3 PHC ENSG00000075415 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 12 98593591-98606379 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA045709 Supported Mitochondria Renal cancer:8.11e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 583.9 SLC25A31 ANT4, DKFZP434N1235 ENSG00000151475 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31 4 127730378-127774299 Predicted membrane proteins, Transporters Evidence at protein level HPA015064, HPA016841, HPA046835, HPA071684 Uncertain Validated Mitochondria Not detected Tissue enriched 849 testis: 84.9 all non-specific tissues: 0.0 SLC25A35 FLJ40217 ENSG00000125434 Solute carrier family 25, member 35 17 8287763-8295343 Predicted membrane proteins, Transporters Evidence at protein level HPA051720 Uncertain Approved Vesicles
Mitochondria Endometrial cancer:3.37e-7 (favourable), Renal cancer:1.14e-6 (favourable), Urothelial cancer:1.91e-5 (favourable) Expressed in all Mixed testis: 19.6 SLC25A36 FLJ10618, PNC2 ENSG00000114120 Solute carrier family 25 (pyrimidine nucleotide carrier), member 36 3 140941830-140979933 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA027036 Approved Approved Nucleus
Mitochondria
Cytosol Urothelial cancer:1.55e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 68.3 SLC25A38 FLJ20551 ENSG00000144659 Solute carrier family 25, member 38 3 39383348-39397351 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041027 Approved Renal cancer:1.58e-5 (favourable), Urothelial cancer:7.29e-4 (favourable) Expressed in all Expressed in all thyroid gland: 65.8 SLC25A39 CGI-69, FLJ22407 ENSG00000013306 Solute carrier family 25, member 39 17 44319625-44324870 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA026785 Approved Renal cancer:3.58e-5 (favourable), Liver cancer:5.90e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 181.5 SLC25A44 FLJ90431, KIAA0446 ENSG00000160785 Solute carrier family 25, member 44 1 156193932-156212796 Predicted membrane proteins, Transporters Evidence at protein level HPA065411 Approved Nucleus
Mitochondria Pancreatic cancer:2.49e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 43.1 SLC25A46 ENSG00000164209 Solute carrier family 25, member 46 5 110738136-110765161 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039601, HPA071582 Approved Supported Mitochondria Thyroid cancer:2.52e-4 (unfavourable), Colorectal cancer:8.41e-4 (favourable) Expressed in all Expressed in all testis: 37.3 SLC25A47 C14orf68 ENSG00000140107 Solute carrier family 25, member 47 14 100323337-100330378 Predicted membrane proteins, Transporters Evidence at transcript level Tissue enriched Tissue enriched 166 liver: 101.0 duodenum: 0.6 SLC25A48 FLJ44862, HDMCP ENSG00000145832 Solute carrier family 25, member 48 5 135834649-135888637 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014674 Uncertain Approved Intermediate filaments
Actin filaments Mixed Tissue enhanced cerebral cortex: 17.7;kidney: 7.3 skeletal muscle: 2.7 SLC25A51 CG7943, MCART1, MGC14836 ENSG00000122696 Solute carrier family 25, member 51 9 37879400-37904353 Predicted membrane proteins, Transporters Evidence at protein level HPA046388, HPA058261 Uncertain Approved Mitochondria Liver cancer:5.67e-5 (unfavourable), Renal cancer:1.52e-4 (favourable), Thyroid cancer:2.21e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 16.4 SLC25A52 MCART2 ENSG00000141437 Solute carrier family 25, member 52 18 31759562-31760880 Predicted membrane proteins Evidence at transcript level HPA046388, HPA058261 Uncertain Approved Mitochondria Not detected Tissue enriched 104 testis: 15.3 breast,duodenum,liver,prostate,skin: 0.1 SLC25A53 MCART6 ENSG00000269743 Solute carrier family 25, member 53 X 104099214-104157027 Predicted membrane proteins Evidence at protein level HPA034959 Uncertain Mixed Mixed cerebral cortex: 2.6 SLC25A6 ANT3, ANT3Y, MGC17525 ENSG00000169100 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 X 1386152-1392724 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Expressed in all Expressed in all duodenum: 294.5 SLC26A11 ENSG00000181045 Solute carrier family 26 (anion exchanger), member 11 17 80219699-80253500 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029893 Approved Supported Nucleoplasm
Golgi apparatus
Vesicles Liver cancer:1.82e-6 (unfavourable), Pancreatic cancer:1.43e-5 (favourable), Endometrial cancer:1.55e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 34.5 SLC26A2 DTD, DTDST ENSG00000155850 Solute carrier family 26 (anion exchanger), member 2 5 149960737-149993455 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041957, HPA058090 Supported Approved Vesicles Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable) Expressed in all Tissue enhanced colon: 215.9;rectum: 209.8 parathyroid gland: 81.4 SLC26A3 CLD, DRA ENSG00000091138 Solute carrier family 26 (anion exchanger), member 3 7 107765467-107803225 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA036055 Approved Tissue enriched Tissue enhanced colon: 1092.5;duodenum: 594.0;rectum: 974.8 seminal vesicle: 183.9 SLC26A4 DFNB4, PDS ENSG00000091137 Solute carrier family 26 (anion exchanger), member 4 7 107660635-107717809 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA042860 Approved Tissue enriched Tissue enriched 28 thyroid gland: 422.9 cerebral cortex: 15.2 SLC26A6 DKFZp586E1422 ENSG00000225697 Solute carrier family 26 (anion exchanger), member 6 3 48625723-48635493 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA048363 Approved Uncertain Cytosol Renal cancer:1.53e-5 (unfavourable), Liver cancer:3.92e-4 (unfavourable) Expressed in all Expressed in all rectum: 24.3 SLC27A2 ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS ENSG00000140284 Solute carrier family 27 (fatty acid transporter), member 2 15 50182196-50236395 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA026089 Supported Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable) Tissue enhanced Group enriched 5 epididymis: 79.2;kidney: 160.9;liver: 145.2 placenta: 24.5 SLC27A4 ACSVL4, FATP4 ENSG00000167114 Solute carrier family 27 (fatty acid transporter), member 4 9 128340646-128361470 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA007293, CAB009771 Approved Supported Vesicles Renal cancer:2.61e-5 (favourable) Expressed in all Expressed in all duodenum: 74.1 SLC27A6 ACSVL2, FACVL2, FATP6, VLCS-H1 ENSG00000113396 Solute carrier family 27 (fatty acid transporter), member 6 5 128538013-129033642 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008987 Approved Approved Nuclear bodies Tissue enriched Tissue enhanced adrenal gland: 32.7;fallopian tube: 33.7 testis: 24.1 SLC28A1 CNT1 ENSG00000156222 Solute carrier family 28 (concentrative nucleoside transporter), member 1 15 84884654-84945796 Predicted membrane proteins, Transporters Evidence at protein level HPA019551 Supported Group enriched Group enriched 26 duodenum: 39.0;kidney: 49.1;liver: 35.4;small intestine: 54.7 placenta: 1.6 SLC29A4 ENT4, FLJ34923 ENSG00000164638 Solute carrier family 29 (equilibrative nucleoside transporter), member 4 7 5274369-5306870 Predicted membrane proteins, Transporters Evidence at protein level HPA052829 Supported Microtubules
Cytokinetic bridge Pancreatic cancer:4.52e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 44.2 cerebral cortex: 12.0 SLC2A14 GLUT14, SLC2A3P3 ENSG00000173262 Solute carrier family 2 (facilitated glucose transporter), member 14 12 7812512-7891148 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA006539 Approved Approved Plasma membrane Tissue enriched Tissue enriched 9 testis: 151.1 breast: 17.2 SLC2A2 GLUT2 ENSG00000163581 Solute carrier family 2 (facilitated glucose transporter), member 2 3 170996348-171026750 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB010444, HPA028997, HPA028998 Supported Approved Nucleoplasm Liver cancer:2.63e-5 (favourable) Tissue enriched Tissue enriched 6 liver: 432.5 duodenum: 67.5 SLC2A5 GLUT5 ENSG00000142583 Solute carrier family 2 (facilitated glucose/fructose transporter), member 5 1 9035107-9088478 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005449 Supported Renal cancer:5.44e-5 (unfavourable) Group enriched Tissue enhanced duodenum: 112.1;small intestine: 94.6;testis: 139.5 bone marrow: 64.6 SLC2A6 GLUT6, GLUT9, HSA011372 ENSG00000160326 Solute carrier family 2 (facilitated glucose transporter), member 6 9 133471095-133479137 Predicted membrane proteins, Transporters Evidence at protein level HPA042272, CAB046014 Uncertain Renal cancer:1.02e-11 (unfavourable), Glioma:1.94e-4 (unfavourable), Liver cancer:8.82e-4 (unfavourable) Expressed in all Mixed appendix: 6.3 SLC2A8 GLUT8, GLUTX1 ENSG00000136856 Solute carrier family 2 (facilitated glucose transporter), member 8 9 127397138-127408424 Predicted membrane proteins, Transporters Evidence at protein level HPA011935 Uncertain Approved Vesicles Cervical cancer:2.57e-6 (favourable), Renal cancer:6.55e-6 (favourable), Pancreatic cancer:9.86e-6 (favourable) Expressed in all Expressed in all testis: 50.1 SLC30A3 ZNT3 ENSG00000115194 Solute carrier family 30 (zinc transporter), member 3 2 27253684-27275817 Predicted membrane proteins, Transporters Evidence at protein level HPA060505, HPA067637 Approved Approved Nucleus
Nucleoli
Vesicles
Cytosol Mixed Group enriched 14 cerebral cortex: 36.7;epididymis: 65.2;testis: 43.6 heart muscle: 3.4 SLC30A5 FLJ12496, FLJ12756, MGC5499, ZnT-5, ZNT5, ZNTL1, ZTL1 ENSG00000145740 Solute carrier family 30 (zinc transporter), member 5 5 69093646-69131069 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035373 Approved Supported Nucleus
Golgi apparatus Expressed in all Expressed in all thyroid gland: 61.6 SLC30A8 ENSG00000164756 Solute carrier family 30 (zinc transporter), member 8 8 116950273-117176714 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Group enriched Tissue enhanced pancreas: 13.2 salivary gland: 5.0 SLC31A1 COPT1, CTR1, hCTR1 ENSG00000136868 Solute carrier family 31 (copper transporter), member 1 9 113221562-113264492 Predicted membrane proteins, Transporters Evidence at protein level HPA013810 Approved Renal cancer:2.20e-6 (favourable), Thyroid cancer:2.03e-4 (unfavourable) Expressed in all Expressed in all liver: 56.5 SLC33A1 ACATN, AT-1, AT1, SPG42 ENSG00000169359 Solute carrier family 33 (acetyl-CoA transporter), member 1 3 155821024-155854429 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA042430 Uncertain Expressed in all Expressed in all thyroid gland: 67.1 SLC34A2 NAPI-3B ENSG00000157765 Solute carrier family 34 (type II sodium/phosphate cotransporter), member 2 4 25655301-25678748 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA037989 Supported Tissue enhanced Tissue enriched 10 lung: 1127.5 fallopian tube: 111.7 SLC35A1 CMPST, hCST ENSG00000164414 Solute carrier family 35 (CMP-sialic acid transporter), member A1 6 87470623-87512336 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:2.70e-6 (unfavourable) Expressed in all Expressed in all prostate: 59.9 SLC35A2 UGALT, UGAT, UGT, UGT1, UGT2, UGTL ENSG00000102100 Solute carrier family 35 (UDP-galactose transporter), member A2 X 48903180-48911958 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036087 Approved Supported Golgi apparatus Liver cancer:9.64e-5 (unfavourable), Breast cancer:3.16e-4 (unfavourable), Stomach cancer:8.23e-4 (favourable) Expressed in all Expressed in all fallopian tube: 44.1 SLC35A3 ENSG00000117620 Solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3 1 99969789-100026979 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA015253 Uncertain Expressed in all Expressed in all rectum: 47.2 SLC35A5 FLJ20730 ENSG00000138459 Solute carrier family 35, member A5 3 112561709-112585577 Predicted membrane proteins, Transporters Evidence at protein level HPA035519, HPA057964 Uncertain Approved Golgi apparatus Renal cancer:4.10e-5 (favourable) Expressed in all Expressed in all thyroid gland: 43.7 SLC35C2 bA394O2.1, C20orf5, CGI-15, OVCOV1 ENSG00000080189 Solute carrier family 35 (GDP-fucose transporter), member C2 20 46345980-46364458 Predicted membrane proteins, Transporters Evidence at protein level HPA027011 Approved Supported Nucleoplasm
Golgi apparatus Liver cancer:1.08e-4 (unfavourable), Renal cancer:8.68e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 36.6 SLC35E2B ENSG00000189339 Solute carrier family 35, member E2B 1 1659529-1692728 Predicted membrane proteins, Transporters Evidence at protein level HPA045641, HPA062711 Uncertain Uncertain Nucleus Urothelial cancer:5.15e-4 (favourable), Head and neck cancer:7.64e-4 (favourable) Expressed in all Expressed in all smooth muscle: 47.0 SLC35F5 FLJ22004 ENSG00000115084 Solute carrier family 35, member F5 2 113705011-113756823 Predicted membrane proteins, Transporters Evidence at transcript level HPA034828, HPA049229 Uncertain Uncertain Plasma membrane Renal cancer:1.71e-5 (favourable), Cervical cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 65.7 SLC36A2 PAT2, TRAMD1, tramdorin ENSG00000186335 Solute carrier family 36 (proton/amino acid symporter), member 2 5 151314978-151347590 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044002, HPA062229 Supported Tissue enriched Group enriched 26 kidney: 67.2;skeletal muscle: 28.1 testis: 1.8 SLC37A3 DKFZp761N0624 ENSG00000157800 Solute carrier family 37, member 3 7 140293693-140404433 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014713, HPA061841 Supported Cytosol Liver cancer:4.78e-5 (unfavourable), Cervical cancer:9.54e-4 (unfavourable) Expressed in all Expressed in all endometrium: 72.5 SLC38A7 FLJ10815 ENSG00000103042 Solute carrier family 38, member 7 16 58665109-58685104 Predicted membrane proteins, Transporters Evidence at protein level HPA041777 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable) Expressed in all Mixed testis: 34.8 SLC38A9 FLJ90709 ENSG00000177058 Solute carrier family 38, member 9 5 55625845-55773194 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043785 Uncertain Approved Nucleoplasm
Vesicles Endometrial cancer:7.24e-5 (unfavourable) Expressed in all Expressed in all placenta: 79.8 SLC39A13 FLJ25785 ENSG00000165915 Solute carrier family 39 (zinc transporter), member 13 11 47407132-47416501 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA043971 Approved Uncertain Cytosol Ovarian cancer:2.73e-5 (unfavourable), Renal cancer:1.96e-4 (favourable), Colorectal cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all placenta: 58.0 SLC39A3 ZIP3 ENSG00000141873 Solute carrier family 39 (zinc transporter), member 3 19 2732204-2740152 Predicted membrane proteins, Transporters Evidence at protein level HPA042139, HPA058526 Uncertain Approved Vesicles Endometrial cancer:9.76e-5 (favourable) Expressed in all Expressed in all testis: 109.9 SLC39A5 ENSG00000139540 Solute carrier family 39 (zinc transporter), member 5 12 56230049-56237846 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA018423 Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:5.05e-4 (favourable) Tissue enhanced Group enriched 12 colon: 74.5;duodenum: 247.0;kidney: 114.6;liver: 85.7;pancreas: 53.1;rectum: 49.7;small intestine: 245.4 gallbladder: 10.0 SLC39A6 LIV-1 ENSG00000141424 Solute carrier family 39 (zinc transporter), member 6 18 36108532-36129385 Predicted membrane proteins, Transporters Evidence at protein level HPA042377 Approved Liver cancer:5.33e-4 (unfavourable) Expressed in all Expressed in all prostate: 209.0 SLC3A2 4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE ENSG00000168003 Solute carrier family 3 (amino acid transporter heavy chain), member 2 11 62856102-62888875 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB010455, HPA017980 Supported Supported Nucleus
Plasma membrane
Cytosol Urothelial cancer:1.48e-4 (unfavourable), Liver cancer:8.17e-4 (unfavourable), Renal cancer:8.22e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 424.3 SLC41A3 FLJ20473 ENSG00000114544 Solute carrier family 41, member 3 3 126006355-126101561 Predicted membrane proteins, Transporters Evidence at protein level HPA045847 Approved Supported Plasma membrane Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable) Expressed in all Expressed in all testis: 79.0 SLC43A1 PB39, POV1, R00504 ENSG00000149150 Solute carrier family 43 (amino acid system L transporter), member 1 11 57484534-57515786 Predicted membrane proteins, Transporters Evidence at protein level HPA018813, HPA018826 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable) Expressed in all Expressed in all liver: 50.0 SLC43A3 DKFZp762A227, Eeg1, FOAP-13, PRO1659, SEEEG-1 ENSG00000134802 Solute carrier family 43, member 3 11 57406954-57427580 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030551 Approved Renal cancer:3.97e-13 (unfavourable) Expressed in all Expressed in all thyroid gland: 121.6 SLC44A2 CTL2 ENSG00000129353 Solute carrier family 44 (choline transporter), member 2 19 10602457-10644559 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003228, HPA070799 Approved Approved Vesicles
Cell Junctions Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable) Expressed in all Expressed in all placenta: 224.3 SLC45A4 KIAA1126 ENSG00000022567 Solute carrier family 45, member 4 8 141207166-141308305 Predicted membrane proteins, Transporters Evidence at protein level HPA023154 Uncertain Approved Plasma membrane Renal cancer:1.73e-6 (favourable) Expressed in all Mixed testis: 21.1 SLC46A1 HCP1, MGC9564, PCFT ENSG00000076351 Solute carrier family 46 (folate transporter), member 1 17 28394756-28407197 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011614 Approved Supported Plasma membrane
Cytosol Glioma:3.90e-4 (unfavourable) Expressed in all Expressed in all duodenum: 97.7 SLC52A2 D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2 ENSG00000185803 Solute carrier family 52 (riboflavin transporter), member 2 8 144354135-144361272 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA063036 Approved Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable) Expressed in all Expressed in all placenta: 24.0 SLC5A12 MGC52019, SMCT2 ENSG00000148942 Solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12 11 26667019-26723427 Predicted membrane proteins, Transporters Evidence at protein level HPA060904 Supported Tissue enriched Tissue enhanced epididymis: 57.8;kidney: 172.6 small intestine: 34.0 SLC6A13 GAT2 ENSG00000010379 Solute carrier family 6 (neurotransmitter transporter), member 13 12 220621-262873 Predicted membrane proteins, Transporters Evidence at protein level HPA036449, HPA052726 Approved Approved Mitochondria Tissue enriched Tissue enriched 14 kidney: 152.9 fallopian tube: 11.2 SLC6A15 FLJ10316, hv7-3, NTT73, SBAT1, V7-3 ENSG00000072041 Solute carrier family 6 (neutral amino acid transporter), member 15 12 84859488-84913615 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008609 Uncertain Approved Nucleoli
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 23.1 placenta: 5.5 SLC6A16 NTT5 ENSG00000063127 Solute carrier family 6, member 16 19 49289638-49325225 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA076812 Approved Golgi apparatus Mixed Tissue enriched 18 testis: 161.8 lymph node: 9.0 SLC6A6 TAUT ENSG00000131389 Solute carrier family 6 (neurotransmitter transporter), member 6 3 14402576-14489349 Predicted membrane proteins, Transporters Evidence at protein level HPA015028, HPA016488 Supported Approved Cell Junctions
Cytosol Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Mixed ovary: 50.7 SLC6A8 CRTR, CT1 ENSG00000130821 Solute carrier family 6 (neurotransmitter transporter), member 8 X 153688099-153696593 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable) Expressed in all Mixed small intestine: 90.8 SLC6A9 GLYT1 ENSG00000196517 Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 1 43991500-44031467 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA013977 Uncertain Approved Nucleus
Golgi apparatus Renal cancer:5.93e-4 (unfavourable), Endometrial cancer:9.50e-4 (unfavourable) Expressed in all Tissue enhanced skin: 49.8 adrenal gland: 31.0 SLC7A6 KIAA0245, LAT-2, LAT3, y+LAT-2 ENSG00000103064 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 16 68264516-68301823 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050713 Uncertain Approved Vesicles
Plasma membrane Urothelial cancer:1.84e-4 (unfavourable) Expressed in all Mixed adipose tissue: 35.1 SLC7A7 LPI, y+LAT-1 ENSG00000155465 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 7 14 22773222-22829820 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036227 Approved Renal cancer:6.28e-6 (unfavourable) Expressed in all Tissue enhanced kidney: 279.7 parathyroid gland: 159.0 SLC7A8 LAT2, LPI-PC1 ENSG00000092068 Solute carrier family 7 (amino acid transporter light chain, L system), member 8 14 23125295-23183674 Predicted membrane proteins, Transporters Evidence at protein level CAB046015, HPA051950, HPA060672 Supported Urothelial cancer:1.52e-4 (unfavourable), Liver cancer:1.97e-4 (unfavourable), Lung cancer:3.15e-4 (favourable) Expressed in all Tissue enriched 8 parathyroid gland: 1066.4 kidney: 131.5 SLC8A2 KIAA1087, NCX2 ENSG00000118160 Solute carrier family 8 (sodium/calcium exchanger), member 2 19 47428017-47472168 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050818, HPA054671 Supported Mixed Tissue enriched 11 cerebral cortex: 68.4 endometrium: 6.2 SLC8A3 NCX3 ENSG00000100678 Solute carrier family 8 (sodium/calcium exchanger), member 3 14 70044217-70189070 Predicted membrane proteins, Transporters Evidence at protein level Tissue enriched Group enriched 6 cerebral cortex: 16.3;skeletal muscle: 6.1 adrenal gland: 1.7 SLC9A9 FLJ35613, NHE9 ENSG00000181804 Solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), member 9 3 143265222-143848531 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA058234 Approved Renal cancer:5.57e-7 (unfavourable), Lung cancer:8.18e-4 (favourable) Expressed in all Mixed placenta: 22.1 SLC9B2 FLJ23984, NHA2, NHEDC2 ENSG00000164038 Solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 4 103019868-103085829 Predicted membrane proteins, Transporters Evidence at protein level HPA047008 Uncertain Approved Nucleoplasm
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 32.6 liver: 20.5 SLCO1A2 OATP, OATP-A, OATP1A2, SLC21A3 ENSG00000084453 Solute carrier organic anion transporter family, member 1A2 12 21264600-21419594 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA071152 Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 28.8 salivary gland: 6.6 SLCO1B7 LST3, SLC21A21 ENSG00000205754 Solute carrier organic anion transporter family, member 1B7 (non-functional) 12 21015696-21092745 Predicted membrane proteins Evidence at transcript level HPA050892 Uncertain Not detected Tissue enriched 21 breast: 42.5 liver: 2.0 SLCO2B1 OATP-B, OATP2B1, SLC21A9 ENSG00000137491 Solute carrier organic anion transporter family, member 2B1 11 75100563-75206549 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020659 Uncertain Expressed in all Expressed in all liver: 123.0 SLCO3A1 OATP-D, OATP3A1, SLC21A11 ENSG00000176463 Solute carrier organic anion transporter family, member 3A1 15 91853695-92172435 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level Endometrial cancer:6.57e-6 (unfavourable), Cervical cancer:8.61e-4 (favourable) Expressed in all Mixed parathyroid gland: 26.5 SLCO4A1 OATP-E, OATP4A1, SLC21A12 ENSG00000101187 Solute carrier organic anion transporter family, member 4A1 20 62642445-62685785 Predicted membrane proteins, Transporters Evidence at protein level HPA030669, HPA030670 Uncertain Approved Cell Junctions Lung cancer:4.74e-4 (unfavourable) Expressed in all Mixed esophagus: 10.6 SMG5 EST1B, KIAA1089, LPTS-RP1, LPTSRP1, RP11-54H19.7, SMG-5 ENSG00000198952 SMG5 nonsense mediated mRNA decay factor 1 156249224-156282825 Predicted membrane proteins Evidence at protein level HPA072651 Supported Cytoplasmic bodies Liver cancer:6.70e-9 (unfavourable), Endometrial cancer:3.39e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 74.7 SMIM7 C19orf42, MGC2747 ENSG00000214046 Small integral membrane protein 7 19 16630751-16660442 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043127 Uncertain Approved Golgi apparatus Expressed in all Expressed in all epididymis: 55.0 SMPD2 ISC1, nSMase ENSG00000135587 Sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase) 6 109440763-109443919 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018110, HPA018125 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable) Expressed in all Mixed testis: 55.6 SMPD3 NSMASE2 ENSG00000103056 Sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) 16 68358325-68448688 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033885, HPA065535, HPA069383 Approved Supported Endoplasmic reticulum Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable) Mixed Tissue enhanced duodenum: 62.7;small intestine: 64.1 stomach: 22.9 SOAT2 ACAT2 ENSG00000167780 Sterol O-acyltransferase 2 12 53103518-53124538 Enzymes, Predicted membrane proteins Evidence at protein level HPA062409 Uncertain Group enriched Tissue enhanced duodenum: 12.4;small intestine: 22.4 spleen: 3.5 SPAG9 CT89, FLJ13450, FLJ14006, FLJ26141, FLJ34602, HLC4, HSS, JLP, KIAA0516, MGC117291, MGC14967, MGC74461, PHET, PIG6, SYD1 ENSG00000008294 Sperm associated antigen 9 17 50962174-51120865 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040446, HPA061458 Approved Validated Microtubule organizing center
Cytosol Urothelial cancer:8.10e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 106.4 SPAM1 HYAL5, PH-20, SPAG15 ENSG00000106304 Sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding) 7 123925237-123971414 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017984 Supported Not detected Tissue enriched 63 testis: 30.0 duodenum,small intestine: 0.4 SPCS1 HSPC033, SPC1, SPC12, YJR010C-A ENSG00000114902 Signal peptidase complex subunit 1 3 52704955-52711146 Predicted membrane proteins Evidence at protein level HPA046091, HPA055273 Supported Approved Golgi apparatus
Vesicles Renal cancer:2.90e-4 (favourable), Colorectal cancer:9.28e-4 (favourable) Expressed in all Expressed in all testis: 215.4 SPCS2 KIAA0102 ENSG00000118363 Signal peptidase complex subunit 2 11 74949247-74979031 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013386 Approved Approved Nucleus Expressed in all Expressed in all epididymis: 264.2 SPG7 CAR, CMAR, SPG5C ENSG00000197912 Spastic paraplegia 7 (pure and complicated autosomal recessive) 16 89490917-89557768 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Endometrial cancer:2.22e-4 (favourable), Urothelial cancer:4.25e-4 (favourable), Pancreatic cancer:4.91e-4 (favourable) Expressed in all Expressed in all thyroid gland: 52.3 SPPL3 DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4 ENSG00000157837 Signal peptide peptidase like 3 12 120762510-120904371 Enzymes, Predicted membrane proteins Evidence at protein level HPA004194, HPA059958 Uncertain Supported Vesicles
Plasma membrane Liver cancer:1.29e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 82.3 SPTLC1 hLCB1, HSAN1, HSN1, LCB1, SPTI ENSG00000090054 Serine palmitoyltransferase, long chain base subunit 1 9 92031999-92115384 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA010860, CAB018747, HPA063907 Supported Supported Endoplasmic reticulum Renal cancer:1.36e-6 (favourable) Expressed in all Expressed in all thyroid gland: 108.0 SPTSSA C14orf147, ssSPTa ENSG00000165389 Serine palmitoyltransferase, small subunit A 14 34432789-34462356 Predicted membrane proteins Evidence at protein level Expressed in all Expressed in all adrenal gland: 90.6 SRD5A3 FLJ13352, SRD5A2L, SRD5A2L1 ENSG00000128039 Steroid 5 alpha-reductase 3 4 55346109-55373096 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027006 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable) Expressed in all Expressed in all gallbladder: 28.3 SREBF1 bHLHd1, SREBP-1c, SREBP1 ENSG00000072310 Sterol regulatory element binding transcription factor 1 17 17810399-17837002 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB005406, HPA043343, HPA043878 Uncertain Supported Golgi apparatus
Cytosol Endometrial cancer:2.66e-4 (favourable), Pancreatic cancer:9.05e-4 (favourable) Expressed in all Expressed in all adrenal gland: 92.9 SREBF2 bHLHd2, SREBP2 ENSG00000198911 Sterol regulatory element binding transcription factor 2 22 41833079-41907308 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA031962, HPA031963 Approved Supported Nucleoplasm
Vesicles
Mitochondria Renal cancer:1.37e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.8 SSPN KRAG, SPN1, SPN2 ENSG00000123096 Sarcospan 12 26121991-26299290 Predicted membrane proteins Evidence at protein level HPA066432 Approved Nucleus
Nuclear membrane Renal cancer:2.77e-5 (unfavourable) Mixed Mixed cervix, uterine: 64.1 SSR3 TRAPG ENSG00000114850 Signal sequence receptor, gamma (translocon-associated protein gamma) 3 156540140-156555184 Predicted membrane proteins Evidence at protein level HPA014906 Approved Approved Uncertain Cytosol Liver cancer:4.46e-7 (unfavourable), Renal cancer:2.84e-4 (unfavourable), Head and neck cancer:3.43e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 203.5 ST3GAL2 SIAT4B, ST3GalA.2, ST3GALII ENSG00000157350 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 16 70375978-70439237 Enzymes, Predicted membrane proteins Evidence at protein level HPA017270 Approved Approved Vesicles Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:2.33e-4 (favourable), Liver cancer:2.79e-4 (unfavourable) Expressed in all Mixed appendix: 15.7 ST3GAL3 MRT12, SIAT6 ENSG00000126091 ST3 beta-galactoside alpha-2,3-sialyltransferase 3 1 43705824-43931165 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051102 Uncertain Expressed in all Expressed in all skeletal muscle: 30.5 ST3GAL5 SIAT9, SIATGM3S, ST3GalV ENSG00000115525 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 2 85839144-85889014 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA034708, HPA040425, HPA068928 Uncertain Approved Vesicles Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable) Expressed in all Mixed thyroid gland: 72.2 ST3GAL6 SIAT10, ST3GALVI ENSG00000064225 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 3 98732236-98821201 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018792 Approved Tissue enhanced Mixed liver: 28.4 ST7 ETS7q, FAM4A, FAM4A1, HELG, RAY1, SEN4, TSG7 ENSG00000004866 Suppression of tumorigenicity 7 7 116953238-117230103 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038325, HPA038326 Approved Supported Nucleoplasm
Cytosol Renal cancer:3.39e-5 (favourable) Expressed in all Expressed in all thyroid gland: 50.9 ST8SIA1 SIAT8, SIAT8A ENSG00000111728 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 12 22063773-22437041 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026775 Approved Mixed Mixed cerebral cortex: 9.1 ST8SIA5 SIAT8E ENSG00000101638 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 18 46667821-46759257 Predicted membrane proteins Evidence at protein level HPA043813, HPA046771 Approved Approved Plasma membrane
Midbody Tissue enriched Tissue enhanced adrenal gland: 5.5;cerebral cortex: 11.5 parathyroid gland: 3.4 STARD3 es64, MLN64 ENSG00000131748 StAR-related lipid transfer (START) domain containing 3 17 39637065-39663484 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level CAB017021 Uncertain Liver cancer:3.60e-5 (unfavourable), Renal cancer:7.70e-4 (unfavourable) Expressed in all Expressed in all testis: 33.3 STK36 FU, KIAA1278 ENSG00000163482 Serine/threonine kinase 36 2 218672026-218702716 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027409, HPA027453, HPA030058 Approved Supported Cytosol Liver cancer:5.20e-4 (unfavourable) Expressed in all Expressed in all testis: 58.8 STRA6 FLJ12541 ENSG00000137868 Stimulated by retinoic acid 6 15 74179466-74212267 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA040839 Approved Approved Nucleus
Cytosol Mixed Tissue enhanced cervix, uterine: 37.3;placenta: 20.4 endometrium: 13.5 STS ARSC, ARSC1 ENSG00000101846 Steroid sulfatase (microsomal), isozyme S X 7219456-7354810 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA002904 Approved Pancreatic cancer:3.47e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 36.3 adipose tissue: 18.9 STT3A ITM1, MGC9042, STT3-A, TMC ENSG00000134910 STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 11 125591712-125625215 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA030735 Approved Uncertain Nucleoplasm
Vesicles
Cytosol Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable) Expressed in all Tissue enriched 6 parathyroid gland: 1111.5 epididymis: 173.1 STX17 FLJ20651 ENSG00000136874 Syntaxin 17 9 99906633-99970341 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001204 Approved Uncertain Nucleoli
Cytosol Renal cancer:1.62e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 36.1 SUN1 FLJ12407, KIAA0810, UNC84A ENSG00000164828 Sad1 and UNC84 domain containing 1 7 816615-896435 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008346, HPA008461 Supported Validated Nuclear membrane Expressed in all Expressed in all endometrium: 120.0 SUN2 UNC84B ENSG00000100242 Sad1 and UNC84 domain containing 2 22 38734725-38794143 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001209 Supported Supported Nuclear membrane Expressed in all Expressed in all lymph node: 120.6 SUN5 dJ726C3.1, SPAG4L, TSARG4 ENSG00000167098 Sad1 and UNC84 domain containing 5 20 32983773-33004433 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048529 Supported Not detected Tissue enriched 409 testis: 40.8 all non-specific tissues: 0.0 SURF1 ENSG00000148290 Surfeit 1 9 133351755-133356676 Disease related genes, Predicted membrane proteins Evidence at protein level CAB033946 Uncertain Renal cancer:6.92e-9 (favourable) Expressed in all Expressed in all epididymis: 46.0 SURF4 ERV29, FLJ22993, MGC102753 ENSG00000148248 Surfeit 4 9 133361449-133376166 Predicted membrane proteins Evidence at protein level HPA064613 Approved Head and neck cancer:1.47e-5 (unfavourable), Breast cancer:5.85e-4 (unfavourable), Liver cancer:8.11e-4 (unfavourable) Expressed in all Expressed in all small intestine: 84.4 SVOP DKFZp761H039 ENSG00000166111 SV2 related protein 12 108907741-109021240 Predicted membrane proteins Evidence at protein level HPA016573 Uncertain Group enriched Tissue enriched 15 cerebral cortex: 32.4 adrenal gland: 2.1 SYNDIG1 C20orf39, FLJ14220, IFITMD5, SynDIG1, TMEM90B ENSG00000101463 Synapse differentiation inducing 1 20 24469199-24666616 Predicted membrane proteins Evidence at protein level HPA059267 Uncertain Supported Vesicles Thyroid cancer:6.16e-6 (unfavourable) Mixed Tissue enhanced cerebral cortex: 26.9 heart muscle: 14.6 SYNDIG1L capucin, IFITMD4, TMEM90A ENSG00000183379 Synapse differentiation inducing 1-like 14 74405893-74426102 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA042594, HPA048487 Uncertain Mixed Tissue enriched 10 epididymis: 13.2 lung: 1.3 SYNGR1 ENSG00000100321 Synaptogyrin 1 22 39349925-39385588 Predicted membrane proteins Evidence at protein level HPA029673, CAB034277 Supported Supported Cytosol Renal cancer:4.98e-7 (favourable), Pancreatic cancer:2.41e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 175.9 SYNGR2 ENSG00000108639 Synaptogyrin 2 17 78168558-78173527 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014742 Approved Approved Golgi apparatus Renal cancer:5.37e-4 (unfavourable) Expressed in all Expressed in all lung: 155.0 SYNGR3 ENSG00000127561 Synaptogyrin 3 16 1989660-1994275 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB034278, HPA042842 Supported Approved Plasma membrane Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable) Mixed Tissue enriched 7 cerebral cortex: 82.8 adrenal gland: 12.5 SYNGR4 ENSG00000105467 Synaptogyrin 4 19 48364395-48376376 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA030075, HPA059286 Approved Approved Golgi apparatus Mixed Tissue enriched 11 testis: 46.8 parathyroid gland: 4.4 SYNPR MGC26651, SPO ENSG00000163630 Synaptoporin 3 63228315-63616921 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051368, HPA061671 Supported Tissue enhanced Tissue enriched 23 cerebral cortex: 78.4 heart muscle: 3.3 SYP MRX96 ENSG00000102003 Synaptophysin X 49187804-49200259 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB000076, HPA002858, CAB055505 Supported Group enriched Tissue enriched 11 cerebral cortex: 573.3 adrenal gland: 51.4 SYPL1 SYPL ENSG00000008282 Synaptophysin-like 1 7 106090503-106112576 Predicted membrane proteins Evidence at protein level HPA014141 Approved Renal cancer:1.25e-9 (favourable) Expressed in all Expressed in all thyroid gland: 194.0 TACR2 NK2R, NKNAR, SKR, TAC2R ENSG00000075073 Tachykinin receptor 2 10 69403903-69416867 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enhanced smooth muscle: 66.9 esophagus: 23.2 TAF1B RAF1B, RAFI63, SL1, TAFI63 ENSG00000115750 TATA box binding protein (TBP)-associated factor, RNA polymerase I, B, 63kDa 2 9843354-9934416 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA071254 Supported Nucleus
Nucleoli Liver cancer:6.94e-7 (unfavourable), Colorectal cancer:8.58e-5 (favourable), Renal cancer:8.55e-4 (favourable) Expressed in all Mixed parathyroid gland: 23.5 TANGO6 FLJ12688, KIAA1746, TMCO7 ENSG00000103047 Transport and golgi organization 6 homolog 16 68843604-69085180 Predicted membrane proteins Evidence at protein level HPA041312 Approved Approved Golgi apparatus
Cytosol Renal cancer:3.20e-4 (favourable) Expressed in all Mixed parathyroid gland: 14.9 TBC1D32 bA57L9.1, BROMI, C6orf170, C6orf171, dJ310J6.1, FLJ30899, FLJ34235 ENSG00000146350 TBC1 domain family, member 32 6 121079494-121334745 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013413 Uncertain Approved Mitochondria Mixed Mixed testis: 6.0 TBCD ENSG00000141556 Tubulin folding cofactor D 17 82752064-82945922 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045200 Approved Liver cancer:2.39e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 58.5 TBXAS1 CYP5, CYP5A1, THAS, TS, TXAS, TXS ENSG00000059377 Thromboxane A synthase 1 (platelet) 7 139777051-140020325 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031257, HPA031258, HPA031259 Supported Supported Vesicles Renal cancer:1.14e-4 (unfavourable) Expressed in all Mixed spleen: 57.1 TERT EST2, hEST2, TCS1, TP2, TRT ENSG00000164362 Telomerase reverse transcriptase 5 1253147-1295069 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA054641, HPA065897 Validated Nucleoplasm Mixed Not detected lymph node,testis: 0.5 TEX10 bA208F1.2, FLJ20287, Ipi1 ENSG00000136891 Testis expressed 10 9 100302077-100352939 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Liver cancer:4.46e-5 (unfavourable) Expressed in all Expressed in all testis: 41.6 TEX2 HT008, KIAA1738, TMEM96 ENSG00000136478 Testis expressed 2 17 64147227-64263301 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020648, HPA057116 Approved Approved Nucleus Colorectal cancer:3.90e-6 (favourable) Expressed in all Expressed in all testis: 99.2 TIGIT DKFZp667A205, FLJ39873, VSIG9, VSTM3 ENSG00000181847 T cell immunoreceptor with Ig and ITIM domains 3 114276913-114310288 Predicted membrane proteins Evidence at protein level Head and neck cancer:3.96e-4 (favourable), Cervical cancer:5.43e-4 (favourable) Mixed Tissue enhanced lymph node: 45.0 spleen: 21.0 TIMM17A TIM17, TIM17A ENSG00000134375 Translocase of inner mitochondrial membrane 17 homolog A (yeast) 1 201955491-201970661 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA010083 Approved Supported Nucleoplasm
Mitochondria Breast cancer:1.98e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 62.9 TIMM17B DXS9822, JM3 ENSG00000126768 Translocase of inner mitochondrial membrane 17 homolog B (yeast) X 48893447-48898143 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029093 Approved Approved Microtubules
Mitochondria Cervical cancer:6.63e-4 (favourable), Urothelial cancer:7.88e-4 (favourable) Expressed in all Expressed in all fallopian tube: 43.4 TIMM22 TEX4 ENSG00000177370 Translocase of inner mitochondrial membrane 22 homolog (yeast) 17 997117-1003671 Predicted membrane proteins Evidence at protein level HPA045138 Uncertain Renal cancer:1.41e-4 (favourable), Pancreatic cancer:3.42e-4 (favourable) Expressed in all Mixed parathyroid gland: 4.3 TIMM23 TIM23 ENSG00000265354 Translocase of inner mitochondrial membrane 23 homolog (yeast) 10 45972449-46003734 Predicted membrane proteins Evidence at protein level HPA031408 Approved Supported Mitochondria Liver cancer:2.77e-5 (unfavourable), Ovarian cancer:6.79e-4 (favourable) Expressed in all Expressed in all testis: 141.6 TIMM23B bA592B15.7 ENSG00000204152 Translocase of inner mitochondrial membrane 23 homolog B (yeast) 10 49942033-49974850 Predicted membrane proteins Evidence at transcript level Expressed in all Mixed bone marrow: 5.5 TIMMDC1 C3orf1, FLJ22597 ENSG00000113845 Translocase of inner mitochondrial membrane domain containing 1 3 119498532-119525090 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA053214, HPA055846 Uncertain Validated Nucleus
Mitochondria Liver cancer:1.12e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 31.5 TM2D1 BBP ENSG00000162604 TM2 domain containing 1 1 61681046-61725423 Predicted membrane proteins Evidence at protein level HPA046058, HPA055621 Approved Validated Nucleoplasm Liver cancer:2.02e-7 (unfavourable) Expressed in all Expressed in all thyroid gland: 67.8 TM2D2 BLP1 ENSG00000169490 TM2 domain containing 2 8 38988808-38996824 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047152, HPA050547 Approved Approved Nucleoplasm
Vesicles
Plasma membrane Colorectal cancer:1.71e-4 (favourable), Breast cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all testis: 51.1 TM2D3 BLP2, FLJ22604 ENSG00000184277 TM2 domain containing 3 15 101621444-101652391 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054064 Uncertain Approved Nucleoplasm
Cytosol Expressed in all Expressed in all cerebral cortex: 97.5 TM4SF19 ENSG00000145107 Transmembrane 4 L six family member 19 3 196319342-196338503 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Tissue enhanced Tissue enhanced testis: 11.3 esophagus,lung: 3.1 TM4SF4 il-TMP ENSG00000169903 Transmembrane 4 L six family member 4 3 149473974-149503281 Predicted membrane proteins, Transporters Evidence at protein level HPA046430 Supported Approved Plasma membrane
Cytosol Group enriched Group enriched 34 duodenum: 595.8;gallbladder: 1326.5;liver: 343.7;small intestine: 515.2 stomach: 20.3 TM7SF3 ENSG00000064115 Transmembrane 7 superfamily member 3 12 26973195-27014434 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041097, HPA057640 Uncertain Approved Nucleus
Cytosol Renal cancer:1.32e-4 (favourable) Expressed in all Expressed in all kidney: 189.4 TMBIM1 LFG3, PP1201, RECS1 ENSG00000135926 Transmembrane BAX inhibitor motif containing 1 2 218274192-218292586 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012093, HPA070824 Approved Supported Vesicles Renal cancer:3.38e-4 (favourable), Pancreatic cancer:4.22e-4 (unfavourable) Expressed in all Expressed in all esophagus: 270.8 TMBIM6 BAXI1, BI-1, TEGT ENSG00000139644 Transmembrane BAX inhibitor motif containing 6 12 49707725-49764934 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA017378 Approved Renal cancer:1.00e-5 (favourable), Head and neck cancer:1.91e-4 (unfavourable), Breast cancer:3.54e-4 (unfavourable) Expressed in all Expressed in all kidney: 1179.3 TMC4 ENSG00000167608 Transmembrane channel-like 4 19 54160108-54173250 Predicted membrane proteins Evidence at protein level HPA048635 Approved Renal cancer:1.54e-8 (favourable) Expressed in all Tissue enhanced duodenum: 31.3 small intestine: 22.6 TMC6 EVER1, EVIN1, LAK-4P ENSG00000141524 Transmembrane channel-like 6 17 78110458-78132407 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA051430 Uncertain Stomach cancer:1.82e-4 (favourable), Urothelial cancer:3.20e-4 (favourable) Expressed in all Expressed in all spleen: 84.5 TMCC1 KIAA0779 ENSG00000172765 Transmembrane and coiled-coil domain family 1 3 129647792-129893576 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053894 Uncertain Renal cancer:1.77e-6 (unfavourable), Pancreatic cancer:1.87e-4 (unfavourable), Liver cancer:9.15e-4 (unfavourable) Expressed in all Expressed in all testis: 25.1 TMCC2 FLJ38497, HUCEP11 ENSG00000133069 Transmembrane and coiled-coil domain family 2 1 205228176-205273343 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014254 Approved Mixed Tissue enhanced bone marrow: 53.3;cerebral cortex: 25.0 placenta: 8.1 TMCC3 KIAA1145 ENSG00000057704 Transmembrane and coiled-coil domain family 3 12 94567124-94650562 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014272 Approved Approved Cytosol Endometrial cancer:4.87e-4 (unfavourable) Expressed in all Mixed placenta: 25.5 TMCO1 HP10122, TMCC4 ENSG00000143183 Transmembrane and coiled-coil domains 1 1 165724293-165827755 Disease related genes, Predicted membrane proteins Evidence at protein level HPA054768 Supported Endoplasmic reticulum Head and neck cancer:5.17e-7 (unfavourable), Renal cancer:1.25e-4 (unfavourable), Liver cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 157.3 TMCO3 C13orf11, FLJ20623 ENSG00000150403 Transmembrane and coiled-coil domains 3 13 113490995-113554590 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039561, HPA048126 Uncertain Approved Cytosol Liver cancer:1.14e-5 (unfavourable), Urothelial cancer:4.10e-4 (unfavourable), Cervical cancer:5.80e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 49.2 TMEFF2 CT120.2, HPP1, TENB2, TPEF, TR ENSG00000144339 Transmembrane protein with EGF-like and two follistatin-like domains 2 2 191949043-192195709 Predicted membrane proteins Evidence at protein level HPA015587 Uncertain Approved Microtubules
Cytokinetic bridge Tissue enriched Tissue enhanced cerebral cortex: 41.1;prostate: 54.9;seminal vesicle: 19.4 epididymis: 10.5 TMEM100 FLJ10970, FLJ37856 ENSG00000166292 Transmembrane protein 100 17 55719627-55732121 Predicted membrane proteins Evidence at protein level HPA055936 Approved Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable) Mixed Tissue enhanced lung: 131.4;placenta: 77.5 epididymis: 44.0 TMEM106C MGC5576 ENSG00000134291 Transmembrane protein 106C 12 47963569-47968878 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047204 Supported Liver cancer:5.27e-8 (unfavourable), Renal cancer:4.62e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 165.9 TMEM107 MGC10744 ENSG00000179029 Transmembrane protein 107 17 8173237-8176399 Predicted membrane proteins Evidence at transcript level HPA052555, HPA059653 Approved Approved Nucleoplasm
Midbody
Midbody ring
Cytosol Endometrial cancer:9.39e-5 (favourable) Expressed in all Mixed fallopian tube: 71.3 TMEM114 ENSG00000232258 Transmembrane protein 114 16 8537605-8590193 Disease related genes, Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 62 seminal vesicle: 28.3 epididymis: 0.4 TMEM116 FLJ90167 ENSG00000198270 Transmembrane protein 116 12 111931282-112013185 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA040720 Approved Approved Nucleoplasm
Microtubules Renal cancer:1.08e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 56.1 testis: 47.8 TMEM117 DKFZp434K2435 ENSG00000139173 Transmembrane protein 117 12 43835967-44389762 Predicted membrane proteins Evidence at transcript level HPA046223 Uncertain Melanoma:3.94e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 7.2 TMEM120A NET29, TMPIT ENSG00000189077 Transmembrane protein 120A 7 75986837-75994659 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Expressed in all Expressed in all small intestine: 73.9 TMEM126A DKFZp586C1924, OPA7 ENSG00000171202 Transmembrane protein 126A 11 85647967-85656547 Disease related genes, Predicted membrane proteins Evidence at protein level HPA046648 Approved Approved Nucleus
Cytosol Liver cancer:8.60e-5 (unfavourable) Expressed in all Expressed in all testis: 66.9 TMEM127 FLJ20507, FLJ22257 ENSG00000135956 Transmembrane protein 127 2 96248516-96265994 Disease related genes, Predicted membrane proteins Evidence at protein level Renal cancer:6.69e-5 (favourable), Liver cancer:6.59e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 110.4 TMEM129 D4S2561E ENSG00000168936 Transmembrane protein 129, E3 ubiquitin protein ligase 4 1715952-1721358 Predicted membrane proteins Evidence at protein level HPA060920 Approved Vesicles Renal cancer:9.64e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 35.6 TMEM131 CC28, KIAA0257, PRO1048, RW1, YR-23 ENSG00000075568 Transmembrane protein 131 2 97756333-97995891 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017678, HPA017682 Approved Uncertain Vesicles
Intermediate filaments Expressed in all Expressed in all parathyroid gland: 46.7 TMEM134 FLJ21749 ENSG00000172663 Transmembrane protein 134 11 67461710-67469272 Predicted membrane proteins Evidence at protein level HPA043744 Approved Supported Cytosol Expressed in all Expressed in all skin: 38.4 TMEM135 FLJ22104 ENSG00000166575 Transmembrane protein 135 11 87037844-87323758 Predicted membrane proteins Evidence at protein level HPA056685, HPA069473 Uncertain Supported Vesicles Renal cancer:9.02e-4 (favourable) Expressed in all Expressed in all adipose tissue: 31.8 TMEM138 HSPC196, JBTS16 ENSG00000149483 Transmembrane protein 138 11 61362001-61369509 Disease related genes, Predicted membrane proteins Evidence at protein level HPA042373 Approved Approved Microtubules Renal cancer:4.12e-6 (unfavourable), Liver cancer:7.90e-4 (unfavourable) Expressed in all Expressed in all epididymis: 24.8 TMEM141 MGC14141 ENSG00000244187 Transmembrane protein 141 9 136791355-136793257 Predicted membrane proteins Evidence at protein level HPA014615, HPA050244 Approved Supported Cell Junctions
Mitochondria Renal cancer:6.63e-4 (favourable) Expressed in all Expressed in all prostate: 214.3 TMEM143 FLJ10922 ENSG00000161558 Transmembrane protein 143 19 48332356-48364237 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014476 Uncertain Approved Nucleoli fibrillar center Renal cancer:1.53e-7 (favourable) Expressed in all Tissue enhanced skeletal muscle: 32.5 heart muscle: 15.9 TMEM144 FLJ11155 ENSG00000164124 Transmembrane protein 144 4 158201604-158255411 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043767, HPA063554 Uncertain Approved Mitochondria Endometrial cancer:2.89e-4 (favourable), Pancreatic cancer:8.48e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 90.8 testis: 46.6 TMEM14B MGC1223 ENSG00000137210 Transmembrane protein 14B 6 10747759-10852753 Predicted membrane proteins Evidence at protein level Liver cancer:9.35e-5 (unfavourable), Endometrial cancer:6.51e-4 (unfavourable), Ovarian cancer:7.41e-4 (favourable) Expressed in all Expressed in all thyroid gland: 204.2 TMEM14EP TMEM14E ENSG00000221962 Transmembrane protein 14E, pseudogene 3 152340527-152340904 Predicted membrane proteins Evidence at transcript level HPA014550 Uncertain Not detected Tissue enhanced skin: 1.0 bone marrow: 0.9 TMEM151B bA444E17.5, C6orf137, TMEM193 ENSG00000178233 Transmembrane protein 151B 6 44270466-44307506 Predicted membrane proteins Evidence at transcript level HPA055167 Uncertain Tissue enhanced Tissue enriched 10 cerebral cortex: 40.1 adrenal gland: 4.0 TMEM156 FLJ23235 ENSG00000121895 Transmembrane protein 156 4 38966744-39032922 Predicted membrane proteins Evidence at transcript level Breast cancer:4.09e-4 (favourable) Mixed Group enriched 6 appendix: 12.2;lymph node: 28.1;spleen: 15.4;tonsil: 25.3;urinary bladder: 5.9 gallbladder: 3.1 TMEM159 promethin ENSG00000011638 Transmembrane protein 159 16 21158377-21180616 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018033, HPA063509 Approved Approved Vesicles Renal cancer:8.11e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all skin: 90.6 TMEM160 FLJ20512 ENSG00000130748 Transmembrane protein 160 19 47045907-47048630 Predicted membrane proteins Evidence at protein level HPA055904 Uncertain Expressed in all Mixed cerebral cortex: 21.0 TMEM161A FLJ20422, FLJ39645 ENSG00000064545 Transmembrane protein 161A 19 19119169-19138513 Predicted membrane proteins Evidence at protein level HPA043365 Approved Approved Cytosol Stomach cancer:2.99e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 20.9 TMEM165 GDT1, TMPT27, TPARL ENSG00000134851 Transmembrane protein 165 4 55395957-55453397 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038299 Supported Supported Golgi apparatus
Vesicles Renal cancer:1.18e-8 (unfavourable), Liver cancer:2.08e-5 (unfavourable) Expressed in all Expressed in all placenta: 86.4 TMEM167B AD-020, C1orf119, FLJ90710 ENSG00000215717 Transmembrane protein 167B 1 109089803-109096934 Predicted membrane proteins Evidence at transcript level Endometrial cancer:8.86e-4 (favourable) Expressed in all Expressed in all thyroid gland: 49.3 TMEM169 FLJ34263 ENSG00000163449 Transmembrane protein 169 2 216081866-216102783 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA070657 Uncertain Approved Focal adhesion sites Mixed Tissue enhanced cerebral cortex: 12.0 thyroid gland: 4.8 TMEM170A FLJ37611, TMEM170 ENSG00000166822 Transmembrane protein 170A 16 75443054-75465497 Predicted membrane proteins Evidence at transcript level HPA055071 Uncertain Renal cancer:2.36e-9 (favourable) Expressed in all Expressed in all testis: 32.6 TMEM174 FLJ31268, MGC13034 ENSG00000164325 Transmembrane protein 174 5 73173195-73175143 Predicted membrane proteins Evidence at protein level HPA037975 Supported Renal cancer:3.30e-6 (favourable) Tissue enriched Tissue enriched 685 kidney: 158.0 thyroid gland: 0.2 TMEM175 MGC4618 ENSG00000127419 Transmembrane protein 175 4 932387-958656 Predicted membrane proteins, Transporters Evidence at protein level HPA057160 Approved Approved Nucleus
Nuclear membrane Pancreatic cancer:9.85e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 20.8 TMEM176A HCA112, MS4B1 ENSG00000002933 Transmembrane protein 176A 7 150800403-150805120 Predicted membrane proteins Evidence at protein level HPA008770 Approved Approved Mitochondria Expressed in all Expressed in all liver: 579.4 TMEM177 MGC10993 ENSG00000144120 Transmembrane protein 177 2 119679167-119686507 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036689, HPA053816 Uncertain Approved Nucleus
Nucleoli fibrillar center Expressed in all Mixed duodenum: 16.9 TMEM179 C14orf90, FLJ42486, TMEM179A ENSG00000258986 Transmembrane protein 179 14 104474678-104605647 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA002942 Uncertain Mitochondria Mixed Group enriched 8 adrenal gland: 14.7;cerebral cortex: 28.0 testis: 2.5 TMEM179B ENSG00000185475 Transmembrane protein 179B 11 62787415-62790405 Predicted membrane proteins Evidence at protein level HPA016585, HPA062068 Validated Nuclear speckles Expressed in all Expressed in all epididymis: 86.2 TMEM180 bA18I14.8, C10orf77, FLJ22529 ENSG00000138111 Transmembrane protein 180 10 102461395-102477045 Predicted membrane proteins, Transporters Evidence at protein level HPA018031 Uncertain Approved Golgi apparatus
Cytosol Cervical cancer:8.29e-4 (favourable), Renal cancer:8.51e-4 (unfavourable) Expressed in all Mixed skin: 8.8 TMEM182 FLJ30294 ENSG00000170417 Transmembrane protein 182 2 102736908-102843893 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045861 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Group enriched 10 heart muscle: 60.3;skeletal muscle: 44.1 prostate: 5.0 TMEM184A MGC9712 ENSG00000164855 Transmembrane protein 184A 7 1542235-1560821 Predicted membrane proteins Evidence at protein level HPA053790, HPA071312 Uncertain Approved Nucleoplasm Colorectal cancer:1.12e-4 (unfavourable), Thyroid cancer:9.94e-4 (unfavourable) Mixed Tissue enhanced skin: 33.5 esophagus: 26.7 TMEM186 C16orf51, DKFZP564K2062 ENSG00000184857 Transmembrane protein 186 16 8780384-8797648 Predicted membrane proteins Evidence at protein level HPA018226, HPA063559 Uncertain Approved Cell Junctions Renal cancer:1.93e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 22.5 TMEM19 FLJ10936 ENSG00000139291 Transmembrane protein 19 12 71686087-71705046 Predicted membrane proteins Evidence at protein level HPA016830 Approved Expressed in all Expressed in all kidney: 40.5 TMEM199 C17orf32, MGC45714 ENSG00000244045 Transmembrane protein 199 17 28357581-28363683 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027051 Uncertain Liver cancer:1.54e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 19.1 TMEM200A KIAA1913, TTMC ENSG00000164484 Transmembrane protein 200A 6 130365734-130443063 Predicted membrane proteins Evidence at protein level HPA014396 Uncertain Renal cancer:3.92e-4 (favourable) Mixed Tissue enhanced endometrium: 64.8 smooth muscle: 29.0 TMEM200B TTMB ENSG00000253304 Transmembrane protein 200B 1 29119428-29123935 Predicted membrane proteins Evidence at transcript level HPA055254 Uncertain Mixed Tissue enhanced endometrium: 68.0 seminal vesicle: 52.6 TMEM200C TTMA ENSG00000206432 Transmembrane protein 200C 18 5882072-5895955 Predicted membrane proteins Evidence at protein level HPA047253, HPA050490 Uncertain Approved Microtubules Tissue enhanced Tissue enhanced adrenal gland: 3.1;cerebral cortex: 3.5 salivary gland: 1.8 TMEM205 MBC3205, UNQ501 ENSG00000105518 Transmembrane protein 205 19 11342776-11346518 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA041504 Approved Approved Nucleoplasm
Nuclear membrane
Endoplasmic reticulum Expressed in all Expressed in all parathyroid gland: 253.1 TMEM206 C1orf75, FLJ10874 ENSG00000065600 Transmembrane protein 206 1 212363931-212414901 Predicted membrane proteins Evidence at protein level HPA008540 Uncertain Liver cancer:3.71e-5 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 25.4 kidney: 10.6 TMEM209 FLJ14803, NET31 ENSG00000146842 Transmembrane protein 209 7 130164715-130207770 Predicted membrane proteins Evidence at protein level HPA031678 Uncertain Approved Nuclear membrane
Nuclear speckles
Vesicles Expressed in all Expressed in all testis: 27.7 TMEM211 bA9F11.1 ENSG00000206069 Transmembrane protein 211 22 24935110-24946695 Predicted membrane proteins Evidence at transcript level HPA066784 Uncertain Tissue enhanced Tissue enhanced cervix, uterine: 4.5;stomach: 3.4 salivary gland: 1.9 TMEM214 FLJ20254 ENSG00000119777 Transmembrane protein 214 2 27032910-27041695 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034551 Supported Endoplasmic reticulum
Golgi apparatus
Cytosol Renal cancer:2.39e-10 (unfavourable), Liver cancer:4.96e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 89.8 TMEM215 ENSG00000188133 Transmembrane protein 215 9 32783499-32787399 Predicted membrane proteins Evidence at transcript level HPA052804 Uncertain Tissue enriched Group enriched 5 cervix, uterine: 1.0;endometrium: 4.8;testis: 4.2;thyroid gland: 1.8 cerebral cortex: 0.5 TMEM216 CORS2, HSPC244, JBTS2, MGC13379, MKS2 ENSG00000187049 Transmembrane protein 216 11 61391687-61398863 Disease related genes, Predicted membrane proteins Evidence at protein level Expressed in all Mixed ovary: 32.3 TMEM218 ENSG00000150433 Transmembrane protein 218 11 125096545-125111763 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038489 Uncertain Approved Plasma membrane
Cytosol Liver cancer:1.93e-5 (unfavourable), Stomach cancer:5.50e-4 (favourable) Expressed in all Expressed in all fallopian tube: 21.7 TMEM219 ENSG00000149932 Transmembrane protein 219 16 29940885-29973052 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059185 Approved Endometrial cancer:5.79e-4 (favourable) Expressed in all Expressed in all fallopian tube: 196.0 TMEM220 ENSG00000187824 Transmembrane protein 220 17 10699015-10730316 Predicted membrane proteins Evidence at protein level Liver cancer:2.23e-5 (favourable), Pancreatic cancer:1.72e-4 (favourable), Glioma:9.39e-4 (unfavourable) Expressed in all Expressed in all liver: 53.9 TMEM222 C1orf160, DKFZP564D0478 ENSG00000186501 Transmembrane protein 222 1 27322145-27336400 Predicted membrane proteins Evidence at protein level HPA016579, HPA059374 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all fallopian tube: 47.4 TMEM223 MGC3196 ENSG00000168569 Transmembrane protein 223 11 62771629-62792021 Predicted membrane proteins Evidence at protein level HPA014504 Approved Approved Nucleus
Nuclear membrane
Mitochondria Expressed in all Expressed in all prostate: 16.9 TMEM229B C14orf83, FLJ33387 ENSG00000198133 Transmembrane protein 229B 14 67447084-67533739 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA046562 Approved Endometrial cancer:1.21e-5 (favourable), Urothelial cancer:1.79e-5 (favourable), Breast cancer:5.38e-4 (favourable) Expressed in all Mixed duodenum: 16.2 TMEM230 C20orf30, HSPC274 ENSG00000089063 Transmembrane protein 230 20 5068232-5113103 Predicted membrane proteins Evidence at protein level HPA009078, HPA061421 Uncertain Validated Endoplasmic reticulum Expressed in all Expressed in all thyroid gland: 226.3 TMEM232 FLJ43080 ENSG00000186952 Transmembrane protein 232 5 110289233-110738956 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049386 Uncertain Not detected Tissue enhanced fallopian tube: 26.1;testis: 35.3 thyroid gland: 7.3 TMEM233 IFITMD2 ENSG00000224982 Transmembrane protein 233 12 119593459-119643066 Predicted membrane proteins Evidence at transcript level HPA047506 Uncertain Tissue enriched Group enriched 5 cerebral cortex: 16.3;skeletal muscle: 11.5;thyroid gland: 21.4 parathyroid gland: 3.1 TMEM235 ENSG00000204278 Transmembrane protein 235 17 78231310-78240987 Predicted membrane proteins Evidence at transcript level HPA053939 Uncertain Tissue enriched Tissue enriched 101 cerebral cortex: 15.7 placenta,testis: 0.1 TMEM238 ENSG00000233493 Transmembrane protein 238 19 55379245-55384598 Predicted membrane proteins Evidence at protein level Renal cancer:8.84e-6 (favourable) Expressed in all Tissue enhanced small intestine: 10.2;stomach: 10.2 colon: 9.4 TMEM239 ENSG00000198326 Transmembrane protein 239 20 2816302-2820284 Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 248 testis: 39.1 endometrium,placenta: 0.1 TMEM242 BM033, C6orf35 ENSG00000215712 Transmembrane protein 242 6 157289386-157323601 Predicted membrane proteins Evidence at protein level HPA025764 Approved Expressed in all Expressed in all cerebral cortex: 17.0 TMEM243 C7orf23, MGC4175, MM-TRAG ENSG00000135185 Transmembrane protein 243, mitochondrial 7 87196160-87220587 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014918 Uncertain Lung cancer:5.45e-4 (favourable), Melanoma:6.84e-4 (unfavourable), Urothelial cancer:9.13e-4 (favourable) Expressed in all Expressed in all thyroid gland: 103.3 TMEM246 C9orf125, MGC12992 ENSG00000165152 Transmembrane protein 246 9 101473171-101533537 Predicted membrane proteins Evidence at protein level HPA011318, HPA054041 Uncertain Approved Mitochondria Renal cancer:1.55e-8 (favourable) Mixed Mixed cerebral cortex: 46.7 TMEM247 ENSG00000187600 Transmembrane protein 247 2 46429190-46484425 Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 27 testis: 35.8 placenta: 1.3 TMEM248 C7orf42, FLJ10099, FLJ13090 ENSG00000106609 Transmembrane protein 248 7 66921225-66958551 Predicted membrane proteins Evidence at protein level HPA016495 Uncertain Approved Vesicles Expressed in all Expressed in all parathyroid gland: 92.0 TMEM249 C8orfK29 ENSG00000261587 Transmembrane protein 249 8 144352219-144354914 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 27 testis: 9.4 epididymis: 0.3 TMEM251 C14orf109, DKFZP564F1123 ENSG00000153485 Transmembrane protein 251 14 93184951-93187089 Predicted membrane proteins Evidence at transcript level HPA048559 Uncertain Approved Golgi apparatus
Cell Junctions Liver cancer:6.14e-7 (unfavourable), Renal cancer:1.10e-4 (favourable) Expressed in all Expressed in all prostate: 27.9 TMEM254 bA369J21.6, C10orf57, FLJ13263 ENSG00000133678 Transmembrane protein 254 10 80078646-80092557 Predicted membrane proteins Evidence at protein level HPA029105 Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all skin: 85.9 TMEM255A FAM70A, FLJ20716 ENSG00000125355 Transmembrane protein 255A X 120258650-120311556 Predicted membrane proteins Evidence at transcript level HPA048470 Uncertain Uncertain Nucleus
Nuclear bodies Group enriched Tissue enhanced ovary: 23.4 cervix, uterine: 10.4 TMEM255B FAM70B, MGC20579 ENSG00000184497 Transmembrane protein 255B 13 113759240-113816995 Predicted membrane proteins Evidence at protein level HPA043334 Approved Approved Nucleoplasm Renal cancer:4.12e-5 (unfavourable) Expressed in all Mixed lung: 8.3 TMEM256 C17orf61, MGC40107 ENSG00000205544 Transmembrane protein 256 17 7402975-7404137 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA062732 Approved Vesicles Renal cancer:9.36e-4 (unfavourable) Expressed in all Expressed in all duodenum: 140.8 TMEM258 C11orf10 ENSG00000134825 Transmembrane protein 258 11 61768501-61792802 Predicted membrane proteins Evidence at protein level HPA044602 Approved Approved Plasma membrane
Cytosol Ovarian cancer:4.37e-4 (favourable) Expressed in all Expressed in all epididymis: 429.6 TMEM26 Em:AC068892.1, MGC35010 ENSG00000196932 Transmembrane protein 26 10 61406643-61453450 Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced spleen: 12.0 endometrium: 6.7 TMEM261 C9orf123, MGC4730 ENSG00000137038 Transmembrane protein 261 9 7796490-7888380 Predicted membrane proteins Evidence at protein level HPA014585 Approved Renal cancer:1.96e-11 (favourable), Endometrial cancer:4.15e-4 (favourable) Expressed in all Expressed in all thyroid gland: 17.3 TMEM262 ENSG00000187066 Transmembrane protein 262 11 65084979-65089375 Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 57 testis: 13.7 cervix, uterine: 0.2 TMEM30A C6orf67, CDC50A, FLJ10856 ENSG00000112697 Transmembrane protein 30A 6 75252924-75284968 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014561 Approved Supported Mitochondria Expressed in all Expressed in all cerebral cortex: 167.9 TMEM30B CDC50B ENSG00000182107 Transmembrane protein 30B 14 61277370-61281840 Predicted membrane proteins, Transporters Evidence at protein level HPA043162 Uncertain Renal cancer:5.89e-5 (favourable) Mixed Mixed parathyroid gland: 80.6 TMEM31 MGC39655 ENSG00000179363 Transmembrane protein 31 X 103710909-103714028 Predicted membrane proteins Evidence at protein level HPA052760 Approved Nucleoli fibrillar center Tissue enhanced Tissue enriched 61 testis: 84.9 ovary,placenta: 1.3 TMEM33 FLJ10525 ENSG00000109133 Transmembrane protein 33 4 41935120-41960572 Predicted membrane proteins Evidence at protein level Renal cancer:1.35e-5 (favourable) Expressed in all Expressed in all thyroid gland: 39.8 TMEM38A MGC3169, TRIC-A ENSG00000072954 Transmembrane protein 38A 19 16661127-16690029 Predicted membrane proteins Evidence at protein level HPA048100, HPA050463 Supported Approved Nucleus Renal cancer:2.99e-10 (favourable), Lung cancer:2.78e-5 (favourable), Ovarian cancer:7.96e-4 (unfavourable) Expressed in all Tissue enriched 9 skeletal muscle: 199.8 cerebral cortex: 23.2 TMEM38B bA219P18.1, C9orf87, D4Ertd89e, FLJ10493, TRIC-B ENSG00000095209 Transmembrane protein 38B 9 105694544-105776612 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018465 Uncertain Renal cancer:7.96e-4 (favourable) Expressed in all Expressed in all testis: 51.9 TMEM39A FLJ10902 ENSG00000176142 Transmembrane protein 39A 3 119429500-119468830 Predicted membrane proteins Evidence at protein level HPA039140 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.00e-5 (unfavourable), Liver cancer:3.26e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 32.9 TMEM40 FLJ11036 ENSG00000088726 Transmembrane protein 40 3 12733525-12769457 Predicted membrane proteins Evidence at protein level HPA044165 Supported Approved Cytosol Tissue enhanced Group enriched 8 esophagus: 89.2;placenta: 23.2;skin: 55.5;tonsil: 24.8 urinary bladder: 6.4 TMEM41B KIAA0033 ENSG00000166471 Transmembrane protein 41B 11 9280654-9314780 Predicted membrane proteins Evidence at protein level HPA014946 Uncertain Approved Peroxisomes Liver cancer:9.18e-6 (unfavourable) Expressed in all Mixed thyroid gland: 22.3 TMEM50B C21orf4 ENSG00000142188 Transmembrane protein 50B 21 33432485-33480011 Predicted membrane proteins Evidence at protein level CAB034199, HPA068995 Approved Approved Nucleoli fibrillar center Head and neck cancer:3.00e-4 (favourable), Lung cancer:3.33e-4 (favourable) Expressed in all Expressed in all thyroid gland: 74.3 TMEM55A DKFZp762O076 ENSG00000155099 Transmembrane protein 55A 8 90993796-91041064 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014591 Approved Liver cancer:3.76e-5 (unfavourable), Cervical cancer:1.01e-4 (unfavourable), Head and neck cancer:1.54e-4 (unfavourable), Stomach cancer:8.01e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.8 TMEM55B C14orf9, MGC26684 ENSG00000165782 Transmembrane protein 55B 14 20457719-20461612 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048528 Approved Renal cancer:1.01e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 41.2 TMEM63C C14orf171, CSC1, DKFZp434P0111, hsCSC1 ENSG00000165548 Transmembrane protein 63C 14 77116568-77259495 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030657 Uncertain Approved Centrosome Mixed Tissue enhanced adrenal gland: 12.9;cerebral cortex: 18.6;testis: 13.8 epididymis: 5.5 TMEM67 JBTS6, MGC26979, MKS3, NPHP11 ENSG00000164953 Transmembrane protein 67 8 93754844-93819234 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA039940 Uncertain Renal cancer:7.62e-4 (unfavourable) Mixed Tissue enhanced fallopian tube: 21.9 testis: 12.8 TMEM68 FLJ32370 ENSG00000167904 Transmembrane protein 68 8 55696424-55773407 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018216, HPA019173 Uncertain Approved Vesicles Expressed in all Expressed in all fallopian tube: 36.6 TMEM70 FLJ20533 ENSG00000175606 Transmembrane protein 70 8 73972437-73982783 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023187, CAB034226 Uncertain Supported Nucleoplasm
Mitochondria Expressed in all Expressed in all skeletal muscle: 30.2 TMEM71 FLJ33069 ENSG00000165071 Transmembrane protein 71 8 132685007-132760712 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058401, HPA070655 Uncertain Validated Mitochondria Mixed Mixed bone marrow,heart muscle: 24.2 TMEM74 FLJ30668, NET36 ENSG00000164841 Transmembrane protein 74 8 108606850-108787615 Predicted membrane proteins Evidence at protein level HPA015672 Uncertain Approved Cytosol Mixed Tissue enhanced cerebral cortex: 6.3 testis: 1.5 TMEM74B C20orf46, FLJ11190 ENSG00000125895 Transmembrane protein 74B 20 1180561-1185415 Predicted membrane proteins Evidence at transcript level HPA045213 Approved Approved Nucleoplasm
Golgi apparatus Renal cancer:2.55e-7 (unfavourable), Pancreatic cancer:3.07e-5 (favourable) Mixed Mixed small intestine: 28.0 TMEM80 FLJ38216 ENSG00000177042 Transmembrane protein 80 11 695428-705028 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA059592, HPA067046 Uncertain Approved Golgi apparatus Renal cancer:2.47e-4 (favourable) Expressed in all Expressed in all thyroid gland: 43.4 TMEM87A DKFZP564G2022 ENSG00000103978 Transmembrane protein 87A 15 42210452-42273663 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018104, HPA018189 Supported Supported Golgi apparatus Expressed in all Expressed in all prostate: 122.4 TMEM88 FLJ20025, MGC71744 ENSG00000167874 Transmembrane protein 88 17 7855065-7856099 Predicted membrane proteins Evidence at protein level HPA052991 Approved Liver cancer:4.43e-6 (favourable), Colorectal cancer:1.16e-4 (unfavourable) Expressed in all Mixed placenta: 34.0 TMEM88B ENSG00000205116 Transmembrane protein 88B 1 1426128-1427787 Predicted membrane proteins Evidence at protein level HPA065743 Supported Tissue enhanced Tissue enriched 13 cerebral cortex: 11.9 testis: 0.9 TMEM8B C9orf127, NAG-5, NGX6 ENSG00000137103 Transmembrane protein 8B 9 35814451-35854847 Predicted membrane proteins Evidence at protein level HPA052130, HPA062701 Approved Approved Vesicles Renal cancer:1.89e-15 (favourable), Pancreatic cancer:3.14e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 26.7 TMEM91 FLJ27310, IFITMD6 ENSG00000142046 Transmembrane protein 91 19 41350911-41384083 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA053240 Uncertain Renal cancer:3.52e-7 (unfavourable), Pancreatic cancer:3.54e-5 (favourable) Expressed in all Expressed in all skin: 31.0 TMEM94 KIAA0195 ENSG00000177728 Transmembrane protein 94 17 75441159-75500090 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008423, HPA050660 Approved Supported Nucleoplasm
Nuclear bodies Pancreatic cancer:2.26e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 54.3 TMEM97 MAC30 ENSG00000109084 Transmembrane protein 97 17 28319095-28328685 Predicted membrane proteins Evidence at protein level HPA044795 Approved Approved Nuclear membrane
Plasma membrane
Cytosol Renal cancer:1.24e-4 (unfavourable) Expressed in all Expressed in all testis: 109.7 TMIGD3 AD026 ENSG00000121933 Transmembrane and immunoglobulin domain containing 3 1 111483348-111563962 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Breast cancer:3.58e-4 (unfavourable) Tissue enriched Tissue enriched 15 testis: 98.4 placenta: 6.5 TMTC1 ARG99, FLJ31400, FLJ41625, OLF ENSG00000133687 Transmembrane and tetratricopeptide repeat containing 1 12 29500840-29784759 Predicted membrane proteins Evidence at protein level HPA016720 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:1.90e-4 (unfavourable), Renal cancer:5.49e-4 (unfavourable) Mixed Tissue enhanced spleen: 61.6 adipose tissue: 41.5 TMTC3 FLJ90492, SMILE ENSG00000139324 Transmembrane and tetratricopeptide repeat containing 3 12 88142296-88199887 Predicted membrane proteins Evidence at protein level HPA038550 Approved Approved Microtubules Expressed in all Mixed skin: 14.9 TMUB1 C7orf21, SB144 ENSG00000164897 Transmembrane and ubiquitin-like domain containing 1 7 151081080-151083546 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029429 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all small intestine: 53.3 TMUB2 MGC3123 ENSG00000168591 Transmembrane and ubiquitin-like domain containing 2 17 44186970-44191731 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043137 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all testis: 48.5 TMX2 PDIA12, TXNDC14 ENSG00000213593 Thioredoxin-related transmembrane protein 2 11 57712600-57740973 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA040282, HPA063763 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.55e-5 (favourable), Urothelial cancer:3.37e-4 (unfavourable), Head and neck cancer:3.64e-4 (unfavourable), Liver cancer:4.11e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 129.2 TNFRSF10A Apo2, CD261, DR4, TRAILR-1 ENSG00000104689 Tumor necrosis factor receptor superfamily, member 10a 8 23190452-23225126 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA050958, HPA054475 Approved Supported Nucleoplasm Pancreatic cancer:1.00e-4 (unfavourable) Expressed in all Mixed lymph node: 16.1 TNFRSF10D CD264, DcR2, TRAILR4, TRUNDD ENSG00000173530 Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain 8 23135588-23164030 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA070971 Approved Plasma membrane
Actin filaments Cervical cancer:1.70e-4 (unfavourable) Expressed in all Mixed gallbladder: 12.7 TPCN1 FLJ20612, KIAA1169, TPC1 ENSG00000186815 Two pore segment channel 1 12 113221050-113298585 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039757 Approved Expressed in all Expressed in all thyroid gland: 53.3 TPTE CT44, PTEN2 ENSG00000274391 Transmembrane phosphatase with tensin homology 21 10521553-10606140 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA049690, HPA068342 Supported Approved Endoplasmic reticulum
Cytosol Tissue enriched Tissue enriched 225 testis: 198.9 epididymis,placenta: 0.8 TRAM1 TRAM, TRAMP ENSG00000067167 Translocation associated membrane protein 1 8 70573442-70608387 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023929 Approved Cervical cancer:2.06e-4 (unfavourable), Renal cancer:7.79e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 316.6 TRIB2 GS3955, TRB2 ENSG00000071575 Tribbles pseudokinase 2 2 12716889-12742734 Enzymes, Predicted membrane proteins Evidence at protein level HPA001305 Approved Approved Nucleoplasm
Cytosol Expressed in all Expressed in all ovary: 116.8 TRPM1 CSNB1C, LTRPC1, MLSN1 ENSG00000134160 Transient receptor potential cation channel, subfamily M, member 1 15 31001061-31161273 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA014779, HPA014785 Approved Uncertain Nucleoplasm
Cytosol Tissue enriched Group enriched 27 skin: 4.8;testis: 2.5 kidney: 0.1 TSC1 hamartin, KIAA0243, LAM, TSC ENSG00000165699 Tuberous sclerosis 1 9 132891348-132944633 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011568, CAB012481, HPA074132 Supported Validated Cytosol Liver cancer:6.03e-6 (unfavourable), Renal cancer:7.91e-4 (favourable), Pancreatic cancer:8.01e-4 (favourable) Expressed in all Expressed in all testis: 34.3 TSPAN11 ENSG00000110900 Tetraspanin 11 12 30926428-30996599 Predicted membrane proteins Evidence at protein level HPA066789 Approved Vesicles Lung cancer:3.43e-4 (favourable), Head and neck cancer:5.28e-4 (favourable) Mixed Mixed cerebral cortex: 18.0 TSPAN12 NET-2, TM4SF12 ENSG00000106025 Tetraspanin 12 7 120787320-120858402 Disease related genes, Predicted membrane proteins Evidence at protein level HPA051570, HPA058244 Uncertain Approved Vesicles
Microtubules Expressed in all Mixed kidney: 90.9 TSPAN16 TM-8, TM4-B, TM4SF16 ENSG00000130167 Tetraspanin 16 19 11296139-11326996 Predicted membrane proteins Evidence at protein level HPA041579 Approved Not detected Tissue enriched 32 testis: 153.1 bone marrow: 4.8 TSPAN17 FBX23, FBXO23, TM4SF17 ENSG00000048140 Tetraspanin 17 5 176647387-176659054 Predicted membrane proteins Evidence at transcript level HPA030447 Approved Nucleoplasm Expressed in all Expressed in all bone marrow: 34.8 TSPAN18 TSPAN ENSG00000157570 Tetraspanin 18 11 44726465-44932421 Predicted membrane proteins Evidence at protein level Expressed in all Mixed smooth muscle: 68.4 TSPAN19 ENSG00000231738 Tetraspanin 19 12 85014311-85036277 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA057066 Uncertain Not detected Tissue enhanced testis: 8.3 lung: 4.6 TSPAN3 TM4-A, TM4SF8, TSPAN-3 ENSG00000140391 Tetraspanin 3 15 77041404-77083984 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015996 Uncertain Approved Nucleoplasm
Golgi apparatus Expressed in all Expressed in all epididymis: 519.8 TSPAN4 NAG-2, TETRASPAN, TM4SF7, TSPAN-4 ENSG00000214063 Tetraspanin 4 11 842808-867116 Predicted membrane proteins Evidence at protein level Liver cancer:1.02e-4 (unfavourable), Glioma:2.57e-4 (unfavourable) Expressed in all Expressed in all spleen: 107.3 TSPAN5 NET-4, TM4SF9, Tspan-5 ENSG00000168785 Tetraspanin 5 4 98470367-98658629 Predicted membrane proteins Evidence at transcript level Renal cancer:7.83e-5 (unfavourable), Stomach cancer:8.56e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 76.1 ovary: 57.0 TTC39A C1orf34, DEME-6, KIAA0452 ENSG00000085831 Tetratricopeptide repeat domain 39A 1 51287258-51345116 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028098, HPA043440 Uncertain Approved Centrosome Liver cancer:5.05e-5 (unfavourable) Mixed Tissue enhanced testis: 87.2 breast: 58.0 TTC39B C9orf52, FLJ33868 ENSG00000155158 Tetratricopeptide repeat domain 39B 9 15163622-15307360 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054804, HPA063162 Uncertain Approved Endoplasmic reticulum Renal cancer:4.08e-7 (favourable), Lung cancer:9.64e-6 (favourable) Expressed in all Mixed gallbladder: 11.0 TTC39C C18orf17, FLJ33761, HsT2697 ENSG00000168234 Tetratricopeptide repeat domain 39C 18 23992773-24135610 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065705, HPA065713 Approved Approved Nucleoplasm Renal cancer:2.60e-5 (unfavourable), Breast cancer:1.48e-4 (favourable) Expressed in all Expressed in all liver: 47.6 TTYH1 ENSG00000167614 Tweety family member 1 19 54415219-54436900 Predicted membrane proteins, Transporters Evidence at protein level HPA023617, HPA050655 Approved Breast cancer:3.64e-4 (favourable) Tissue enriched Tissue enriched 27 cerebral cortex: 57.9 testis: 2.1 TTYH3 KIAA1691 ENSG00000136295 Tweety family member 3 7 2631951-2664802 Predicted membrane proteins Evidence at protein level HPA053520 Uncertain Liver cancer:2.53e-5 (unfavourable), Renal cancer:2.58e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 62.4 TUSC3 MGC13453, MRT7, N33, OST3A ENSG00000104723 Tumor suppressor candidate 3 8 15417215-15766649 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA049851, HPA049974 Approved Thyroid cancer:7.86e-4 (favourable) Expressed in all Mixed epididymis: 140.7 TUSC5 IFITMD3, LOST1 ENSG00000184811 Tumor suppressor candidate 5 17 1279663-1300987 Predicted membrane proteins Evidence at protein level HPA050825 Approved Tissue enhanced Tissue enriched 18 adipose tissue: 109.9 breast: 6.0 TVP23A FAM18A, YDR084C ENSG00000166676 Trans-golgi network vesicle protein 23 homolog A (S. cerevisiae) 16 10760919-10818794 Predicted membrane proteins Evidence at transcript level HPA060582 Uncertain Approved Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 6.3 ovary: 3.2 TVP23B CGI-148, FAM18B, FAM18B1, YDR084C ENSG00000171928 Trans-golgi network vesicle protein 23 homolog B (S. cerevisiae) 17 18780995-18806714 Predicted membrane proteins Evidence at protein level HPA019585, HPA065603 Uncertain Approved Golgi apparatus Expressed in all Expressed in all thyroid gland: 78.3 TVP23C FAM18B2, MGC8763 ENSG00000175106 Trans-golgi network vesicle protein 23 homolog C (S. cerevisiae) 17 15502264-15563595 Predicted membrane proteins Evidence at protein level HPA019585, HPA065603 Uncertain Validated Golgi apparatus Mixed Mixed thyroid gland: 10.3 UBAC2 FLJ30548, PHGDHL1, RP11-178C10.1 ENSG00000134882 UBA domain containing 2 13 99200774-99386434 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013448 Approved Approved Cytosol Pancreatic cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 35.6 UBR2 bA49A4.1, C6orf133, dJ392M17.3, KIAA0349 ENSG00000024048 Ubiquitin protein ligase E3 component n-recognin 2 6 42564062-42693504 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027869, HPA027880 Approved Approved Nucleoplasm
Plasma membrane Ovarian cancer:1.65e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 30.0 UBR4 KIAA0462, KIAA1307, RBAF600, ZUBR1 ENSG00000127481 Ubiquitin protein ligase E3 component n-recognin 4 1 19074506-19210276 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013394, HPA021046 Approved Supported Nucleoplasm
Centrosome
Cytosol Expressed in all Expressed in all skin: 90.6 ULK4 FAM7C1, FLJ20574, REC01035 ENSG00000168038 Unc-51 like kinase 4 3 41246599-41962430 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017930 Uncertain Approved Nucleoplasm
Mitochondria
Cytosol Mixed Tissue enhanced testis: 37.9 parathyroid gland: 14.2 UMOD ENSG00000169344 Uromodulin 16 20333052-20356301 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009446, HPA043420, HPA054721 Supported Tissue enriched Tissue enriched 718 kidney: 2377.1 cerebral cortex: 3.3 UNC50 GMH1, UNCL, URP ENSG00000115446 Unc-50 homolog (C. elegans) 2 98608579-98618515 Predicted membrane proteins Evidence at protein level HPA027009 Approved Liver cancer:4.89e-5 (unfavourable), Breast cancer:4.79e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 105.7 VEZT DKFZP761C241 ENSG00000028203 Vezatin, adherens junctions transmembrane protein 12 95217746-95302790 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004811, HPA017066 Approved Supported Nucleoplasm
Cytosol Renal cancer:1.93e-5 (unfavourable), Liver cancer:1.71e-4 (unfavourable), Stomach cancer:3.68e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 31.2 VKORC1L1 ENSG00000196715 Vitamin K epoxide reductase complex, subunit 1-like 1 7 65873267-65959563 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA053954 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all adipose tissue: 57.3 VMA21 MEAX, XMEA ENSG00000160131 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) X 151396515-151409364 Disease related genes, Predicted membrane proteins Evidence at protein level HPA010972 Uncertain Cervical cancer:2.30e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 30.1 VTCN1 B7-H4, B7H4, B7S1, B7X, FLJ22418 ENSG00000134258 V-set domain containing T cell activation inhibitor 1 1 117143587-117210960 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054200 Approved Approved Plasma membrane
Cell Junctions
Focal adhesion sites Group enriched Tissue enhanced breast: 127.6;fallopian tube: 50.8 cervix, uterine: 21.9 VWA9 C15orf44, DKFZP564O1664 ENSG00000138614 Von Willebrand factor A domain containing 9 15 65578753-65611289 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040255, HPA040651 Approved Approved Nucleoplasm
Nuclear membrane
Nuclear bodies
Mitochondria Expressed in all Expressed in all fallopian tube: 38.7 WAC BM-016, FLJ31290, MGC10753, PRO1741, Wwp4 ENSG00000095787 WW domain containing adaptor with coiled-coil 10 28532493-28623112 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036528, HPA042609 Approved Supported Nucleoplasm Liver cancer:9.27e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 129.7 WDR45 JM5, NBIA5, WDRX1, WIPI4 ENSG00000196998 WD repeat domain 45 X 49071470-49101170 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027562 Uncertain Approved Nucleoli Cervical cancer:1.21e-4 (favourable), Head and neck cancer:1.61e-4 (favourable) Expressed in all Expressed in all epididymis: 133.5 WFS1 DFNA14, DFNA38, DFNA6, DIDMOAD, WFS ENSG00000109501 Wolfram syndrome 1 (wolframin) 4 6269849-6303265 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029128 Approved Endometrial cancer:1.13e-6 (favourable), Thyroid cancer:3.13e-4 (unfavourable) Expressed in all Mixed ovary: 61.4 WLS C1orf139, EVI, FLJ23091, GPR177, mig-14, MRP, wls ENSG00000116729 Wntless Wnt ligand secretion mediator 1 68098473-68233120 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA069520 Approved Supported Endoplasmic reticulum Renal cancer:3.67e-7 (favourable), Urothelial cancer:3.51e-4 (unfavourable), Breast cancer:4.03e-4 (favourable), Ovarian cancer:9.43e-4 (favourable) Expressed in all Expressed in all epididymis: 160.7 WNT2B WNT13, XWNT2 ENSG00000134245 Wingless-type MMTV integration site family, member 2B 1 112466541-112530165 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060696, HPA066368 Uncertain Approved Vesicles Tissue enhanced Mixed seminal vesicle: 20.0 WRB CHD5, GET1 ENSG00000182093 Tryptophan rich basic protein 21 39380244-39428528 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018527 Approved Expressed in all Expressed in all fallopian tube: 107.8 XKR9 ENSG00000221947 XK, Kell blood group complex subunit-related family, member 9 8 70669365-70790371 Predicted membrane proteins, Transporters Evidence at transcript level HPA044430 Uncertain Approved Mitochondria Pancreatic cancer:7.20e-4 (unfavourable) Mixed Tissue enhanced testis: 14.1 small intestine: 6.2 XKRX XKR2, XPLAC ENSG00000182489 XK, Kell blood group complex subunit-related, X-linked X 100913445-100929433 Predicted membrane proteins, Transporters Evidence at transcript level Thyroid cancer:3.52e-4 (favourable) Mixed Tissue enhanced skin: 9.5 tonsil: 3.3 XXbac-BPG32J3.19 ENSG00000250641 6 31706904-31717918 Predicted membrane proteins No evidence HPA008053 Uncertain Tissue enriched Not detected testis: 0.5 YIF1A 54TM, FinGER7, YIF1, YIF1P ENSG00000174851 Yip1 interacting factor homolog A (S. cerevisiae) 11 66284580-66289170 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014840 Approved Supported Golgi apparatus
Vesicles
Microtubule organizing center Urothelial cancer:8.70e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 61.2 YIF1B FinGER8 ENSG00000167645 Yip1 interacting factor homolog B (S. cerevisiae) 19 38305104-38317273 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039328, HPA055257, HPA062675 Approved Approved Golgi apparatus
Vesicles Liver cancer:4.53e-5 (unfavourable), Pancreatic cancer:1.88e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 49.6 YIPF3 C6orf109, dJ337H4.3, DKFZp566C243, FinGER3, KLIP1 ENSG00000137207 Yip1 domain family, member 3 6 43511827-43516990 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014859, HPA063699 Supported Validated Nucleoplasm
Golgi apparatus Expressed in all Expressed in all parathyroid gland: 140.3 ZDHHC1 C16orf1, HSU90653, ZNF377 ENSG00000159714 Zinc finger, DHHC-type containing 1 16 67394419-67416833 Enzymes, Predicted membrane proteins Evidence at transcript level HPA042531, HPA048659 Uncertain Approved Cytosol Endometrial cancer:1.25e-6 (favourable), Renal cancer:1.55e-6 (favourable), Pancreatic cancer:5.99e-4 (favourable) Expressed in all Mixed fallopian tube: 31.4 ZDHHC14 FLJ20984, NEW1CP ENSG00000175048 Zinc finger, DHHC-type containing 14 6 157381133-157678146 Enzymes, Predicted membrane proteins Evidence at protein level HPA046033, HPA063754 Uncertain Approved Nucleoli
Mitochondria Pancreatic cancer:6.93e-4 (favourable) Expressed in all Mixed endometrium: 12.3 ZDHHC16 APH2 ENSG00000171307 Zinc finger, DHHC-type containing 16 10 97446131-97457370 Enzymes, Predicted membrane proteins Evidence at protein level HPA039893, HPA040214 Uncertain Supported Nucleus
Nuclear membrane
Cytosol Expressed in all Expressed in all placenta: 31.3 ZDHHC18 DKFZp667O2416 ENSG00000204160 Zinc finger, DHHC-type containing 18 1 26826710-26857602 Enzymes, Predicted membrane proteins Evidence at protein level HPA040234 Approved Approved Microtubules Renal cancer:1.36e-10 (unfavourable), Liver cancer:7.42e-7 (unfavourable), Glioma:9.53e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 75.3 ZDHHC20 FLJ25952 ENSG00000180776 Zinc finger, DHHC-type containing 20 13 21372573-21459370 Enzymes, Predicted membrane proteins Evidence at protein level HPA014483, HPA014702 Approved Uncertain Vesicles
Plasma membrane
Mitochondria Renal cancer:1.01e-4 (unfavourable), Pancreatic cancer:6.55e-4 (unfavourable) Expressed in all Expressed in all testis: 60.4 ZDHHC3 GODZ, ZNF373 ENSG00000163812 Zinc finger, DHHC-type containing 3 3 44915257-44976185 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB012465, HPA016616 Approved Approved Golgi apparatus Renal cancer:1.81e-8 (favourable), Liver cancer:1.37e-4 (unfavourable), Colorectal cancer:3.43e-4 (favourable) Expressed in all Expressed in all skin: 65.4 ZDHHC4 FLJ10479, ZNF374 ENSG00000136247 Zinc finger, DHHC-type containing 4 7 6577434-6589374 Enzymes, Predicted membrane proteins Evidence at protein level HPA032124, HPA064358 Approved Approved Nuclear bodies Renal cancer:1.18e-7 (favourable), Head and neck cancer:3.95e-6 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable), Cervical cancer:9.35e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 77.5 ZDHHC5 KIAA1748, ZNF375 ENSG00000156599 Zinc finger, DHHC-type containing 5 11 57667747-57701187 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014670 Approved Approved Nucleoplasm
Plasma membrane
Cell Junctions
Cytosol Pancreatic cancer:6.74e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 86.1 ZDHHC7 FLJ10792, FLJ20279, SERZ-B, SERZ1, ZNF370 ENSG00000153786 Zinc finger, DHHC-type containing 7 16 84974181-85011535 Enzymes, Predicted membrane proteins Evidence at protein level HPA019215, HPA059054, HPA059642 Uncertain Validated Golgi apparatus Renal cancer:1.12e-5 (favourable), Liver cancer:4.20e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 63.6 ZDHHC8 KIAA1292, ZNF378 ENSG00000099904 Zinc finger, DHHC-type containing 8 22 20129456-20148007 Enzymes, Predicted membrane proteins Evidence at protein level HPA003422 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:4.04e-4 (unfavourable), Cervical cancer:9.68e-4 (unfavourable) Expressed in all Expressed in all spleen: 30.2 ZDHHC9 CGI-89, CXorf11, ZDHHC10, ZNF379, ZNF380 ENSG00000188706 Zinc finger, DHHC-type containing 9 X 129803288-129843909 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA031814 Uncertain Supported Golgi apparatus
Cytosol Cervical cancer:4.64e-5 (unfavourable), Breast cancer:9.77e-5 (unfavourable), Head and neck cancer:2.45e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 71.2 ZFYVE27 FLJ32919, SPG33 ENSG00000155256 Zinc finger, FYVE domain containing 27 10 97737121-97760907 Disease related genes, Predicted membrane proteins Evidence at protein level HPA037523, HPA069876 Approved Approved Nucleoplasm
Cytosol Colorectal cancer:6.91e-4 (unfavourable), Stomach cancer:7.54e-4 (favourable), Urothelial cancer:7.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 33.4 ZZEF1 FLJ10821, KIAA0399, ZZZ4 ENSG00000074755 Zinc finger, ZZ-type with EF-hand domain 1 17 4004445-4143020 Predicted membrane proteins Evidence at protein level HPA031778, HPA031790 Uncertain Approved Nucleoplasm
Mitochondria Head and neck cancer:1.02e-4 (favourable), Pancreatic cancer:6.08e-4 (favourable) Expressed in all Expressed in all small intestine: 26.3